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ABSTRACT OF DISSERTATION

METHODS DEVELOPMENT AND APPLICATION OF TWO-DIMENSIONAL GEL
ELECTROPHORESIS AND MASS SPECTROMETRY IN PROTEOMICS
The development of a highly sensitive ruthenium-based fluorescent staining solution is
described in this dissertation. The in-house synthesized ruthenium complex (RuMS)
containing both sulfonated and non-sulfonated ligand has detection limit of 1 ng of
protein that is better than colloidal coomassie, silver and ruthenium complex containing
all sulfonated ligands (RuBPS). RuMS stain has 100-fold dynamic range and does not
interfere with subsequent mass spectral identification of proteins. The capability of inhouse synthesis of the staining solution makes it a viable cost-effective alternative to the
expensive commercially available fluorescent stain, Sypro Ruby. The low detection limit,
broad linear dynamic range and compatibility with mass spectrometry, make the
development of this stain a worthwhile pursuit. The staining solution was utilized in
subsequent applications of two-dimensional gel electrophoresis (2-DE) technology.
Proteomics methodology utilizing 2-DE and mass spectrometry was applied to
investigate the effect of malathion on the proteome of human neuroblastoma cells.
Results indicated that out of 122 proteins that were identified from the neuroblastoma
proteome, sixteen proteins were down-regulated while five proteins were significantly
up-regulated after treatment with malathion. Significant down-regulation of calcium
modulators like calmodulin and calgizarrin and other key chaperones makes the
malathion-treated cells highly prone to oxidative stress. With increased awareness in
pesticide related adverse effects, identification of altered proteins in malathion-treated
human neuroblastoma cells is a critical finding.
Proteomics is a major area of research in the identification of biomarkers for diseases. A
novel immunoprecipitation method developed in this work allowed for successful
isolation and identification of albumin-interactome in cerebrospinal fluid (CSF) that is
usually under-represented in standard CSF analysis using 2-DE. A key finding is the
differential expression of various isoforms of proteins in CSF albumin-interactome from
Alzheimer’s disease (AD) subjects. The data implicate the acidic isoform of
prostaglandin D2 synthase (PGDS2) as a potential biomarker for AD. An understanding

of the differential expression of these protein isoforms in AD will provide insight into the
etiology of the disease and this can have far-reaching implication on drug development
leading to the cure or even preventation of the disease.

KEYWORDS: proteomics, 2-DE, mass spectrometry, OP toxicity and Alzheimer’s
disease
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CHAPTER ONE
INTRODUCTION
Successful completion of the Human Genome Project led to the surprising finding that
there are far fewer genes in the human genome that actually code for proteins than there
are proteins in the human proteome. This discrepancy implied that gene analysis alone is
not sufficient to understand the complexity of life. The rapidly growing field of
proteomics that involves the global analysis of proteins was initiated to enable better
understanding of proteins- the functional entities of life. Marked improvements in various
proteomics tools are essential for continued exploitation of this technology in various
fields of research.
Proteomics is the subject of this dissertation. This work has been organized into three
main data chapters. Two techniques that were employed in this work are two-dimensional
gel electrophoresis and mass spectrometry. Development of a sensitive staining solution
that is a key component of proteomics technology utilizing two-dimensional gel
electrophoresis is discussed in this dissertation. The technology was applied in two
different areas of research namely environmental toxicology and biomarker discovery.

A FLUORESCENT RUTHENIUM COMPLEX FOR STAINING PROTEINS
SEPARATED BY SDS-PAGE

1.1 Study Goal
The goal of this project is to synthesize a ruthenium chelate, optimize the solvent
composition so that the stain can be used to detect proteins separated by gel
electrophoresis with better sensitivity than RuBPS and can be used as a cost-effective
alternative to Sypro Ruby.
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1.2 Study Hypothesis
The hypothesis is that ruthenium complex with both sulfonated and non-sulfonated
ligands will provide better sensitivity than the RuBPS complex that contains all
sulfonated ligands and the development of the stain in-house will prove to be costeffective.

1.3 Study Rational
Commonly employed staining solutions to visualize proteins in polyacrylamide gels have
inherent disadvantages associated with them like low linear dynamic response for silver
stain and low detection limits for Coomassie blue. Improved techniques for the detection
of proteins in 2-DE gels involve staining with fluorescent dyes, such as Sypro Ruby.
Sypro Ruby is a ruthenium-based dye that has detection limit of approximately 1-2 ng of
protein and about three orders of magnitude of linear dynamic range of quantification.
An alternative to Sypro Ruby staining based on ruthenium (II) tris (bathophenanthroline
disulfonate) (RuBPS) has been developed by Rabilloud et al. We synthesized RuBPS in
our lab following the published Rabilloud protocol to stain proteins. It was observed that
RuBPS stain, an all-sulfonated ligand-containing complex had poor sensitivity compared
to Sypro Ruby and could detect only about 5 ng of protein on the gel. This prompted us
to explore the possibility of having both sulfonated and non-sulfonated ligands attached
to the ruthenium complex. We predict that the presence of both sulfonated and nonsulfonated ligands attached to ruthenium chelate in an appropriate solvent may result in
an additive, synergistic interaction of the different ligands of dye molecules with the
proteins and in turn improve sensitivity. Since the dye can be synthesized in-house it
provides for a cost-effective means to stain proteins.
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1.4 Specific Aims
The specific aims are to synthesize and optimize the formulation of a ruthenium complex
containing both sulfonated and non-sulfonated ligands, to achieve maximum sensitivity
in detecting proteins in gels.

PROTEOMIC INVESTIGATION OF MALATHION-INDUCED DIFFERENTIAL
PROTEIN EXPRESSION IN HUMAN NEUROBLASTOMA CELLS

2.1 Study Goal
The goal is to investigate the effect of malathion on the proteome of human
neuroblastoma cells using 2-DE and mass spectrometry.

2.2 Study Hypothesis
The hypothesis is that treatment of human neuroblastoma cells with malathion, a safe
organophosphate insecticide, does not cause significant alteration in levels of protein.

2.3 Study Rational
An increasing body of literature suggests that developmental exposure to the
organophosphate chlorpyrifos results in biochemical and behavioral abnormalities in
young animals. It was also reported that chlorpyrifos could cause developmental
neurotoxicity in exposed young children. Malathion, on the other hand, is a more benign
organophosphate and is being used in huge quantities to eradicate pests in both
agriculture and the household. There is general lack of data in literature on the effects of
pesticide exposure at the protein level. This study was initiated to conduct a proteomic
investigation on the effect of pesticides and we predict that malathion, a safer
organophosphate, compared to other potent organophosphates like chlorpyrifos, does not
cause significant alteration in levels of protein.
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2.4 Specific Aim
The specific aim is to study the effect of malathion, if any, on protein expression in
human neuroblastoma using proteomic tools namely 2-DE and mass spectrometry.

COMPARISON OF ALBUMIN-INTERACTOME IN VENTRICULAR
CEREBROSPINAL FLUID BETWEEN ALZHEIMER’S DISEASE SUBJECTS
AND NORMAL SUBJECTS

3.1 Study Goal
The primary goal of this project is to identify biomarkers for Alzheimer’s disease by
comparing the albumin-interactome in CSF between Alzheimer’s disease subjects and
normal subjects.

3.2 Study Hypothesis
The hypothesis is that alterations in levels of proteins that constitute the CSF albumininteractome will provide insight into Alzheimer’s disease pathology.

3.3 Study Rational
CSF is an ideal target to identify protein biomarkers for diseases like Alzheimer’s disease
(AD) that affect the brain. Two-dimensional gel electrophoresis (2-DE) appears
particularly well-suited for such analyses since it has the ability to resolve the complex
protein mixture into individual protein spots in a polyacrylamide gel. However, a major
challenge associated with the analysis of CSF by 2-DE is the very large dynamic range of
CSF protein expression. The CSF proteome consists mostly of albumin, transferrin,
immunoglobulins and these represent greater than 70% of the total protein in CSF. One
way to overcome the dynamic range problem is to remove the most abundant proteins
albumin and immunoglobulins using commercially available depletion kits. However,
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there is increasing evidence that depletion of these most abundant proteins could lead to
concomitant removal of other small proteins and peptides that might be interacting with
the high abundant proteins. This would mean loss of valuable information about these
potential biomarkers for the disease. The increased awareness that small proteins and
peptides interact with the most abundant proteins like albumin led us to selectively isolate
and identify the CSF albumin-interactome using immunoprecipitation technique.

3.4 Specific Aim
There are two specific aims in pursuit of this goal. The first specific aim is to isolate the
albumin-interactome by immunoprecipitation and identify the protein components that
constitute the albumin-interactome, using mass spectrometry.
The second specific aim is to compare the albumin-interactome in CSF between AD and
control subjects to identify biomarkers for AD.

5

CHAPTER TWO

BACKGROUND
Main technologies utilized in the preparation of this work are 2-DE and mass
spectrometry and this chapter provides background information and literature review on
these two techniques. Statistical treatment of data is also briefly discussed here.

2.1 TWO-DIMENSIONAL GEL ELECTROPHORESIS (2-DE)
Two-dimensional gel electrophoresis (2-DE) is a powerful and widely used method for
the analysis of complex mixture of proteins like biological fluids, cell extracts, tissue
samples etc. This technique was first introduced by O’Farrell [1], Klose [2] and Scheele
[3] in 1975 to map proteins from Escherichia coli, mouse and guinea pig respectively. 2DE separates proteins by exploiting two properties of proteins in orthogonal directions. In
the first dimension called the isoelectric focusing step, proteins are separated based on
their isoelectric point (pI). In the second dimension step, sodium dodecyl sulfate –
polyacrylamide gel electrophoresis (SDS-PAGE) proteins are separated based on their
molecular weight (Mr). Development of immobilized pH gradient (IPG) strips coupled
with pre-cast polyacrylamide gels and introduction of new sensitive fluorescent stains
have greatly improved the capacity, sensitivity and reproducibility of 2-DE.
In the original technique, carrier ampholytes were used to form a pH gradient under the
influence of electric field and the first dimension isoelectric focusing was performed in
carrier ampholyte containing polyacrylamide tube gels. In the current method developed
by Gorg et al. [4, 5] the carrier ampholyte-generated pH gradient is replaced with IPG
strips. This change overcomes limitations like reproducibility, handling and resolution of
carrier ampholyte generated pH gradient gels. After 2-DE separation, proteins separated
on a polyacrylamide gel are subjected to “in-gel” proteolytic digestion. The resulting
peptides are analyzed by either matrix assisted laser desorption ionization (MALDI) or
liquid chromatography tandem mass spectrometry (LC-MS/MS) and the mass spectrum is
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searched against protein database for identification. The major steps involved in the
proteomics approach utilizing 2-DE are sample preparation, protein separation by
isoelectric focusing, equilibration with SDS buffer, separation by SDS-PAGE, protein
detection using sensitive staining solution, analysis and quantification using image
analysis software, spot excision and in-gel enzymatic digestion and finally identification
using mass spectrometry (Figure 2.1). Each step in 2-DE will be discussed in detail in the
following sections.
•

Sample preparation

Appropriate sample preparation is absolutely essential for good 2-DE results. The method
of sample preparation depends on the aim of the research. Various factors such as
solubility, size, charge and isoelectric point (pI) of proteins of interest play critical role.
Sample preparation/solubilization is important in reducing the complexity of a protein
mixture. There is a wide range of solubilization cocktails available to researchers but it
should be kept in mind that the sample to be loaded on a 2-DE must be of low ionic
strength denaturing buffer that maintains the native charge of the protein and keeps them
soluble.
An effective sample preparation procedure should be able to achieve the following:
1. Solubilize the proteins including hydrophobic proteins: denature the proteins
to break the non-covalent interactions and break disulfide bonds.
2. Prevent protein aggregation but keep the proteins in solution.
3. Prevent post-extraction modifications like degradation or chemical
modifications of the proteins.
4. Remove IEF interfering species like nucleic acids and salts. In 2-DE, proteins
are the analyte and hence anything other than proteins are contaminants, some
of which that can affect IEF must be completely removed.
5. Provide proteins of interest at a detectable level which might require removal
of abundant proteins especially when handling biological fluids
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Figure 2.1 2-DE approach in bottom-up proteomics
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•

Rationale for Solubilization

Forces such as disulfide bonds and non-covalent interactions hold proteins together. The
non-covalent forces are mainly ionic bonds, hydrogen bonds and hydrophobic
interactions. The hydrophobic interaction is because of the presence of water and the side
chains of apolar amino acids like leucine, valine, isoleucine, phenylalanine, tryptophan
and tyrosine pack together and form “hydrophobic core” of the protein due to the
thermodynamically unfavorable exposure to water molecules. Therefore, a good
solubilization buffer should break the ionic bonds, hydrogen bonds, hydrophobic
interactions and disulfide bonds under IEF-compatible conditions i.e. very low salts and
other charged molecules. Rabilloud describes a detailed review on solubilization of
proteins for electrophoresis [6].
Solubilization of proteins is usually achieved by the use of chaotropic agents, detergents,
reducing agents, buffers and ampholytes. Structures of common reagents used are given
in figure 2.2.
Chaotropic agent: Chaotropic compounds are chemicals that disrupt hydrogen bonding
between and within proteins. They prevent protein aggregation and formation of
secondary structure that can alter protein mobility. Neutral urea in concentration of 8M is
usually used as a chaotrope in 2-DE that completely unfolds the protein to random coil
and exposes the ionizable groups. However, care must be taken not to heat ureacontaining solutions above 37°C as urea hydrolyses and carbamylation of protein occurs.
Neither must the temperature of the solution go below 4°C since urea precipitates at this
temperature. Thiourea is also sometimes used in addition to urea to increase the solubility
of otherwise difficult-to-solubilize proteins like membrane proteins [7].
Detergent: In addition to the chaotropic agent, a detergent is also added to facilitate
protein solubility. There are a number of cationic, anionic and zwitterionic compounds
that can be used as detergents. For IEF, zwitterionic or non-ionic detergent is the best to
use, as it is uncharged. The detergent aids in protein solubilization and prevents its
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aggregation by disrupting the hydrophobic interactions. Originally the nonionic detergent
Triton X-100 was used [1, 2] but subsequently it was shown that the zwitterionic
detergent CHAPS was more effective. Detergents are usually used in concentrations upto
4% [8]. The anionic detergent SDS can be used as it is a very effective protein solubilizer
but because of the charge and the ability to form associations with proteins it can affect
IEF. The negative effect of SDS on IEF can be minimized by the addition of another
detergent in combination with SDS and keeping the detergent to SDS ratio about 8:1 [9].
New detergents like SB 3-10 and ASB-14 that have great potential are being used in
proteomics studies [10].
Reducing agent: Reducing agents are used in sample preparation to break the disulfide
bond between cysteine residues between and within proteins. Compounds used as
reducing agents in 2-DE are either sulfydryl or phosphine reducing agents. Examples of
sulfydryl containing compounds are dithiothrietol (DTT) and β-mercaptoethanol (βME).
Examples of phosphine reductants include tributylphosphine (TBP) and triscarboxyethylphosphine (TCEP). The phosphine containing reductants are more effective
than the sulfydryl compounds and can be used in lower concentrations. Following
reduction of disulfide bonds, the free –SH groups are protected by alkylation using
iodoacetamide. This prevents oxidative crosslinking of –SH groups.
Carrier ampholytes and buffer: Carrier ampholytes are small, amphoteric substances
that have great buffering capacity at their pI. They are added in sample solubilization
buffer to enhance protein solubility. They prevent protein aggregation due to chargecharge interaction. They are used typically in concentrations of <0.2% (w/v) in the
sample buffer. Since they carry current, high concentrations of carrier ampholytes slow
down IEF till they are focused at their pI and hence limit the voltage.
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Figure 2.2 Structures of common reagents used in 2-DE sample buffer
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•

FIRST DIMENSION – ISOELECTRIC FOCUSING (IEF)

The first dimension in 2-DE separation is the isoelectric focusing. IEF is an
electrophoretic method that separates proteins according to their isoelectric point (pI).
Proteins are amphoteric biomolecules carrying both negative and positive charges on the
same molecule. The isoelectric point of a protein is the pH at which the protein carriers
no net charge. Proteins are positively charged at a pH below their isoelectric point and are
negatively charged at a pH above their pI. For IEF separation, pH gradient is essential
and mixture of proteins is separated in the pH gradient as they move under the influence
of an electric field. A protein that is positively charged will move towards the cathode
until it reaches a pH at which it carries a net zero charge (pH equal to its pI) and does not
migrate further as it does not see the electric field at this point (Figure 2.3). If for some
reason the protein diffuses from its pI point, it is immediately focused back to position.
This is the focusing effect of IEF. The degree of resolution is determined by the pH
gradient and voltage applied. Typically IEF is performed at high voltages. IEF carried out
under denaturing conditions gives the best resolution, as the proteins are all completely
denatured and exists in only one conformation.
The original method of IEF depended on pH gradient formed by carrier ampholytes in
polyacrylamide tube gels [1, 2]. The carrier ampholytes comprise of small amphoteric
molecules with pIs spanning a specific pH range. When voltage is applied, the carrier
ampholyte with the most negative charge will move towards the anode, the molecule with
the most positive charge will move towards the cathode and a pH gradient is established.
However, the major disadvantage of a pH gradient formed by carrier ampholytes is the
drift in the pH. These molecules are unstable and suffer batch-to-batch reproducibility.
The polyacrylamide tube gels have low mechanical stability and also suffer from batchto-batch differences.

12

+

8.8

3.4

4.3

5.8

6.9

Before
focusing

7.1
9.8

+

-

After focusing
3.4

4.3

5.8

6.9

7.1

8.8

9.8

Figure 2.3 Isoelectric focusing. A mixture of proteins resolved on a pH 3-10 IPG strip
according to their pIs
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Gorg et al. developed another method to form pH gradient polyacrylamide gels[4, 5, 11].
An immobilized pH gradient polyacrylamide gel strip was developed by covalently
incorporating a gradient of acidic and basic buffering groups into the polyacrylamide gel
at the time of its polymerization. The buffers are called acrylamido buffers that are welldefined molecules with a single acidic or basic buffering group linked to an acrylamide
monomer. The immobilized pH gradients are formed using two solutions, one containing
a relatively acidic mixture of acrylamido buffers and other containing basic mixture. The
concentrations of the various solutions define the pH range. During polymerization the
acrylamido portion of the buffer co-polymerizes with the acrylamide and bisacrylamide
monomers to form a polyacrylamide gel. The gel is cast onto a plastic backing for easy
handling and is usually dried which can be rehydrated with the sample.
Low voltage is applied sometimes to aid the sample rehydration, a process called active
rehydration that is carried out typically for 12 hours (overnight). IPG strips are a marked
improvement over tube gels in the following aspects:
•

The first dimension separation is more reproducible because the covalently
fixed gradient cannot drift

•

The plastic backing provides easy handling

•

With the IPG technology desired pH range can be developed

•

The IPG strips have greater loading capacity for protein [11]

•

The protein sample can be introduced into the IPG strip during rehydration
[12]

Samples can be loaded onto an IPG strip either during rehydration or after rehydration of
the IPG strip via sample cups.

14

Sample loading during rehydration of the IPG strip is the most common method and has
multitude of advantages such as:
•

Large quantities of proteins can be loaded [12]

•

Because the sample is not applied at one single place like when using sample
cup, this method eliminates precipitation of proteins

The rehydration buffer also called sample buffer contains urea, DTT, CHAPS, IPG buffer
and bromophenol blue (dye). The sample is dissolved in the rehydration buffer and added
to the sample tray. The IPG strip is placed over the sample and is allowed to rehydrate for
about 12 hours (or overnight). A low voltage is applied to facilitate the entry of protein
into the gel during rehydration. A layer of mineral oil is added above the IPG strip mainly
to minimize sample evaporation and urea crystallization. After the IPG strip is rehydrated
with the sample, IEF can be performed. IEF is usually carried out at high voltages up to
4000 V. A typical IEF protocol generally proceeds through a series of voltage steps that
begin at a low value. The initial low voltage is to separate the salt (which is collected by
the paper wicks placed at either ends of the IPG strip) from the sample. The voltage is
gradually increased to a final desired focusing voltage that is held for several hours.
Many factors affect the time required for focusing. Optimization of the protocol is
essential to achieve good separation. After focusing, the IPG strips are equilibrated with
buffers containing DTT and iodoacetamide. The equilibration is to saturate the IPG strip
with the SDS, reduce and alkylate any disulfide bonds.
The equilibration solution has several components in it. A solution of 50 mM tris, pH 8.8
maintains the IPG strip pH in a range appropriate for the second dimension separation
and 6M urea and 30% glycerol reduces electroendosmosis by increasing the viscosity of
the buffer and helps in the transfer of proteins from the first to the second dimension.
DTT in the solution preserves reduced state of the denatured proteins while ioacetamide
alkylates the reduced disulfide bonds and residual DTT to prevent point streaking seen
especially in silver stained gels.
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SDS in the equilibration buffer denatures proteins and forms negatively charged proteinSDS complexes, which facilitates separation in the second dimension based on molecular
weight. After equilibration of IPG strips, they are ready for the second dimension
separation.
•

SECOND DIMENSION- SODIUM DODECYL SULFATEPOLYACRYLAMIDE GEL ELECTROPHORESIS (SDS-PAGE)

The separation of biomolecules in an electric field is called electrophoresis. The method
of protein separation by electrophoresis employs polyacrylamide gel as a support medium
and SDS as the denaturant and hence called SDS-polyacrylamide gel electrophoresis
(SDS-PAGE). SDS is an anionic detergent that denatures proteins by wrapping around
their peptide backbone in a ratio of approximately 1.4 SDS to 1 protein. The bound SDS
masks the charge of the protein itself giving it a net negative charge. The proteins are
totally unfolded and carry a net negative charge and separation is based on molecular
weight of the protein. The most commonly used buffer system is the tris-glycine system
described by Laemmli [13].
Polyacrylamide gel: Polyacrylamide gel is the polymerization product of the monomer
acrylamide and a crosslinking comonomer, most commonly bisacrylamide. The
polymerization is started and propagated via a free radical reaction. The chemical
N,N,N',N'-tetramethylethylenediamine (TEMED) causes ammonium per sulfate (APS) to
produce sulfate radical. The radicals react with the acrylamide and bisacrylamide leading
to polymerization. Single percentage acrylamide gels provide good resolution of proteins
that fall within a narrow molecular weight range. However, gradient polyacrylamide gels
give excellent resolution of wide range of molecular weight and the decrease in pore size
allows for sharper protein spots. The percentage of total acrylamide monomer is referred
to as %T and this value determines the pore size of the gel. The greater the %T, the
smaller is the pore size of the gel. In gradient gels, percentage of acrylamide increases
from top to bottom of the gel while the pore size decreases, allowing smaller proteins to
travel more towards the bottom of the gel resulting in better separation.
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2.2 MASS SPECTROMETRY
An essential tool in addition to the protein separation technology, for proteomics, is mass
spectrometry (MS). MS is an ubiquitous analytical tool in a number of fields including
chemistry, biochemistry, pharmacy and medicine. The history of MS dates back to 1897
when Sir J.J. Thomson of the Cavendish laboratory at the Cambridge University, while
studying electrical discharges in gases discovered the electron. He then went on to build
the first ever known mass spectrometer in the first decade of the 20th century for the
measurement of mass to charge ratio (m/z) of ions [14]. In this instrument, ions from
discharge tubes were passed through both electrical and magnetic fields, by virtue of
which they take parabolic trajectories. The ions were then detected on a fluorescent
screen or photographic plate. Since then, MS has changed tremendously and is still
undergoing improvements.
The basic principle of mass spectrometry is to generate ions of the analyte by suitable
method, to separate the ions by their m/z values and to detect them quantitatively and
qualitatively by their respective m/z value and abundance. A mass spectrometer consists
of an ion source, a mass analyzer and a detector, which are operated under high vacuum
(schematic shown in figure 2.4). Ions are separated in a mass analyzer on the basis of m/z
and can be manipulated by electric or magnetic fields to direct ions to a detector in a m/z
dependent manner. A mass spectrum is the two dimensional representation of the signal
intensity versus the m/z. The intensity of the peaks (signals) directly reflects the
abundance of ionic species of that respective m/z. The mass-to-charge ratio, m/z, is
dimensionless as it is a ratio between the mass number of the ion and the number of
charge on it.

Instrumentation
Basic types of mass analyzers are given in Table 2.1. MS instrumentation has undergone
tremendous change since its introduction in 1946 by Stephens [15]. Highly sensitive,
robust instruments have been developed that can reliably analyze proteins. The two mass
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analyzers that were used for the preparation of this dissertation namely, ion trap and timeof-flight are discussed below.

Sample inlet

Atmosphere/
vacuum

Mass
analyzer

Ion source

High vacuum

Figure 2.4 General scheme of a mass spectrometer
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Detector

Data
system

Table 2.1 Types of different mass analyzers

TYPE

Acronym

Principle

pulsed ion beam dispersed in time
Time-of-flight

TOF

and separated by time of flight

Continuous ion beam is deflected
Magnetic sector

B

in magnetic and separated based
on the momentum

Continuous ion beam in Rf
Quadrupole

Q

quadrupole field, separated on the
basis of stable trajectories

Ions trapped in the 3D trap under
Quadrupole ion trap

QIT

the influence of Rf field and
separated based on stable
trajectories

Ions are trapped and separated by
Fourier transform ion cyclotron

FT-ICR

cyclotron frequency in a magnetic
field
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•

QUADRUPOLE ION TRAP (QIT)

Introduction
The origin of ion trap goes back to the work of Paul and Steinwedel [16, 17] that was
recognized by the presentation of shared 1989 Nobel Prize in Physics to Wolfgang Paul.
QIT also known as 3D trap consists of an arrangement of three hyperbolic electrodes- a
ring electrode and two end caps (Figure 2.5). In the normal mode of use, the end caps are
connected to earth potential (grounded) while a radiofrequency (RF) fundamental
potential (driving potential) typically 1 MHz is applied to the ring electrode. By virtue of
the driving potential, ions are held stable within the ion trap. By gradually increasing the
amplitude of the driving potential, ions become more energetic and their trajectories
become unstable along the axis of symmetry (z axis) of the trap. As a result, the ions in
order of increasing m/z value are ejected from the trap through holes in one of the endcap and are detected by the channeltron electron multiplier. The resulting signal
represents a mass spectrum. This mode of operation is called mass-selective ejection. The
working principle of the 3D trap is based on creating stable trajectories for ions of a
certain m/z or m/z range while removing unwanted ions by colliding them with the walls
or by axial ejection from the trap due to their unstable trajectories.

Theory of the “perfect” Quadrupole ion trap
The theory of quadrupole ion trap is best explained by equations that govern both the
electric field in the trap and the motion of ions inside. The potential φx,y,z developed
within the trap on applying both RF and DC (direct current) potential to the ring electrode
is given by
Φ x, y ,z =

(U − V cos Ωt ) ⎡ x 2 + y 2 − 2 z 2 ⎤ + (U − V cos Ωt )
2

⎢
⎣

r02

⎥
⎦

2

where,
U is maximum DC potential and V the maximum RF potential
Ω is the angular frequency of the RF potential
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r is the internal radius of the ring electrode
2z is the distance between the end-cap electrodes (for perfect quadrupole field r2 =
2z2 however a different relation was shown to work better) and
t is the time
The motion of ions in a quadrupole field is described mathematically by solutions to the
Mathieu equation, which has the general form
d 2u
+ (au − 2qu cos 2ξ )u = 0
dξ 2

where,
u = x, y and z directions
ξ = Ωt/2
The trapping parameters a and q which are fundamental for the operation of the ion trap
is derived as

qz =

4eV
8eU
and a z = − 2 2
2
2
mr Ω
mr Ω

Equation (1)

The form of an ion trajectory in the r-z plane has the general appearance of a Lissajous
curve composed of two fundamental frequency components ωr.0 and ωz.0 of the secular
motion with a super imposed micromotion of frequency Ω/2π Hz. The graphical
representation of stable solutions to the Mathieu equation is called the stability diagram
(Figure 2.6). Ions can be stored in the trap provided they are stable in both r and z
direction. The βz = 1 line intersects the qz axis at q=0.908, this is the ejection limit of the
ion from the trap. The parameter β appears in the solution to the Mathieu equation and
defines the secular frequency of oscillation of the ion. When the values of U and V are
held constant and the driving frequency Ω is reduced, the values of both az and qz will
increase and at one point the (az, qz) coordinate of the ion will cross the boundary and the
trajectory will become unstable. Keeping the frequency Ω constant and increasing the V
can achieve a similar effect.
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Figure 2.5 Typical quadrupole iontrap comprising of the two endcap electrode and the
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Figure 2.6 Mathieu stability diagram for quadrupole ion trap (QIT).
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In most ion traps, end-caps are grounded and a RF potential is applied to the ring
electrode. By gradually increasing the RF amplitude, the motion of ions become
progressively more energetic and they eventually develop unstable trajectories in the
order of increasing m/z. When qz reaches the value of qeject = 0.908 along the az = 0 line,
the ion motion remains stable in the radial plane while the axial component of the
trajectory becomes unstable so that ions are ejected from the trap. This method of ion
ejection is referred to as mass selective axial instability [18]. Trapped ions of a given m/z
oscillate at a frequency known as the secular frequency that is proportional to the angular
frequency of the applied RF. Stafford et al. discovered that a helium damping gas of ~1
mTorr within the trap greatly improved both the sensitivity and the mass resolution of the
instrument [19]. The light helium (He) atoms collide with heavier ions; this reduces their
kinetic energy, and they migrate to the center of the trap. Consequently, when being
ejected ions tend to start from essentially the same position along the axis of the trap
hence improved resolution and with minimum radial dispersion forming a tightly focused
ion beam that cleanly passes through holes in the end-cap electrode, resulting in greater
sensitivity.

Stretched geometry

The performance of the quadrupole ion trap is affected by imperfections in the
quadrupolar electric fields used to trap ions. For a perfect quadrupole field, the geometry
of the ion trap should be such that r2 = 2z2. However, the commercial ion traps have a
“stretched geometry” in which the shapes of the endcap and the ring electrode are
retained but the distance between them is extended by about 11%. This was shown to
increase the signal intensity and improve resolution. The trapping parameters are now
calculated using the actual r and z as follows:

ar =

8 eU
m (r

2

+ 2 z )Ω
2

qr = −

2

and
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4eV
m( r + 2 z 2 )Ω 2
2

az = −

16 eU
m (r

2

+ 2 z 2 )Ω

qr =

2

8 eV
m (r

2

+ 2 z 2 )Ω

2

Mass Range extension

By rearranging the equation for the trapping parameters, we get

⎛ m ⎞
⎟ max =
⎜
⎝ z ⎠
q

4 eV
ej

(r

2

+ 2 z 2 )Ω

2

where qej is 0.908 and Vmax is the maximum value for the RF potential. In order to
increase the m/z value for a given Vmax, we can either reduce r and/ or Ω or reduce the q
value. The most efficient way to accomplish mass range extension is by resonant ion
ejection. Resonant ejection requires cooling of ions towards the center of the trap with the
help of Helium buffer gas. Resonance excitation is brought about by matching the
frequency of the supplementary potential applied to the endcap electrodes to the secular
frequency of the ion. The ion will absorb the energy from the applied field and the
trajectory will increase linearly towards the endcap until the ion becomes unstable and is
ejected.

Instrument and Its Operation

LCQ Classic:

The instrument used for the analysis/identification of proteins is the Thermo Electron
Corporation LCQ Classic (San Jose, CA). The ions will be pre-formed by solution phase
chemistry before the analyte reaches the probe. This is accomplished by adding a proton
donor such as formic acid to the mobile phase. A potential of + 4kV is applied at the
heated capillary. By virtue of the potential, positive ions move towards the tip and a
Taylor cone is formed. The Taylor cone emits very small charged droplets, which are
desolvated by a combination of nitrogen gas (nebulizer) and heated capillary. The
charged gas phase ion molecules are steered into the ion trap. There are two octapoles in
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the LCQ Classic. The main purpose of these octapoles is to transmit ions from the exit of
the skimmer to the ion trap and allow any remaining neutrals or opposite charge ions to
be lost in vacuum. Ions are transmitted as a beam by the first octapole which then passes
through the inter octapole lens and are refocused into the trap by the second octapole. The
inter octapole lens has a tunable charge that is opposite to the ions of interest so that they
are accelerated towards the second octapole. The second octapole has a even higher
voltage so that the ions finally enter the ion trap. The RF frequency of the octapole is
typically around 2400 Hz, which focuses ions into a beam. The octapoles act only as lens
focusing ions and in no way take part in the mass selection. Once the ions enter the ion
trap, it is here that they are selected and scanned-out to be detected.
There are four basic steps involved in an ion trap operation. These include collection,
isolation, excitation and ejection of ions. During a full scan event which is the simplest,
all ions regardless of mass are collected inside the trap and ejected resulting in a
spectrum, that displays the ion count of each mass. RF is applied to the ring electrode to
collect all ions. The endcap electrodes are held at ground. The RF frequency applied at
the ring electrode in a LCQ Classic is 760 kHz. Due to this RF, the ions oscillate towards
and away from the center of the trap along the radial axis. Due to the oscillating RF
frequency, the trapped ions never hit the electrodes and thus are maintained inside the
trap. The use of buffer gas greatly improved sensitivity and resolution of low mass ions.
By cooling ions by collision with He gas, the kinetic energy of the ions entering the trap
is reduced and their trajectories collapse to the center of the trap. With each collision
some of the kinetic energy is converted to vibrational energy and heat, both of which
quickly dissipate. The net result is loss of kinetic energy without much change in the
vibrational energy to cause fragmentation. Thus ions cooled down in the center of the
trap can be scanned out resulting in increased sensitivity and resolution.
The theory of ion trap has been discussed earlier in a previous section. In an LCQ, the
above equations are even simpler. The r and z are dimensions of the ion trap which will
remain constant for a trap, Ω the angular frequency of the drive potential is 760 kHz and
the DC component U is zero, so rearranging the above q equation
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⎛ V ⎞
⎟
q = k ⎜⎜
⎟⎟
m
⎜
⎝ e⎠
The only variable that affects an ion’s stability is the q value, the ion’s m/e and the RF
amplitude (V). All ions trapped inside an ion trap will have an a value of zero and a q
value that extends from 0 to 0.908 (q=0.908 is called the edge of stability) depending
upon their mass. At given RF amplitude, the q value is inversely proportional to the mass
of the ion, meaning smaller ions will have larger q value than heavier ions. In LCQ, RF
amplitude is ramped from a low voltage to high voltage and in this process the q value of
the ions will increase. When an ion of particular mass reaches the qz value of 0.908, its
trajectory will become unstable in the z direction (axial) and it is scanned out of the hole
in the endcap into the detector (Figure 2.7).

qz axis
0.908

Ramp RF amplitude and ions leave the trap in the order of increasing mass
Figure 2.7 Mass selective instability scan

When the q value is increased by increasing the RF voltage, the ion whose q value
becomes 0.908 and that is close to the exit hole will eject out of the trap immediately
while other ions of the same mass that continue to have stable trajectories and stay within
the trap, will have chaotic motion from collisions with other ions and He atoms. This will
affect the resolution. To prevent this, a RF potential is applied at the endcaps, which is
exactly 180° out of phase from another. So, when the entrance endcap is of positive
polarity, the positive ions are repelled from it and attracted towards the exit endcap as it
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has negative polarity. However, in less than a second, the polarity of the endcaps
interchange and the ions are again repelled form the exit endcap. In this way, the ions are
oscillating in the trap back and forth in a group. Hence, when the q value of a particular
mass of ion is reached, the same mass ions are ejected as a group and this increases
resolution. This type of ejection is called resonance ejection. The frequency of RF
applied to the endcap in the LCQ classic is about 320 kHz. This however reduces the q
value to 0.83.

Tandem Mass Spectrometry
For a full scan, all ions that enter the ion trap are ejected and detected and a full MS scan
spectrum is obtained. In the case of tandem mass spectrometry (MS/MS), the ions are all
collected inside the trap and the ion of interested mass is specifically isolated from the
other ions of different masses. Ejecting the other ions with different m/z values isolates
ions of m/z of interest. This is accomplished by applying a resonant frequency equal to
the secular frequency with which the ions oscillate and by doing so their trajectories are
made unstable and they exit the trap. Now the isolated precursor ion has to fragment to
give product ions for MS/MS. This is done by excitation. Excitation of precursor ion is
accomplished by applying a RF voltage at the endcap. This voltage that is very small in
amplitude causes the fragmentation of the precursor ion along with collision with He
buffer gas. RF voltage applied to the endcap to bring about fragmentation is called tickle
voltage. Before the precursor ion is excited it must be cooled to a lower q value, so that
most of the fragment ions remain inside the trap (Remember, the q value is inversely
proportional to the mass of the ion. If the precursor ion fragmented at a large q value then
the fragment ions which are low in mass than the precursor ion will have greater q values
and will be ejected out of the trap). So, in order to trap small fragment ions it is essential
to cool down the precursor to a lower q value (not 0.83). The fragment ions will not
resonate at the same frequency as the precursor ion (frequency is mass dependent) and
hence will cool down due to collision with the He atoms down to the center of the trap.
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The final step in both full scan and MS/MS is ejection in which ions are scanned out of
the trap and to the detector in order of small mass to large mass. Ramping the ring
electrode RF amplitude to increase the q value of all ions in the trap and scan them out
from small to large mass – mass selective scanning performs ejection. At the same time,
RF is applied to the endcap that makes the ions of same mass oscillate as a group and
they scan out at the same time – resonance ejection.
Detection system comprises of the conversion dynode and electron multiplier. The
conversion dynode is held at a very high voltage of about -15kV (for positive ions) and
the ions exiting the trap are accelerated towards the conversion dynode because of the
high negative potential. The ion strikes the dynode and secondary particles like electrons
are emitted towards the electron multiplier. The electron multiplier increases the electron
current for each ion. When a secondary particle strikes at the cathode, several electrons
are given off, these electrons strike the inner walls of the cathode to give off more
electrons, and thus signal is amplified. These electrons are detected by the anode and
signal is digitized.

Time-of-flight (TOF) mass analyzer

Introduction

Stephens described the construction of a time-of-flight mass spectrometer in the year
1946 [15]. The principle of TOF is ions of different m/z are dispersed in time during their
flight along the field-free drift path of known length. In other words, population of ions
with different m/z but constant kinetic energy will have different velocities while moving
in a field-free region of constant length. Provided the ions start at the same time or at
least within a short time interval, the lighter ions will arrive earlier at the detector than the
heavier ions. This however demands that ions emerge from a pulsed source. This
separation-in-time technique is different from the separation-in-space of traditional
magnetic sectors and quadrupole scanning instruments. The first commercial TOF
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instrument was by Bendix in 1950. These were designed for gas-chromatography mass
spectrometry (GC-MS). The main advantages of a TOF instrument are:
1. in theory, m/z is unlimited
2. from a single ionizing event, the mass spectrum is obtained within a very short
period of time
3. highly sensitive
4. recent improvements in the TOF instrumentation allows for tandem mass
experiments

Principle of TOF Instruments

1. Velocity of ions

The electric charge q of an ion of mass m is equal to the number of charge z times the
electron charge e
Thus,

q = ez
(Note: For singly charged ions q = z)
Force F = Eq
But F = ma where a is acceleration
Therefore,

Eq = ma
a=

Eq
m

a=

du
dt

u=∫

Eq
dt
m
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⎛ Eq ⎞
u = u 0 +⎜
⎟t
⎝ m⎠
t a=

u −u o
E

⎛m⎞
⎜⎜ ⎟⎟
⎝q⎠

We know that the potential energy of ions is converted to their kinetic energy,
qE =

1 2
mv
2

where E is electric field strength and v is drift velocity
Therefore,
1

⎛ 2 Eq ⎞ 2
v=⎜
⎟
⎝ m ⎠

Drift time t D =

D
where D is length of the drift tube
v
1

⎛ m ⎞2
⎟⎟
t D = D⎜⎜
⎝ 2 Eq ⎠

Equation (2)

Observed time-of-flight TOF = t 0 + t a + t D + t d
where,
t0 is time after which the ions starts to accelerate
ta time the ion actually accelerates
tD time in the drift tube when it moves with constant velocity and
td is the response time of the detection system

31

Mass Resolution

In MS, mass resolution is usually given by m/Δm where Δm is the difference in mass. In
TOFMS, since it is separation-in-time domain and from Equation 2
m is proportional to t2
m = At 2
Therefore,

dm
= 2 At
dt
dm
⎛ dt ⎞
= 2⎜ ⎟
dt
⎝ t ⎠

Thus,
m
t
=
Δm Δt

where,
Δt is the full width at half maximum height of the peak (FWHM)

Linear Time-of-flight

A schematic of a linear TOF instrument is shown in figure 2.8. The analyte is in a sample
holder or “target” on which a pulsed laser is focused. An acceleration voltage is applied
between this target and an electrode that is grounded. Due to the potential applied, ions
that are formed and desorbed during the laser pulse are extracted and accelerated into the
flight tube. They drift down a field-free region and hit the detector at the end. This kind
of instrument in which ions travel in a straight line from the point of formation/desorption
to detection is called a linear TOF.
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Laser

Field-free drift region

E
Detector

Acceleration
area

D

Figure 2.8 A schematic of a linear TOF instrument. Two ions of different mass ARE

shown in figure as blue and red filled circles. D is the length of the flight tube and E is
the electric field applied to accelerate the ions.
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The ions theoretically posses similar kinetic energy at the point of desorption and as they
drift in the flight tube, they are separated by their masses. The lighter ions travel faster
than the heavier ones. However in practice, the pulse is not felt by all ions to the same
intensity and a kinetic energy distribution for each discrete m/z exists. This lowers the
resolution by creating a time-of-flight distribution for each m/z [20]. Effects of initial
time, space and kinetic energy distribution on mass resolution is shown in linear TOF are
shown in figure 2.9.

Solution to the energy distribution problem

A technique called time-lag focusing or delayed extraction was introduced by Wiley and
McLaren [21] to overcome the energy distribution. Ionization can be confined to a small
distance and extraction of ions carried out with a delay in time. They devised an
instrument with a pulsed two-grid ion source to compensate for the spatial distribution. In
1966, Mamyrin and coworkers proposed the use of “reflectron” (ReTOF), wherein the
more energetic ions follow a longer trajectory to overcome the temporal spread due to
difference in initial velocity [22]. The reflectron, essentially a mirror, consists of a
decelerating and reflecting field (Figure 2.10). For ions of the same m/z entering such a
field, those with higher kinetic energy (and velocity) will penetrate the decelerating field
further than ions with lower kinetic energy. Therefore the faster ions will spend more
time within the reflecting field, and ‘catch up’ with lower energy ions further down the
flight path. By adjusting the reflectron voltages it is possible to achieve a time-focusing
plane. In this ideal case, the resolution of the peaks in the mass spectrum will only be
dependent on the time-width of ion formation. The angle of ion entry into the reflectron is
set at slightly away from 90° and the ions take a different path after being reflected. This
allows the detector to be placed in a path not along the axis of the ion entry from the
source. The reflector increases the flight path and hence the dispersion in time-of-flight,
the effect is negligible when compared to the capability of the reflectron to compensate
for the initial energy difference. The other time-widening parameters that can affect
resolution are temporal and spatial distribution (figure 2.9) and metastable ion formation.
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Figure 2.9 Effect of initial time, space and kinetic energy distributions in linear TOF
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Figure 2.10 Schematic of the ReTOF
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Reflecting
voltage

Temporal distribution:

The differences in time of ion formation and limitations of the detection system
contribute to the temporal distribution. The ions formed at different times with the same
kinetic energy will travel the field-free region maintaining a constant difference in time.
The resolution is given by
m
t
=
Δm Δt

As dt is constant, the mass resolution can be improved by increasing the flight time by
either decreasing the accelerating potential or my increasing the length of the flight tube.
By applying the potential after a delay, all ions experience the accelerating voltage at
about the same time and dt is reduced.

Spatial distribution

When same mass ions are formed at the same time with the same kinetic energy but at
different locations, the ions formed at the rear of the source will experience larger
potential gradient than the ions formed close to the extraction grid. Ions at the rear will
enter the flight tube later but will reach the detector faster than ions formed close to the
grid because of the higher velocities. The extraction field can be adjusted such that the
ions arrive at a space focus plane in the drift region at the same time. The space focus
plane is independent of mass hence ions of different mass arrive at the plane at different
times. Delayed extraction can also reduce the spatial distribution.

Fragmentation and Mass Resolution

Fragmentation occurs due to excess of internal energy in the ion during the ionization
process. In MS, fragmentation can provide a wealth of information on the identity of the
compound. If the compound is an organic molecule it provides information on the
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functionality and if it is a protein the information can be used to deduce sequence
information. The different types of fragmentation are shown in figure 2.11.

Prompt fragmentation

Metastable fragmentation

Post-source
fragmentation

Figure 2.11 Different types of fragmentation that can occur in TOF. Red filled circle is

parent ion while black filled circle is fragment from the parent ion.
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Prompt fragmentation: If the molecule fragments at the source due to the ionization

impact, it is called prompt fragmentation. The fragment ions have same velocity but since
they have different mass they arrive at the detector at different times.
Metastable fragmentation: If the fragmentation occurs in the acceleration region, then the

ions reach the detector at times between the molecular ion and its fragment resulting in
poor resolution. The ions cause tailing of the molecular ion peak and increased
background noise.
Post-source fragmentation/decay: Any fragmentation is undesirable when the goal is to

identify molecular ion. However, with MALDI the fragmentation can be used to get
sequence information and is like a tandem MS/MS. Ions which fragment in the field-free
region of the drift tube, retain essentially the same velocity as intact ions This
fragmentation is called post-source decay (PSD) and is a result of the laser irradiation and
collision with other molecules (e.g. residual gas). The reflector will separate precursor
and metastable decay ions by their difference in kinetic energy. PSD can be employed to
obtain sequence information from peptides.

2.3 IONIZATION TECHNIQUES

Ionization techniques are critical for converting molecules into ions that can be analyzed
by mass spectrometry. The challenge with biomolecules is to convert the zwitterionic
molecules into gas-phase ions without fragmenting. However, there has been incredible
progress in the ionization techniques that now successful biological mass spectrometry
can be carried out. Two ionization techniques employed in the work towards this
dissertation are discussed below.

Electrospray

Electrospray is essentially a transport process wherein ions in solution are transferred to
gas phase. The application of ES as a source of gas phase ions for mass spectrometric
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studies was first proposed by Dole [23] in 1968 but the work was very focused on
polymers and was not explored any further. The groundbreaking application of ES was
the ionization of biomolecules and their subsequent analysis by mass spectrometry, a
work done by Yamashita and Fenn [24, 25] and John Fenn won the 2002 Nobel Prize in
chemistry for his work on Electrospray-Mass Spectrometry (ESMS). The overall process
of ES involves production of charged droplets at the capillary tip, shrinkage of the drop
by solvent evaporation and subsequent disintegration to form a small drop with a charge
on it and transfer into gas phase (Figure 2.12).
A solution of the analyte is passed through a capillary tube to which a potential of about 4
kV is applied. The counter electrode is a plate with an orifice leading to the mass
analyzer. Since the capillary has a fine tip, the electric field is very high. The typical
solution in the capillary is a polar solvent in which the analyte is soluble. When potential
is applied, the positive and negative ions in solution will move under the influence of the
electric field and in this case the positive ions will move towards the tip of the capillary
i.e. towards the meniscus of the solution. Bombarding against the walls of the capillary
neutralizes the negative ions. The positive ions at the very tip repel each other and this
causes the meniscus to expand and a cone is formed called the Taylor cone[26] and if the
potential is high enough, the cone expands and a fine jet of ions can be sprayed from the
capillary tip. Drops of ions are drifted towards the counter electrode and in this process
solvent evaporation occurs and the drop shrinks. As the drop reduces in size, it splits into
smaller droplets and finally gas phase charged analyte molecules are formed which drift
into the mass analyzer through the holes in the counter electrode.
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Figure 2.12 Ion formation in Electrospray
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There are two theories for the formation of charged analyte molecules from the Taylor
cone – Charge residue model (CRM) and Ion evaporation model (IEM) (Figure 2.13).
Each of these theories are discussed briefly below.

Charge Residue Model

This mechanism was proposed by Dole [23] depends on the formation of extremely small
droplets which should contain only one ion. Solvent evaporation at atmospheric pressure
from such a droplet will lead to a gas phase ion. As the drop shrinks, the columbic energy
exceeds the surface tension of the drop (Rayleigh limit) at which point fission occurs and
the droplet is ripped apart. This fission process continues until small charged ion is
formed.

Ion Evaporation Model

Iribane and Thomson proposed a new mechanism for the production of gas phase ions
from charged droplets [27, 28]. Their theory describes that the radii of the droplets
decrease to a given size (solvent evaporates) and direct ion emission takes place from the
droplets due to columbic repulsion. A detailed explanation on ESMS analysis of proteins
will be discussed in the following section.
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Matrix assisted laser desorption ionization (MALDI)

Early 1960s was the advent of laser desorption ionization (LDI), which involves the
irradiation of low-mass organic molecules with a high intensity laser to form ions that can
be mass analyzed. Laser desorption, however, could not ionize large biomolecules.
Matrix assisted laser desorption ionization (MALDI) was developed by Karas and
Hillenkamp in the late 1980s [29] and is one of the two “soft ionization” techniques that
was capable of ionizing proteins. The other soft ionization technique is the Electrospray
(ES) that was discussed earlier. Koichi Tanaka received the Nobel Prize for Chemistry in
2002 [30], for his developments in the field of MALDI [31].

Principle:

MALDI involves the use of matrix to successfully ionize proteins. The analyte is mixed
thoroughly with a small organic substance. The organic substance has strong absorbance
at the laser wavelength that causes the co-crystallization of both matrix and analyte. The
incorporation of analyte molecules in the lattice of the matrix crystal is the pre-condition
for the laser desorption/ionization process. The crystallized surface of the sample is then
exposed to laser (typically nitrogen laser 337 nm-UV wavelength) under high vacuum
(Figure 2.14). This causes the evaporation of analyte molecules into gas phase. The target
on which the sample is crystallized is floated at about 20 kV. Depending upon the
polarity of ions, they are accelerated towards the mass analyzer, which is usually the
TOF. The mechanism of ionization is still is topic of debate and is not very clear.

43

Sample
Matrix
Target

Laser
Desorption

+
+

Ionization
+

+

Figure 2.14 Matrix assisted laser desorption ionization (MALDI)
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Lasers:

A number of laser wavelengths can be used ranging from ultraviolet (UV) to infrared
(IR). UV lasers are emitting pulses of 3-10 ns duration while those of IR are in the range
of 6-200 ns. UV lasers include Nd-YAG laser (yttrium-aluminum-garnet crystals doped
with neodymium) at wavelengths of 335 nm (tripled frequency) or 266 (four-fold
frequency) and nitrogen laser operating at a wavelength of 337 nm. IR lasers include ErYAG laser (yttrium-aluminum-garnet doped with erbium) that work at wavelengths 294
μm.

Matrix:

The matrix is usually a small aromatic organic compound that can absorb energy at the
laser wavelength. For the analysis of proteins, α-cyano-4-hydroxycinnamic acid (HCCA),
dihydroxy benzoic acid (DHB) and sinapinic acid (SA) are the most used matrices. The
structures of these matrices are shown in figure 2.15.
A good matrix must have the following properties:
•

Have high extinction coefficient at the laser wavelength so that it can absorb
the laser energy

•

Be miscible with the analyte so that the analyte can co-crystallize with it

•

Be stable in vacuum – should not sublime

•

Have proper functional group to provide proton and hence act as a proton
donor for the analyte

•

Should be easily crystallized
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Figure 2.15 Chemical structures of different matrices
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There are a number of ways to “spot” the sample on a target (sample holder). These are
all variations of the basic dried-droplet method which was introduced by Hillenkamp and
Karas in 1988 [32] where the matrix is simply added to the sample on the target, mixed
by pipetting up and down and allowed to air dry. The non-volatile substances may be
washed away, but this method tolerates salts better than the other spotting techniques.
The second common method is the Overlay method, which involves the use of a fast
evaporation to form the first layer of crystals. Then a layer of mixture of analyte and
matrix is applied and allowed to dry. The third method is the sandwich method; here the
analyte is sandwiched between two layers of matrix.

Vacuum:

Vacuum system is an integral part of any mass spectrometer. The reason for maintaining
vacuum in a mass spectrometer is the “mean free path”. The mean free path is defined as
the average distance between molecules before they collide with each other. It is given by
the mathematical formula
Mean free path = 5 * 10-3 Torr cm / P torr
At atmospheric pressure (7.6 x 102 torr), the mean free path will be 2 x10-6 inches, which
is 500 nm. At this distance, there will be lot of collisions and the ions do not accelerate
but travel with a constant velocity. The collisions could also bring about ion/ion reactions
which are not desired. Hence the mean free path should be kept to a maximum and this
can be achieved by decreasing the pressure in the system.

2.4 WESTERN BLOTTING

Blotting is the transfer of biomolecules separated on a gel onto a membrane like
nitrocellulose or polyvinylidene difluoride (PVDF) (Figure 2.16). Blotting was first
performed by Southern in 1975 to transfer DNA from agarose gels to nitrocellulose
membranes [33]. Since then blotting has been applied to both RNA and proteins in both
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agarose and polyacrylamide gels [34, 35]. Towbin et al. came up with the electrophoretic
transfer of proteins from polyacrylamide gels [36]. Western blotting also known as
protein blotting or immunoblotting consists of the following steps:
•

Immobilization of proteins on a membrane by electrophoretic transfer from a
gel (Figure 2.16)

•

Unoccupied sites on the membrane are saturated (blocked) to prevent nonspecific binding of the primary antibody – blocking is done with 5% non fat
dry milk or bovine serum albumin (BSA)

•

The blot is probed using primary antibody against the protein of interest

•

Secondary antibody that is specific for the primary antibody is used for mainly
amplification purposes. The secondary antibody can be radiolabeled or
conjugated with an enzyme

•

Incubation with detection reagents to generate signals that can be quantified

•

Detection using autoradiography

•

Analyze using image analysis software
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Figure 2.16 Gel-membrane sandwich in western blotting
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A number of blotting membranes are available each with a particular advantage
depending on the needs of the experiment. The most commonly used membranes are
nitrocellulose (NC) and poly (vinylidene difluoride) (PVDF). Nitrocellulose was one of
the first membranes used for western blotting. The membrane can be easily wetted and is
compatible with a wide variety of detection systems. When using nitrocellulose, the
transfer buffer should have methanol. PVDF is a hydrophobic support suitable for
proteins. PVDF has a high binding capacity, is more mechanically, and chemically stable
than nitrocellulose. PVDF membranes need to be pre-wetted with methanol but the
transfer buffer need not contain methanol. Once the proteins are transferred to the
membrane, blocked and incubated with the primary antibody for the specific protein of
interest, the membrane is incubated with the secondary antibody that is specific for the
primary antibody. The secondary antibody can be labeled with either enzyme or
radioactive element. The labeling method involving enzyme conjugated secondary
antibody specifically the horseradish peroxidase conjugated secondary antibody system
(ECL) for detection will be discussed in detail.
Enhanced Chemiluminescence Labeling (ECL)
Luminescence is defined as the emission of light resulting from the dissipation of energy
from a substance in an excited state. In chemiluminescence, the excitation is brought
about by a chemical reaction. One of the most clearly understood system is the
horseradish peroxidase/H2O2 catalyzed oxidation of luminol in alkaline conditions. The
luminol is in an excited state following oxidation and then decays to the ground state by
emitting the excess energy in the form of light. Enhanced chemiluminescence is achieved
by carrying out the oxidation of luminol in the presence of enhancers like phenols [37]
(Figure 2.17). This increases the light output approximately 1000 fold and also extends
the time of light emission. The light produced by this enhanced chemiluminescence peaks
after 5-20 min and the decays slowly. The maximum light emission is at 428 nm and this
can be detected by exposure to X-ray film. The X-ray film is then developed and the
bands analyzed using image analysis software.
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2.5 STATISTICAL TREATMENT OF DATA

Several statistical approaches were used to determine the significance of data obtained,
including analysis of variance (ANOVA) with Dunnett’s post hoc test (ABSTAT) for cell
viability data and 2-tailed student’s t test for the differential expression of proteins in 2DE gels (PD Quest).
•

Cell viability data

Cell viability studies were carried out in 96-well culture plates. The cell cutures were
treated with various concentrations of malathion-25 µM, 50 µM, 100 µM, 250 µM, 500
µM, 1000 and 2000 µM of malathion. The cells in eight wells were treated with each
concentration of malathion and the absorbance of the formazan crystals formed were
recorded using a multi-well plate reader. The absorbance from malathion treated cells
were calculated as percentage of absorbance from control cells (not treated with
malathion). ANOVA with Dunnett’s post hoc test was performed to determine the
significance of the data.
•

Malathion study

2-DE was performed four times on whole cell lysate from control cell cultures (no
malathion) and cell cultures treated with 100 μM malathion for 24 hours and 2 times each
on 100 μM malathion for 48 hours, its corresponding control samples and 2 times each on
50 μM malathion for 48 hours and the corresponding control samples. The average
number of spots detected from the fluorescence-stained gel images using the PD Quest
software was about 400 spots in the treated and control gels. Spot quantity was measured
using PD Quest software. Spot quantity is the total intensity of the spot and this
corresponds to the amount of protein in the actual spot in the gel. PD Quest software uses
Gaussian modeling to create “ideal” spots that can be easily identified and quantified. A
Gaussian spot is a 3-D representation of the original scanned spot and this conversion of
the scanned image to Gaussian image is carried out because the image of a spot conforms
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to a Gaussian curve. The formula for calculating the quantity of Gaussian spots in PD
Quest is:

spot height ∗ π ∗ σ x ∗ σ y
where,
spot height is the peak of the Gaussian representation of the spot
that is measured in optical density (OD),
σx is the standard deviation of the Gaussian distribution of the spot
in the direction of the X axis and
σy is the standard deviation of the Gaussian distribution of the spot
in the direction of the Y axis.
Normalization of the spot quantity is carried out to avoid any non-expression related
variations. The spot quantities were normalized to the total density of the gel image. In
this normalization method, the raw quantity of each protein spot in the gel is divided by
the total intensity of the all pixels in the image. Duplicate gels were run for 16 hour and
48 hour treated samples and their corresponding control samples (no treatment with
malathion) while four gels each were run for 24 hour malathion treatment and its
corresponding control sample. The PD Quest software was used to perform statistical
analysis of the differential protein expression. The software allows the selection of
various statistical tests that can be used to determine the significance of data. The
normalized spot quantities from gels carried out for treatments and their corresponding
control samples were subjected to student’s t test. Student’s t test determines the
significance of difference in mean spot volumes between treated and control samples.
The difference in spot volume was considered significant at p values <0.05 at confidence
level of 95%.

•

AD CSF study

A volume of 400 μL each of post mortem human ventricular CSF from 6 AD subjects and
6 control subjects (normal) were individually subjected to crude isolation of albumin53

interactome using Microcon cut-off filters and 2-DE was carried out on each of these
samples. The protein spot quantities were calculated using PD Quest software, as
described above. Similar to the malathion study, spot quantities were normalized to total
density of the gel image. Normalized spot quantities were compared between AD and
control subjects and statistical significance of differences in spot quantities was
determined by Student’s t test using the PD Quest software. The difference in spot
volume was considered significant at p values <0.05 at confidence level of 95%.
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CHAPTER THREE

A FLUORESCENT RUTHENIUM COMPLEX FOR STAINING PROTEINS
SEPARATED BY SDS-PAGE

3.1 Introduction

Two-dimensional gel electrophoresis (2-DE) is a technique that involves the separation of
complex mixtures of proteins based upon their isoelectric point and molecular weight [1].
2-DE is a major player in proteomics, the success of which depends on the detection
method used to visualize and quantify proteins in the gel. A myriad of staining and
visualization protocols are available for proteins [38-43]. Radioactive labeling is by far
the most sensitive method of detection[44] but because of inherent problems like hazards
involved in handling radioactive materials, limited shelf-life, waste disposal and nonsuitability for subsequent mass spectrometry analysis, it has been replaced by other dyes.
Traditional protein stains that are commonly employed include Coomassie Brilliant Blue
R-250 (CBB R-250), colloidal Coomassie blue G-250 (CBB G-250) and silver stains.
Coomassie brilliant blue R-250 involves easy staining and de-staining of proteins in gels
[45, 46]. However, the major disadvantage of this dye is its low sensitivity. CBB R-250
can detect μg to sub-μg levels of proteins [40, 47]. Therefore, either high loads of protein
must be used or the analysis is limited to most abundant proteins. CBB R-250 is a nonpolar, sulfonated aromatic dye (Figure 3.1), a solution of which is made up in methanol
and acetic acid, and the gel is incubated in this staining solution. Acetic acid enhances the
ionic interaction of the dye with the basic amino acids like arginine and lysine as well as
hydrophobic interaction with amino acids like tyrosine, tryptophan, histidine and
phenylalanine in proteins [45]. The excess dye is removed by incubating the gel in a
solution of methanol and acetic acid. Sensitivity is improved with the use of Coomassie
G-250 (a dimethylated derivative of CBB R-250) (Figure 3.2, [48]). CBB G-250 interacts
with the protein in a manner similar to CBB R-250 but it is a colloidal suspension and has
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minimum background staining. CBB G-250 can detect 1 ng of protein; however, involves
a number of repeated staining and de-staining steps and is laborious and time consuming.
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Figure 3.1 Structure of Coomassie brilliant blue R-250 (CBB R-250)
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Figure 3.2 Structure of Coomassie brilliant blue G-250 (CBB G-250)
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Another protein stain that is commonly employed in gel electrophoresis is acidic silver
nitrate (AgNO3). Even though silver nitrate stain has better sensitivity (down to 0.5 ng of
protein) than CBB R-250, it generally involves multiple steps that often require freshly
prepared reagents and critical timing that result in constant hands-on activity. Typically,
two kinds of silver staining are used for the detection of proteins in gels: acidic silver
nitrate and alkaline silver diamine [42]. The acidic silver nitrate staining protocol relies
on the impregnation of the gel with silver ions and its subsequent reduction to metallic
silver at alkaline pH using formaldehyde [47, 49]. The alkaline silver diamine involves
the formation of soluble silver diamine complexes with the proteins and subsequent
reduction of the silver with formaldehyde in an acidified developer [47, 49]. Silver ions
interact with amino acids like cysteine, lysine and histidine in proteins. Silver stain has
poor dynamic range [50]. There is also evidence of peptide losses with silver stain and
problems in identification by mass spectrometry [51].
An alternative to the use of the above mentioned colorimetric dyes is fluorescent protein
labels. With recent developments in new imaging systems, fluorescent detection of
proteins has re-surfaced. Fluorescent detection of proteins can be divided into two
categories: covalent and non-covalent. In covalent labeling, proteins are derivatized with
fluorescent compounds prior to separation by electrophoresis. A critical factor that should
be kept in mind while using these compounds is the difference in migration of derivatized
and un-derivatized proteins in the gel. Also, derivatization of proteins is not always 100%
efficient, and in some cases could lead to other non-specific side reactions that can
possibly affect interpretation of mass spectra. Non-covalent labeling, in contrast, is
performed after electrophoresis. Here the fluorophore interacts directly with the protein
or via SDS-protein complex non-covalently. Sypro Ruby is a ruthenium-based metal
complex luminescent stain developed by Molecular Probes (Eugene, OR) [43].
Advantages of Sypro Ruby include high sensitivity and high linear dynamic range;
however, it is highly expensive to buy commercially patented Sypro Ruby and hence not
cost-effective. Rabilloud et al. reported the synthesis and use of Ruthenium [52]
tris(bathophenanthroline disulfonate) [RuBPS] for detection of proteins in gels with
minimal interference on subsequent analysis using mass spectrometry [53]. RuBPS is a
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fluorescent ruthenium complex that can be synthesized in the lab and has been shown to
detect proteins separated by SDS-PAGE with high sensitivity and high linear range.
Since RuBPS can be prepared in the lab, it offers varied possibilities for modifications
and improvements in formulation. In addition, different staining and destaining protocols
have been reported for RuBPS [54-56]. Lamanda et al. have improved RuBPS staining
by mainly changing the reagent concentration, pH and solvent for staining and destaining
of the chelate.
We explored the possibility of using RuBPS staining solution in our lab and proceeded to
synthesize the ruthenium complex in-house using the Rabilloud protocol. Five hundred
milliliter of Sypro Ruby solution can be used to stain only 2 large format gels and it is not
advisable to re-use the stain. Considering the number of gels run in our lab on a daily
basis, we wanted to explore cost-effective options for fluorescent staining.
The goal of this project was to synthesize and optimize the formulation of a ruthenium
complex that could be used as a cost-effective fluorescent protein stain after gel
electrophoresis.

3.2 Materials and Methods

3.2a Chemicals
Low range marker proteins for SDS-PAGE (Bio-Rad Labs, CA) had equal amounts of
rabbit muscle phosphorylase B (97 kDa), bovine serum albumin (66 kDa), hen egg white
ovalbumin (45 kDa), bovine carbonic anhydrase (31 kDa), soybean trypsin inhibitor (21
kDa), hen egg white lysozyme (14 kDa). The silver nitrate stain (ProteoSilver Plus) was
from Sigma (St. Louis, MO), Colloidal Coomassie Blue from Fisher Scientific (Fairlawn,
NJ) and Sypro Ruby was obtained from Molecular probes (Eugene, OR). Other
electrophoresis chemicals like SDS, ammonium persulfate, TEMED, acrylamide,
bisacrylamide, tris base and glycine were purchased from Sigma (St. Louis, MO).
Potassium pentachloro ruthenate was purchased from Alfa Aesar (Ward Hill, MA),
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bathophenanthroline and bathophenanthroline disulfonate were purchased from GFS
Chemicals (Columbus, OH) and the fluorescent RuMS was purchased from Biotium
(Hayward, CA).

3.2b Synthesis of Ruthenium II tris (bathophenanthroline disulfonate) (RuBPS)
RuBPS (Figure 3.3) was synthesized using the protocol published by Rabilloud et al.[53].
Briefly, 0.089 g of potassium pentachloro aqua ruthenate (K2Cl5 Ru.H2O) was dissolved
in 10 mL of boiling water and kept under reflux. A reddish brown solution was obtained.
A three molar equivalent of bathophenanthroline disulfonate, disodium salt (0.4 g) was
added to the solution and refluxing was continued for about 20 min till the solution
turned deep greenish brown. A reducing solution of 8 mM sodium ascorbate dissolved in
10 mL of water was prepared and added to the solution and refluxing was continued for
another 20 min until the solution turned orange brown. After cooling, the pH was
adjusted to 7 with sodium hydroxide and the volume was adjusted to 50 mL with absolute
alcohol. The final concentration of the stock solution was approximately 500 μM.

3.2c Synthesis of Ruthenium II (bis (bathophenanthroline disulfonate)
(bathophenanthroline)) (RuDS)
RuDS (Figure 3.4) was synthesized similar to RuBPS as described in the previous
section. However, 2 molar equivalents of bathophenanthroline disulfonate disodium salt
(0.2684 g) and one molar equivalent of bathophenanthroline (0.0833 g) were mixed with
0.089 g of ruthenium salt, refluxed and the synthesis continued as explained in the
previous section. The concentration of RuDS solution is 500 μM.
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3.2d Synthesis of Ruthenium II (bis (bathophenanthroline) (bathophenanthroline
disulfonate)) (RuMS)
The fluorescent ruthenium chelate RuMS (Figure 3.5) was synthesized as described
previously [53] with slight modifications. A 0.089 g of potassium pentachloro aqua
ruthenate (K2Cl5 Ru.H2O) was dissolved in 10 mL of boiling water and kept under reflux.
A reddish brown solution was obtained. One molar equivalent of bathophenanthroline
disulfonate, disodium salt (0.1342 g) and 2 molar equivalents of bathophenanthroline
(0.1666 g) were added and refluxing was continued for another 20 min until the solution
turned deep greenish brown. A reducing solution of 8 mM sodium ascorbate dissolved in
10 mL of water was added to the refluxing solution and refluxing was continued for
another 20 min until the solution turned orange brown. After cooling, the pH was
adjusted to 7 with sodium hydroxide and volume adjusted to 50 mL with absolute
alcohol. The final concentration of stock solution was approximately 500 μM.

3.2e 1D gel electrophoresis
Proteins that make up the low range molecular weight markers from Bio-Rad were
separated by SDS-PAGE in the standard Laemmeli Tris-glycine system [13]. The
molecular weight markers were diluted 100 and 2000 fold in SDS sample buffer to reach
a concentration of 20 and 1 ng/μL respectively for each protein in the mixture. The
required volumes were loaded on top of a 12% separating and 4% stacking mini
polyacrylamide gel (7 cm) to give appropriate amounts of each protein band ranging from
100 ng to 0.5 ng. The running buffer contained 25 mM Tris, 192 mM glycine and 0.1%
SDS, pH 8.3 and electrophoresis was performed at constant 150 V until the dye front
reached the bottom of the gel.
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3.2f Characterization of in-house synthesized ruthenium complexes
•

Fluorescence spectroscopy

Excitation and emission spectra of RuMS was obtained using Spex 1681 0.22 m
spectrofluorometer. Emission wavelength was set to 610 nm and excitation spectrum was
collected from 250 to 550 nm. For the emission spectrum, the excitation wavelength was
set to 470 nm and the spectrum was collected from 500 to 750 nm.

•

MALDI-TOF mass spectrometry

Both MALDI and laser desoprtion mass spectra were generated for the in-house
synthesized ruthenium complexes using the Bruker Autoflex time-of-flight mass
spectrometer (Billerica, MA). For MALDI spectra, a solution of 1 μL HCCA (10 mg/mL
of α-cyano-4-hydroxycinnamic acid in 90% acetone and 2% TFA) was spotted on a
sample target. A volume of 0.2 μL stock ruthenium complex solution was spotted on the
matrix spot, allowed to air dry and spectra were acquired.

•

Paper chromatography

Paper chromatography was carried out on a Whatmann filter paper with various
percentages of solvents like tetrahydrofuran, water and ethanol as solvents. Two
microliter of the in-house synthesized ruthenium complexes were spotted about 1 cm
above the base of the paper and separation carried out in a closed chamber until the
solvent front traveled about three fourths of the distance on the paper.

•

Crystallization

Crystallization of in-house synthesized ruthenium complexes was carried out to obtain Xray crystallography data on these different complexes. Various percentages of solvents
like ethanol, isopropyl alcohol and THF were tried for this purpose.
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3.2g Staining of mini gels
•

Colloidal Coomassie blue stain

Colloidal Coomassie blue staining of SDS-PAGE gels were performed as described by
Neuhoff et al. [48]. Briefly, gels were fixed with 50 mL of aqueous solution containing
1.3% (w/v) of ortho phosphoric acid and 20% (v/v) methanol for 1 hour. Staining
solution was prepared by mixing 1 mL of freshly prepared staining solution B (containing
aqueous 5% (w/v) Coomassie brilliant Blue G-250) and 40 mL of aqueous staining
solution A (containing 2% w/v of ortho phosphoric acid, 10% w/v ammonium sulfate)
with 10 mL of methanol. The gels were stained overnight in the staining solution. The
next day, gels were transferred into a neutralization buffer containing aqueous 0.1 M
Tris-base pH 6.5 (titrated with ortho phosphoric acid) for 2 min. The background was
then washed with 25% methanol solution for less than 1 min and gels were transferred
into an aqueous stabilizing solution containing 20% ammonium sulfate. The gels stay in
the stabilization solution for a day and further staining was carried out as mentioned
above without the fixing step. Staining was repeated three times which improved
sensitivity and at the end of the third staining step about 0.5 ng of protein was detected.
The volumes mentioned here are for one gel.

•

Silver stain

Silver staining was performed using Pierce Proteosilver Plus kit (Rockford, IL). Staining
was carried out as per manufacturer’s instruction. Briefly, the gels were fixed in 50%
ethanol and 10% acetic acid solution overnight. Thenthe gels were washed with 30%
ethanol for 10 min, decanted the ethanol solution and washed with ultra pure water for 10
min. The gels were incubated in the sensitizing solution (500 μL of Proteosilver
Sensitizer in 50 mL ultra pure water) for about 10 min. Gels were washed twice with
water for 10 min each and then incubated in silver solution (500 μL of Proteosilver Silver
in 50 mL ultra pure water). After a brief wash in water, the gels were developed in the
developer solution (2.5 mL of Proteosilver developer and 50 μL developer 2 in 50 mL of
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ultrapure water) until desired staining is achieved and 2.5 mL of Proteosilver stop
solution was added to this developer solution to stop the reaction and incubated the gel in
this solution for about 5 min. Carbon dioxide formed was seen as bubbles in the solution.
The solution was discarded and the gels were incubated in ultrapure water for about 15
min. The gels were stored in pure water. All solutions were prepared freshly before use.
Silver nitrate binds to proteins (amino acids- cysteine, lysine and histidine) in the gel
under weakly acidic pH. The silver ions bound to proteins are reduced by formaldehyde
at alkaline pH to form metallic silver which gives the protein black to dark brown color
the intensity of which depends on the concentration of protein present.

•

Sypro Ruby staining

Gels were stained with Sypro Ruby per manufacturer’s instructions [43]. Briefly, gels
were incubated in the Sypro Ruby solution overnight. The volume of staining solution
used is about 50 mL per mini gel, which is roughly 10 times the volume of the gel. After
staining, gels were rinsed in 10% methanol and 7% acetic acid for at least 30 min to
remove residual dye and then stored in fresh pure water.

•

Ruthenium II tris (bathophenanthroline disulfonate) staining

Staining and destaining for RuBPS was performed using the most recent modified
protocol [56]. Briefly, proteins in the gel were fixed using 30% ethanol and 10% acetic
acid solution overnight. The gels were washed with 20% ethanol three times 30 min each
and then incubated in 150 nM (15 μL in 50 mL of 20% ethanol) staining solution for 6
hours. The gels were equilibrated with water for about 10 min and then background stain
was removed by washing in destaining solution containing 40% ethanol and 10% acetic
acid overnight. The gels were then washed in water for 10 min and scanned.
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•

Ruthenium II (bis (bathophenanthroline disulfonate)) (bathophenathroline)
staining (RuDS)

Staining of gels with the RuDS form of the ruthenium complex was performed similar to
RuBPS staining protocol with some modifications. Gels were fixed overnight with 30%
ethanol and 10% glacial acetic acid and washed with 20% ethanol solution three times 30
min each time. Gels were incubated in staining solution containing 150 nM of RuDS in
20% ethanol (15 μL of the stock in 50 mL of 20% ethanol) overnight, quickly rinsed with
water and then destained with 10% ethanol and 5% acetic acid till desired intensity was
obtained and the gel was scanned.

•

Ruthenium II (bis (bathophenanthroline) (bathophenanthroline disulfonate))
staining (RuMS)

Various solvents were tested for optimal staining of proteins with RuMS. The protocol
that gave best signal to noise ratio is described here. Briefly, RuBPS staining and
destaining protocol [53] was used with slight modification. The gels were fixed overnight
with 30% v/v ethanol and 10% v/v acetic acid. The gels were then rinsed with 20%
ethanol three times 30 min each and incubated in staining solution overnight in 20%
ethanol containing 150 nM of the ruthenium chelate (15 μL of stock solution in 50 mL
20% ethanol). Gels were washed for at least 15 min with water. Stained gels were stored
in pure water.

•

Commercial RuMS staining

A stock staining solution of 16 μM of commercial source of RuMS was prepared by
dissolving 1 mg of the fluorescent compound in 50 mL of absolute alcohol. An aliquot of
the stock staining solution (4 mL in 20% ethanol – 125nM) was used to stain proteins in
gels.
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3.2h Imaging of stained gels
Stained gels were scanned with a Versadoc 3000 scanner from Bio-Rad (Hercules, CA).
Sypro Ruby and ruthenium chelate stained gels were visualized using 520 nm emission
filter and UV light. CBB G-250 and silver stained gels were visualized on a white light
background using a 610 nm emission filter. Exposure time for Sypro Ruby and ruthenium
complex stained gels were 2.5 sec while for colloidal Coomassie and silver exposure time
was 0.5 sec. Images were analyzed by Quantity One software. Band volumes were
estimated after applying global background correction. The images were taken under
essentially identical settings and with the same instrumentation to enable direct
comparison.

3.2i In-gel proteolysis
Protein bands were excised from the gel using the Spot-cutter from Bio-Rad and in-gel
proteolysis was carried out with trypsin. In brief, the gel pieces were washed 6 times
alternating with 50 mM NH4HCO3 and 1:1 ACN: NH4HCO3 (50 mM) for 5 min each at
20°C and dried with ACN for 10 min at 20°C. A volume of 10 μL of trypsin (66.67 ng) in
25 mM NH4HCO3 was added and gel pieces allowed to swell for 30 min at 20°C and
digested at 50°C for 4 hours. Peptides were extracted with 10 μL of 1% aq. formic acid at
20°C for 30 min.

3.2j In-gel trypsin digestion of proteins from silver stained gels
Trypsin digestion of proteins from silver stained gels was performed as described by
Mann et al. [57] with slight modifications. In short, all pre-washing steps were omitted.
The gels plugs were excised and shrunk with acetonitrile and dried in a vacuum
centrifuge. A volume of 10 mM dithiothreitol (DTT) in 50 mM NH4HCO3 sufficient
enough to cover the gels pieces was added and incubated at 56°C for 1 hour. After
cooling the samples to room temperature, 55 mM iodoacetamide in 50 mM NH4HCO3
was added and incubated at room temperature for 45 min in the dark. The gel pieces were
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then washed with 50 mM NH4HCO3 for 10 min, dehydrated with acetonitrile. Ten μL of
trypsin (66.67 ng) in 25 mM NH4HCO3 was added and gel pieces allowed to swell for 30
min at 20°C and digested at 37°C overnight. Peptides were extracted with one change of
25 mM NH4HCO3 and three changes of 5% formic acid in 50% acetonitrile at room
temperature for 20 min each time and dried down.

3.2k MALDI-TOF mass spectrometry
MALDI-TOF mass spectra were generated using Bruker Autoflex (Billerica, MA) in the
reflectron mode. HCCA matrix solution was spotted on an Anchorchip target and 1.5 μL
of peptide solution was spotted on top of the matrix and allowed to dry. On-target
washing was carried out with 0.2% TFA. The spectra were externally calibrated against
the monoisotopic mass of a standard solution containing 1 µg/µL bradykinin ([M+H]+
757.399), vasopressin ([M+H]+ 1084.445), angiotension II ([M+H]+1046.542), substance
P ([M+H]+ 1347.735) and oxidized form of substance P ([M+H]+ 1363.731) and
internally calibrated using the known trypsin autolysis peaks. Database search was
performed using the Mascot software (www.matrixscience.com).

3.2l Liquid Chromatography-Tandem Mass spectrometry
The trypsin digested samples were analyzed using a Thermo Corporation’s LCQ Classic
quadrupole ion trap mass spectrometer (San Jose, CA). The tryptic peptides were
resolved on a fused silica capillary column. The column was fabricated in-house by
packing 15 cm of Phenomenex Polymer X (3 μm particle size) into a 320 μm I.D fused
silica capillary using a home-made stainless steel packing cell pressurized with helium to
1000 psi. The tryptic peptides were eluted using a typical gradient elution. Spectra were
acquired with a probe spray voltage of 4 kV and a heated capillary temperature of 175ºC.
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3.3 Results

3.3a Characterization of ruthenium complexes
•

Fluorescence spectroscopy

Excitation and emission spectra of the ruthenium complex RuMS synthesized in the lab
were recorded using a Spex 1681 spectrofluorometer (Figure 3.6). There are two
absorption peaks for the complex similar to Sypro Ruby, one at ~280 nm and a broad one
at ~450 nm. The fluorescence emission spectrum has one broad peak at 610nm.

•

MALDI-TOF mass spectrometry

Mass spectrometry was employed to characterize the in-house synthesized ruthenium
complexes. The base peak observed in all the spectra obtained for the various ruthenium
complexes is an m/z of 766 (Figure 3.7-3.9). Table 3.1 gives the different mass peaks that
were observed in the MALDI-TOF spectra for various in-house synthesized ruthenium
complexes.

•

Paper chromatography

The highly polar nature of sulfonic acid groups in the ruthenium complexes makes it
difficult to separate the complexes using thin layer chromatography (TLC). Since the
silanol groups in silica gel are also polar, the polar complex binds tightly to the solid
phase and will not move much with the mobile phase. Under such circumstance, paper
chromatography is a better option to resolve the polar complexes. Table 3.2 summarizes
the chromatographic data for these compounds.
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Figure 3.6 Excitation (A) and Emission (B) spectra of in-house RuMS

72

Table 3.1 Peaks observed in MALDI-TOF mass spectrum of different ruthenium

complexes synthesized in-house. x – indicates ion not observed while 3 - indicates observation of
the ion in the mass spectrum

Form of Complex

Peaks
(m/z)

RuNS

RuMS

RuDS

RuBPS

x

x

3

Probable ion

(all
nonsulfonated
ligand)

457.96

x

(base peak)
766.05

801.02

3

3

3

(base peak)

(base peak)

(base peak)

3

3

3

Found in sulfonated ligand mass
spectrum

x

Ruthenium attached to two

3

Ruthenium attached to two

bathophenanthrolines

bathophenanthrolines and a Cl

Very small amount found in non
sulfonated ligand mass spectrum

817.49

3

3

3

x

1098

3

3

x

x

Ruthenium + three bathophenanthroline

1113

3

3

3

x

Very small amount found in the non-

1194

x

3

3

3

Ruthenium MS minus a SO3
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Figure 3.7 MALDI-TOF spectrum of ruthenium tris bathophenanthroline using HCCA matrix. Inset A is expanded mass range from
750-850 m/z and inset B is expanded mass range from 1080-1150 m/z
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Figure 3.8 MALDI-TOF spectra of in-house synthesized RuMS complexes using HCCA matrix. Inset A is expanded mass range
from 750-850 m/z and inset B is expanded mass range from 1080-1150 m/z
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Figure 3.9 MALDI-TOF spectra of in-house synthesized RuDS complexes using HCCA matrix. Inset A is expanded mass range
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77

m/z

Table3.2. Summary of chromatographic data for various in-house synthesized ruthenium

complexes.

Rf values (distance traveled by the component/distance
Compound

traveled by the solvent)
Water

50:50 water: THF

In-house RuMS

0.42, 0

0.16, 0.33

RuDS

0.42, 1

0.66, 0.83

RuBPS

0.42, 1

0.66, 0.83

Commercial RuMS

0.42

1.0

3.3b Staining efficiency of various ruthenium complexes synthesized in-house
A comparison of the effectiveness of three different in-house synthesized ruthenium
complexes showed that RuMS form worked best by detecting 0.5-1 ng of protein (Figure
3.11). Sensitivity of the RuBPS was only about 5 ng of protein.

3.3c Optimization of in-house RuMS stain
A critical parameter for successful staining of proteins is the formulation of the stain in a
suitable solvent. Various solvents like ethanol, methanol and isopropyl alcohol were used
as solvent for the formulation of RuMS (Figure 3.12, 3.13). The concentration of RuMS
in the working solution was also optimized (Figure 3.14). Desired staining of proteins
with minimal background was obtained with 150 nM RuMS in 20% ethanol solution.
When solvent other than ethanol was used or when greater concentration of ethanol was
used in the formulation, there was increased background staining due to non-specific
binding of the stain to the polyacrylamide matrix.
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Figure 3.11 Serial dilutions of standard low range marker proteins stained with in-house

synthesized ruthenium complexes.The amount of protein indicated is nanogram of each
low-range marker protein.
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Figure 3.12 Optimization of solvent for staining proteins with in-house synthesized

RuMS. (A) 20% methanol, (B) 20% ethanol and (C) 20% isopropyl alcohol. The amount
of protein indicated is nanogram of each low-range marker protein.
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Figure 3.13 Optimization of ethanol composition for in-house RuMS staining solution.

(A) 20% ethanol and (B) 50% ethanol. The amount of protein indicated is nanogram of
each low-range marker protein.
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Figure 3.14 Optimization of concentration of in-house RuMS in the staining solution.

(A) 150 nM RuMS and (B) 200 nM RuMS. The amount of protein indicated is nanogram
of each low-range marker protein.
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3.3d Optimization of commercial RuMS stain
Commercial RuMS was purchased from Biotium (Hayward, CA) and used to stain
proteins in gels. Figure 3.15 and 3.16 show the gel images for the optimization of solvent
for commercial RuMS stain. Figure 3.17 is the gel image for the optimization of
concentration of RuMS in the staining solution. The commercial RuMS staining was
compared to the in-house synthesized RuMS stained gel (Figure 3.18).
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Figure 3.15 Optimization of solvent composition for commercial RuMS staining

solution. Different solvents were used to stain the gels (A) 50% aq. ethanol, (B) 50% aq.
isopropyl alcohol. The amount of protein indicated is nanogram of each low-range
marker protein.
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Figure 3.16 Optimization of solvent composition for commercial RuMS staining

solution. Different solvents were used to stain the gels (A) 20% aq. ethanol and (B) 20%
aq. isopropyl alcohol. 20% aq. ethanol gave the maximum sensitivity with least
background staining. The amount of protein indicated is nanogram of each low-range
marker protein.
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Figure 3.17 Optimization of concentration of commercial RuMS in the staining solution.

(A) 62.5 nM (B) 125 nM and (C) 250 nM of commercial RuMS in staining solution. The
amount of protein indicated is nanogram of each low-range marker protein.
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Figure 3.18 Comparison in staining between in-house synthesized RuMS and

commercial RuMS. The amount of protein indicated is nanogram of each low-range
marker protein.
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3.3e Sensitivity of various staining solutions
To assess the staining sensitivity of silver, colloidal coomassie, Sypro Ruby and in-house
ruthenium II (bis (bathophenanthroline) (bathophenanthroline disulfonate)), serial
dilutions of the low range molecular weight markers from 100 to 0.5 ng per lane was
separated by SDS-PAGE. A batch of three gels was run for each stain and all 12 gels
were run to the same pattern. Figure 3.19 gives the representative gels stained with
colloidal Coomassie, silver, commercial Sypro Ruby and in-lab made ruthenium
complex.

3.3f Linear dynamic range
To compare the linearity in staining of standard proteins between different stains, the
volume of the protein band which represented the total pixel density of each band with
the background density removed were measured using Quantity One imaging software
and exported to Microsoft Excel (Table 3.3, Figure 3.20 and 3.21). The band volumes for
5 ng of standard proteins were normalized to values from Sypro ruby stained gel and the
histogram plotted to compare sensitivity of the different stains (Figure 3.22).
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Figure 3.19 Representative gels stained with colloidal CCB G250 (A), Silver nitrate (B),

in-house synthesized RuMS (C) and Sypro Ruby (D). The amount of protein indicated is
nanogram of each low-range marker protein.
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Figure 3.20 Linearity of staining of standard proteins using colloidal Coomassie (A) and

silver (B). Key for proteins () phosphorylase B; () bovine serum albumin; ()
ovalbumin; (¯) carbonic anhydrase; (¼) trypsin inhibitor; (y) lysozyme
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Figure 3.21 Linearity of staining of standard proteins using in-house RuMS (a) and

Sypro Ruby (b). Key for proteins () phosphorylase B; () bovine serum albumin; ()
ovalbumin; (¯) carbonic anhydrase; (¼) trypsin inhibitor; (y) lysozyme
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Table 3.3 Band volumes for different loads of standard proteins in gels stained with

different staining solutions

Protein band volume ± standard deviation

(intensity units/ mm2)

Amount
of

Phosphorylase

BSA

Ovalbumin

protein

Carbonic

Trypsin

anhydrase

Inhibitor

Lysozyme

loaded
(ng)

Silver

CCB G250

Sypro
Ruby

RuMS

100

1550 ± 8.9

1690 ± 9.3

1581 ± 9.8

1756 ± 8.1

2089 ± 18

1818 ± 12

50

1337 ± 10

1470 ± 7.5

1401 ± 9.7

1585 ± 9.0

1760 ± 13

1640 ± 16

25

1198 ± 12

1298 ± 4.1

1269 ± 9.0

1403 ± 9.4

1497 ± 18

1336 ± 15

10

1076 ± 8

1172 ± 5.4

1137 ± 9.2

1306± 6.5

1352 ± 17

1228 ± 11

5

1010 ± 6

1132 ± 1.4

1108 ± 8.4

1260 ± 4.1

1277 ± 17

1170 ± 12

1

1001 ± 6

1070 ± 5.6

1098 ± 4.3

1204 ± 2.1

1191 ± 16

1114 ± 12

½

991 ± 6

1095 ± 0.33

1066 ± 4.4

1194 ± 3.0

1045 ± 23

1086 ± 11

100

1345 ± 11

1432± 8.70

1036 ± 10

1573 ± 7.5

1880 ±0.9

1167 ± 13

50

1053 ± 10

1160 ± 10

860 ± 11

1293 ± 9.5

1401 ±8.0

854 ± 13

25

905 ± 16

1006 ± 12

771 ± 12

1132 ± 10

1185 ± 12

697 ± 16

10

816 ± 16

902 ± 13

723 ± 13

1029 ± 17

1000 ±8.9

553 ± 14

5

748 ± 18

848 ± 13

676 ± 18

961 ± 16

877 ± 6.4

N/A

1

675 ± 22

756 ± 14

N/A

871 ± 11

783 ± 7.6

N/A

½

656 ± 22

720 ± 15

N/A

741 ± 7.5

717 ± 4.6

N/A

100

683 ± 2.0

848 ± 1.5

652 ± 3.4

581 ± 2.9

1175 ±1.0

502 ± 2.2

50

452 ± 2.4

503 ± 3.7

427 ± 1.9

360 ± 3.1

662 ± 2.2

332 ± 3.0

25

335 ± 3.6

340 ± 3.8

323 ± 4.9

246 ± 3.3

451 ± 4.0

257 ± 4.3

10

269 ± 4.8

234 ± 4.7

243 ± 4.5

204 ± 1.5

283 ± 2.5

203 ± 1.5

5

236 ± 5.1

140 ± 0.71

186 ± 1.6

186 ± 5.4

199 ± 4.5

155 ± 7.7

1

176 ± 3.4

124 ± 4.0

145 ± 6.2

157 ± 4.5

136 ± 7.4

142 ± 11

½

156 ± 5.1

105 ± 2.6

110 ± 1.8

119 ± 5.1

113 ± .88

113 ± 1.8

100

321 ± 3.6

371 ± 1.7

415 ± 3.4

358 ± 2.4

525 ± 1.6

339 ± 3.8

50

262 ± 3.3

294 ± 2.8

345 ± 3.4

285 ± 4.1

392 ± 3.0

274 ± 3.6

25

233 ± 5.1

249 ± 2.3

285 ± 4.3

257 ± 2.1

318 ± 1.2

238 ± 4.6

10

222 ± 3.5

224 ± 1.7

265 ± 4.0

228 ± 2.9

282 ± 1.6

212 ± 2.5

5

210 ± 2.0

219 ± 1.4

256 ± 2.1

219 ± 1.6

255 ± 5.0

198 ± 4.4

1

201 ± 1.1

206 ± 5.5

243 ± 4.1

206 ± 3.0

223 ± 4.7

191 ± 3.8

½

195 ± 2.0

194 ± 2.7

242 ± 4.5

205 ± 3.8

202 ± 3.3

184 ± 2.8
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Figure 3.22 Histogram of normalized band volume for 5 ng of standard proteins (Phos-

phoshorylase A, BSA- bovine serum albumin, Oval- ovalbumin, CA- carbonic anhydrase,
Tryp- trypsin inhibitor and Lyso- lysozyme) in gel stained with different stains.
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3.3g Compatibility with mass spectrometry
Improved detection of protein alone is not sufficient for successful proteomic studies.
The stain must be compatible with subsequent protein identification by mass
spectrometry. To evaluate the compatibility of different stains with mass spectrometry,
gels plugs were harvested and in-gel proteolysis was carried out with trypsin. The
resulting tryptic peptides were subjected to both matrix assisted laser desorption
ionization (MALDI-TOF) and liquid chromatography tandem mass spectrometry (LCMS/MS).

•

Stain compatibility with MALDI-TOF

Tryptic peptides were subjected to MALDI-MS as described earlier. A representative
peptide mass fingerprint (PMF) analysis for all the 100 ng BSA protein is shown in figure
3.23. The summarized MALDI data from all the trypsin-digested proteins is provided in
table 3.4

•

Stain compatibility with LC-MS/MS

Data dependent MS/MS experiments were performed on a Thermo LCQ Classic
quadrupole ion trap mass spectrometer. Mass spectra were searched against the human
sub database from the Swiss-Prot database using Mascot algorithm. One missed trypsin
cleavage was allowed and a variable modification of oxidation of methionine was set.
Peptide tolerance and MS/MS tolerance were both set at ± 0.8 Da. Representative spectra
are shown in figure 3.24. Table 3.5 summarizes the LC-MS/MS data for all the trypsindigested samples.
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Figure 3.23 MALDI-TOF spectra for 100 ng of bovine serum albumin from gels stained

with different stains.
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Table 3.4 Summary of MALDI-TOF data for different protein loads of standard proteins (BSA- bovine serum albumin and

trypsin inhibitor) in gel stained with various stains- CCB G250- colloidal coomassie, silver nitrate, Sypro Ruby and in-house
RuMS.
Stain

Protein

ng of

# of

protein

peptides

Database

Mowse

match

score

Sequence of matched peptides

%
Coverage

detected
IETMREK (M-oxidized), YLYEIAR,NECFLSHK,
100

7

yes

92

11

50

4

no

55

n/a

25

3

no

40

n/a

ALKAWSVAR, DTHKSEIAHR, LGEYGFQNALIVR
YLYEIAR, DTHKSEIAHR, LGEYGFQNALIVR,
KVPQVSTPTLVEVSR
YLYEIAR, LGEYGFQNALIVR,
KVPQVSTPTLVEVSR

BSA
QNCDQFEK,
10

2

no

28

n/a

NYQEAKDAFLGSFLYEYSR

5

0

no

n/a

n/a

n/a

CCB

GIGTIISSPYR, NKPLVVQFQK,

G250

100

4

yes

77

22

VSDDEFNNYK,
AAPTGNERCPLTVVQSR
AAPTGNER, GIGTIISSPYR,

Trypsin

50

3

yes

57

13

FIAEGHPLSLK

25

5

yes

95

15

NKPLVVQFQK,

10

0

no

n/a

n/a

n/a

5

2

no

38

n/a

GIGTIISSPYR, NKPLVVQFQK

AAPTGNER, GIGTIISSPYR,

inhibitor

GIGTIISSPYRIR, NKPLVVQFQKLDK

95

Stain

Protein

ng of

# of

Database

Mowse

%

protein

peptides

match

score

Coverage

Sequence of matched peptides

detected

BSA

Acidic

100

3

no

40

n/a

TVMENFVAFVDK, LSQKFPK, KQTALVELLK

50

0

no

n/a

n/a

n/a

25

0

no

n/a

n/a

n/a

10

2

no

27

n/a

TVMENFVAFVDK, LCVLHEK

5

3

no

40

n/a

LRCASIQK, LUVSTQTALA, CCTESLVNR

1

0

no

n/a

n/a

n/a
AAPTGNER, NELDKGIGTIISSPYR, GIGTIISSPYR,

Silver

IGENKDAMDGWFR,IGENKDAMDGWFR (M-oxidized),

nitrate
100

8

yes

134

26

50

5

yes

76

14

DAMDGWFR, VSDDEFNNYK, NKPLVVQFQK
AAPTGNER, GIGTIISSPYR, IGENKDAMDGWFR,
DAMDGWFR,DAMDGWFR (M-oxidized)
AAPTGNER, NELDKGIGTIISSPYR, GIGTIISSPYR,
IGENKDAMDGWFR,IGENKDAMDGWFR (M-oxidized),

Trypsin inhibitor

25

8

yes

115

21

DAMDGWFR,DAMDGWFR (M-oxidized),
NKPLVVQFQK

10

0

no

n/a

n/a

n/a

5

0

no

n/a

n/a

n/a

1

0

no

n/a

n/a

n/a
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Stain

Protein

ng of

# of

Database

Mowse

%

protein

peptides

match

score

Coverage

Sequence of matched peptides

detected
FKDLGEEHFK, LVNELTEFAK, YLYEIAR,
DAFLGSFLYEYSR,RHPEYAVSVLLR,
100

7

yes

98

12

HLVDEPQNLIK, LGEYGFQNALIVR
FKDLGEEHFK, LVNELTEFAK,
YLYEIAR, DAFLGSFLYEYSR,

50

8

yes

104

14

RHPEYAVSVLLR,HLVDEPQNLIK,
LGEYGFQNALIVR, KVPQVSTPTLVEVSR

BSA

FKDLGEEHFK, LVNELTEFAK,
25

6

yes

84

10

10

0

no

n/a

n/a

5

0

no

n/a

n/a

YLYEIAR, RHPEYAVSVLLR,
HLVDEPQNLIK, LGEYGFQNALIVR

13
Sypro

100

3

yes

57

n/a
n/a
AAPTGNER, GIGTIISSPYR,
FIAEGHPLSLK

Ruby

AAPTGNER, GIGTIISSPYR,
50

3

yes

57

13

NKPLVVQFQK
KNHGLSR, AAPTGNER,

Trypsin

25

5

yes

95

21

GIGTIISSPYR, FIAEGHPLSLK, CPLTVVQSR
AAPTGNER, GIGTIISSPYR,

inhibitor
10

5

yes

95

23

NKPLVVQFQK, FIAEGHPLSLK,
VSDDEFNNYK

5

0

no

97

n/a

n/a

n/a

Stain

Protein

ng of

# of

Database

Mowse

%

protein

peptides

match

score

Coverage

Sequence of matched peptides

detected
YLYEIAR, SEIAHRFK,TPVSEKVTK,
RHPEYAVSVLLR,LGEYGFQNALIVR,
100

8

yes

113

14

DAFLGSFLYEYSRKVPQVSTPTLVEVSR,
LGEYGFQNALIVRYTR
YLYEIAR, LVNELTEFAK, FKDLGEEHFK,
AFLGSFLYEYSR, DTHKSEIAHR, RHPEYAVSVLLR,

BSA

LGEYGFQNALIVR,KVPQVSTPTLVEVSR,
50

9

yes

130

14

HLVDEPQNLIKQNCDQFEK
YLYEIAR, RHPEYAVSVLLR, LGEYGFQNALIVR,

25

5

yes

72

17

DAFLGSFLYEYSR,KVPQVSTPTLVEVSR
DTHKSEIAHR, HKPKATEEQLK,

RuMS

10

3

no

43

n/a

DDPHACYSTVFDK

5

1

no

15

n/a

LCVLHEK
AAPTGNER, DAMDGWFR
(M-Oxidized), GIGTIISSPYR, FIAEGHPLSLK,
NKPLVVQFQK, IGENKDAMDGWFR (M-Oxidized),
NELDKGIGTIISSPYR

100

7

yes

134

26

50

4

yes

76

18

NKPLVVQFQK, FIAEGHPLSLK

25

3

yes

57

13

AAPTGNER, GIGTIISSPYR, FIAEGHPLSLK

10

5

yes

95

23

AAPTGNER, CPLTVVQSR

AAPTGNER, GIGTIISSPYR,

Trypsin
inhibitor

GIGTIISSPYR,NKPLVVQFQK, FIAEGHPLSLK

5

0

no

98

n/a

n/a

n/a

Colloidal coomassie

Silver nitrate

HLVDEPQNLIK (38)

HLVDEPQNLIK (33)

Sypro Ruby

In-house RuMS

HLVDEPQNLIK (43)

HLVDEPQNLIK (44)

Figure 3.24 MS/MS fragmentation of a BSA peptide (HLVDEPQNLIK) from gels

stained with different stains as indicated. The ion intensity is given with parenthesis
beside the peptide sequence in the figure.
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Table 3.5 Summary of LC-MS/MS data for different protein loads of standard proteins (BSA- bovine serum albumin and

Trypsin inhibitor) from gels stained with various stains

Stain

Protein

ng of

# of peptides

Database

Mowse

%

protein

matched

match

score

coverage

100

2

yes

113

3

50

3

yes

113

6

25

2

yes

102

4

10

0

no

n/a

n/a

5

0

no

n/a

n/a

Sequence of matched peptides

HLVDEPQNLIK, LGEYGFQNALIVR
HLVDEPQNLIK, LGEYGFQNALIVR,
KVPQVSTPTLVEVSR
DEFLGTFLYEYSR,

BSA

KAPQVSTPTLVEIGR
n/a
n/a
NELDKGIGTIISSPYR,
GIGTIISSPYR, FIAEGHPLSLK,

CCB

100

6

yes

213

27

G250

IGENKDAMDGWFR, VSDDEFNNYK,
NKPLVVQFQK
NELDKGIGTIISSPYR,
GIGTIISSPYR, FIAEGHPLSLK,

Trypsin

50

6

yes

267

27

IGENKDAMDGWFR,VSDDEFNNYK,
NKPLVVQFQK

inhibitor

NELDKGIGTIISSPYR,
25

2

yes

57

13

10

2

yes

54

12

5

0

no

n/a

n/a

IGENKDAMDGWFR
NELDKGIGTIISSPYR,

100

FIAEGHPLSLK
n/a

Protein
Stain

ng of

# of peptides

Database

Mowse

%

protein

matched

match

score

coverage

Sequence of matched peptides

FKDLGEEHFK, LVNELTEFAK,RHPYFYAPELLYYANK,
HPYFYAPELLYYANK,DAFLGSFYEYSR,
RHPEYAVSVLLR,HLVDEPQNLIK, LGEYGFQNALIVR,
KVPQVSTPTLVEVSR

100

9

yes

421

16

50

7

yes

295

11

LGEYGFQNALIVR, HPEYAVSVLLR, LVVSTQTALA

25

2

yes

76

3

LGEYGFQNALIVR, HPEYAVSVLLR

10

0

no

n/a

n/a

n/a

5

0

no

n/a

n/a

n/a

100

3

yes

78

14

GIGTIISSPYR, VSDDEFNNYK, NKPLVVQFQK

50

5

yes

225

23

25

0

no

n/a

n/a

n/a

10

0

no

n/a

n/a

n/a

5

0

no

n/a

n/a

n/a

LVNELTEFAK, RHPEYAVSVLLR, DAFLGSFLYEYSR, HLVDEPQNLIK

BSA

Acidic
Silver
nitrate

GIGTIISSPYR, FIAEGHPLSLK, VSDDEFNNYK, NKPLVVQFQK,

Trypsin inhibitor

101

DAMDGWFR

Stain

Protein

ng of

# of peptides

Database

Mowse

%

protein

matched

match

score

coverage

Sequence of matched peptides

DAFLGSFLYEYSR,
RHPEYAVSVLLR, HLVDEPQNLIK,
100

6

yes

220

12

LGEYGFQNALIVR,
KVPQVSTPTLVEVSR,
TVMENFVAFDK

50

2

yes

56

3

LGEYGFQNALIVR, LVNELTEFAK

25

4

yes

148

8

LGEYGFQNALIVR,

10

2

yes

52

4

KVPQVSTPTLVEVSR,

5

0

no

n/a

n/a

100

4

yes

170

17

50

5

yes

210

21

FIAEGHPLSLK, VSDDEFNNYK,

25

4

yes

146

19

GIGTIISSPYR, FIAEGHPLSLK,

10

2

yes

62

9

GIGTIISSPYR, NKPLVVQFQK

5

0

no

n/a

n/a

DAFLGSFLYEYSR, HLVDEPQNLIK,

BSA

KVPQVSTPTLVEVSR
LVNELTEFAK
Sypro Ruby

n/a
NELDKGIGTIISSPYR, GIGTIISSPYR,
FIAEGHPLSLK, VSDDEFNNYK
NELDKGIGTIISSPYR, GIGTIISSPYR,
NKPLVVQFQK

Trypsin
inhibitor

VSDDEFNNYK, NKPLVVQFQK

102

n/a

Stain

Protein

ng of

# of peptides

Database

Mowse

%

protein

matched

match

score

coverage

Sequence of matched peptides

LVVSTQTALA, QTALVELLK, KQTALVELLK, LVNELTEFAK,
HPEYAVSVLLR, RHPEYAVSVLLR, HLVDEPQNLIK,
LGEYGFQNALIVR, TVMENFVAFVDK (M-oxidized),
100

12

yes

558

19

DAFLGSFLYEYSR, KVPQVSTPTLVEVSR, HPYFYAPELLYYANK
AEFVEVTK, YLYEIAR, QTALVELLK, LVNELTEFAK, FKDLGEEHFK,
HLVDEPQNLIK, RHPEYAVSVLLR,GEYGFQNALIVR,

BSA
50

12

yes

590

22

KVPQVSTPTLVEVSR, TVMENFVAFVDK (M-oxidized),
DAFLGSFLYEYSR, RHPYFYAPELLYYANK

25

1

yes

51

2

LGEYGFQNALIVR

10

1

yes

42

1

HLVDEPQNLIK

5

0

no

n/a

n/a

100

5

yes

283

21

50

6

yes

333

27

25

3

yes

80

12

10

1

no

21

4

5

0

no

n/a

n/a

n/a
NELDKGIGTIISSPYR, GIGTIISSPYR, FIAEGHPLSLK, VSDDEFNNYK,

RuMS

NKPLVVQFQK

NELDKGIGTIISSPYR, GIGTIISSPYR, FIAEGHPLSLK, VSDDEFNNYK,
Trypsin
inhibitor

NKPLVVQFQK, IGENKDAMDGWFR (M-oxidized)
NELDKGIGTIISSPYR, GIGTIISSPYR, FIAEGHPLSLK

103

VSDDEFNNYK
n/a

3.4 Discussion

The primary aim of this work was to synthesize a fluorescent ruthenium complex to use
as a cost-effective stain in visualizing proteins in gels after electrophoresis. A
commercially available fluorescent protein stain is the Sypro Ruby, which has high
sensitivity and linear dynamic range crucial for a successful proteomic study utilizing 2DE. However, 500 mL of Sypro Ruby solution can be used to stain only two large format
gels. Considering the huge number of gels run in a typical proteomic lab like ours, use of
Sypro Ruby is not very cost-effective. Rabilloud et al. synthesized RuBPS in-lab to use
as an alternative to the expensive Sypro Ruby [53]. This prompted us to test the usability
of this RuBPS in our lab and we synthesized the chelate in-house using the protocol
published by Rabilloud et al. As shown in figure 3.11, the sensitivity of the RuBPS stain
synthesized in-house was relatively poor, with a detection limit of about 5 ng of protein.
Since RuBPS is ruthenium attached to three bathophenanthroline disulfonate ligands, we
explored the possibility of having both sulfonated and non-sulfonated
bathophenanthroline moieties attached to the central ruthenium atom. Our rational was
that different kinds of ligands may result in a synergistic effect in interacting with the
protein and thereby enhance sensitivity. Analysis of the commercial Sypro Ruby by
MALDI-TOF in our lab showed evidence for the presence of a non-sulfonated ligand in
the solution (data not shown). This impelled us to synthesize ruthenium complex with
both sulfonated and non-sulfonated ligands and hence two complexes RuMS and RuDS
were synthesized in addition to RuBPS. Synthesis of RuMS and RuDS were carried out
using modification of protocol published by Rabilloud [53].

3.4a Characterization of in-house synthesized ruthenium complexes
Various techniques like fluorescence spectroscopy, mass spectrometry and paper
chromatography were carried out to characterize the in-house synthesized ruthenium
complexes. Fluorescence spectroscopy of all the three ruthenium complexes synthesized
in-house gave spectra similar to Sypro Ruby in overall appearance and in values for λex
and λem maxima. Figure 3.6 gives the excitation and emission spectra for RuMS, for
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example. There are two absorption peaks, one at ~280 nm and a broad one at ~450 nm.
The fluorescence emission spectrum has one broad peak at 610nm. The similar spectra
obtained for the ruthenium complexes indicate that they possess similar fluorescence
properties.
RuNS (ruthenium attached to three bathophenanthroline ligands – no sulfonates) was
bought from a commercial source and solution made up in-house. The various in-house
synthesized ruthenium complexes and RuNS were subjected to MALDI-TOF mass
spectrometry. Different matrices were employed like HCCA, SA and DCTB, but none
enabled visualization of the expected m/z peak (RuNS (ruthenium tris
bathophenanthroline) [M+H]+ = 1098, RuMS [M+H]+ = 1258, RuDS [M+H]+ = 1464 and
RuBPS [M+H]+ = 1670). The base peak observed in all the spectra obtained was an m/z
of 766. From spectra (Figures 3.7-3.10) obtained for the three complexes including RuNS
in HCCA matrix, it is clear that each compound is breaking apart and some of the peaks
observed match the m/z for fragments of the original complex. The peak with m/z = 766
could be the ruthenium ion attached to 2 bathophenanthrolines ligands. Table 3.1 gives
different mass peaks that were observed in the MALDI-TOF spectra for the various
complexes. The mass spectral characterization of in-house synthesized ruthenium
complexes was not successful in clearly elucidating the structure.
Paper chromatography was performed to help us in the identification of these complexes.
Table 3.2 summarizes the retention factors (Rf) obtained for ruthenium complexes in two
different solvents. Two compounds were seen in each of the ruthenium complexes shown
by the two Rf values. RuDS and RuBPS have similar retention factors indicating that the
major constituents in both these preparations are the same compounds. RuMS, on the
other hand, had different Rf values compared to RuDS and RuBPS. There is one spot in
RuMS with Rf value of zero in water indicating that it is highly polar in nature. This
could be the sulfonated ligand or some other polar ruthenium complex. All the three
ruthenium complexes appeared to have one compound common to all. The commercial
RuMS had an Rf value or 0.42 in water that is present in all the in-house synthesized
ruthenium complexes. Comaprison of Rf values between commercial and in-house RuMS
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complex indicated that the in-house synthesized RuMS was indeed made up of RuMS
complex and one other complex with Rf value of zero.
The three ruthenium complexes differed in terms of their staining abilities (Figure 3.11).
In-house RuMS provided the greatest sensitivity with a limit of detection of 0.5 to 1 ng,
versus 5-10 ng for RuBPS and 25-50 ng for RuDS. Since RuMS clearly had the best
sensitivity among the three complexes, characterization of RuMS is important. Mass
spectral data clearly indicates that the ruthenium complexes are highly unstable and
fragment in the mass spectrometer. However, from the fragmentation pattern there is
evidence for the presence of RuMS complex in the RuMS stock solution. Paper
chromatography data indicates that the RuMS solution synthesized is a mixture of two
complexes. The difficulty faced in obtaining crystals from the RuMS solution (in an
attempt to characterize the complex by X-ray crystallography) further suggests that the
solution is a mixture and not pure RuMS complex. Due to the paucity of this material,
further structural elucidations were not pursued. However, the data suggests that the inhouse synthesized RuMS solution contained RuMS and another minor component.
Since RuMS gave the most sensitivity in staining proteins, the following discussions will
be mainly focused on RuMS. The next section is a discussion on the optimization
protocols for RuMS staining that were carried out to achieve the maximum sensitivity.

3.4b Optimization of staining protocol using in-house RuMS
Solvent composition of the staining solution is highly critical for successful staining.
Therefore, various solvents like ethanol, methanol and isopropyl alcohol were used as
solvent for the formulation of RuMS stock solution. As seen in figures 3.12 and 3.13, the
stain had little background and high sensitivity when ethanol was used as a solvent. The
concentration of RuMS in the working solution was also optimized (Figure 3.14). Desired
staining of proteins with minimal background staining was obtained with 150 nM RuMS
in 20% ethanol solution. When solvents other than ethanol were used or when greater
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concentrations of ethanol were used in the formulation, there was increased background
staining due to non-specific binding of the stain to the polyacrylamide matrix.
The optimized staining protocol of the in-house synthesized RuMS detected proteins
down to 0.5 ng in gels. As discussed earlier, greatest challenge was in characterizing the
synthesized complex. Even though there was significant evidence for the presence of
RuMS complex in the stock solution, there is lack of concrete data to support this
observation. We looked at other ways to confirm the identification. In our search to do so,
we came to know of a company Biotium (Hayward, CA) that was started during the
course of this work, sells the fluorescent ruthenium complexes. The commercial RuMS
was purchased in order to test its staining efficiency using standard marker proteins. The
in-house synthesized RuMS stain was compared to this commercial RuMS in terms of
sensitivity and specificity and to give further structural information on the synthetic stain
by inference. Again for commercial RuMS, the formulation is very critical and hence
various solvents like 20% v/v, and 50% v/v of both ethanol and isopropyl alcohol were
used as solvents. As seen in figures 3.15 and 3.16, the stain had little background and
high sensitivity when ethanol was used as the solvent. The background staining was high
when isopropyl alcohol was used. Different percentage of ethanol also gave high
background due to non-specific binding of the stain to the gel matrix. Therefore, the most
suitable solvent for ruthenium complex to stain proteins with high sensitivity but with
minimal background staining of the gel was obtained with 20% ethanol in the final
working solution. Concentration of ruthenium complex in the staining solution was also
optimized (Figure 3.17). Desired staining of the proteins with again minimal background
staining was obtained with 100 nM of in-house RuMS and 125 nM commercial RuMS,
both in 20% ethanol solution.
There exists subtle difference in staining efficiency of the in-house synthesized RuMS
compared to the 99% pure commercial RuMS (Figure 3.18). In commercial RuMS
stained gel, more non-specific binding occurs even at 10 ng of protein while there is
negligible background with the in-house RuMS staining solution, leading us to speculate
that the minor component present in the in-house synthesized RuMS solution enhanced
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the staining ability of the ruthenium complex. From the paper chromatography data, we
suspect this contaminant is most probably RuBPS, another form of ruthenium complex.
RuMS and RuBPS have similar ligands attached to the central ruthenium atom. However,
they differ in the number of sulfonate groups attached to the bathophenanthroline ligands.
RuMS has two sulfonate groups attached to one bathophenanthroline ligand while
RuBPS has six sulfonate groups. Thus RuMS is more hydrophobic than RuBPS complex.
Goldstein et al. have reported the crystal structure of ruthenium tris bathophenanthroline
complex (RuNS) in which they propose that the bathophenanthroline ligands of different
molecules stack-up to form a cluster [58]. The features seen in the crystal and molecular
structure of ruthenium tris bathophenanthroline can be used to construct models for the
interaction between the different forms of ruthenium complexes in RuMS staining
solution that can explain the improved sensitivity observed with the in-house RuMS.
In one plausible model, one of the hydrophobic bathophenanthroline groups of RuMS
interact with hydrophobic residues in the protein. The other two ligands of RuMS,
namely bathophenanthroline disulfonate and bathophenanthroline are aligned outside.
The sulfonate group has a tetrahedral structure and since the group is not in the same
plane as the aromatic ring, it destabilizes possible π-π stacking of its
bathophenanthroline/phenyl groups with bathophenanthroline/phenyl groups of another
ruthenium complex. However, the bathophenanthroline moiety with no sulfonate is
accessible for π-π stacking and a second dye molecule can easily stack-up with this
complex. In this way, the dye molecules stack-up with each other so as to allow for more
dye molecules to bind to a protein, thereby significantly increasing the dye to protein
ratio with an amplication in the signal generated. This stacking up of planar ring
structures with extensive conjugation of π orbitals has been reported by Skoog et al. and
Congdon et al. [59, 60]. The stacking of coomassie dye molecules with a similar structure
as that of the ruthenium complex has been proposed for the improved sensitivity with the
blue silver protocol [61]. If this same concept of π-stacking occurs in the case of our “inhouse RuMS” staining protocol, this would very well explain the substantial increment in
sensitivity. Due to the presence of two different forms of ruthenium complexes in the inhouse synthesized RuMS staining solution, there are more numbers of dye molecules
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binding to proteins. So even low levels of protein are detected since more dye molecules
bind. On the other hand, with just the RuMS form in the staining solution, as in the case
of commercial RuMS, there is only one form of ruthenium complex. Even though the
stacking-up of the dye molecules is possible, RuMS being more hydrophobic than
RuBPS, also non-specifically binds to the polyacrylamide gel matrix which considerably
reduces sensitivity.
Hence by having both RuMS and RuBPS in a staining solution, we achieve the right
balance in hydrophobicity and hydrophilicity of the final staining solution required to
detect the proteins with improved sensitivity. The characterization of the in-house
syntheized RuMS staining solution is necessary to validate the proposed model and future
work should involve new experiments characterizing the material to ensure exploitation
of the in-house synthesized RuMS stain’s potential to the fullest.
The optimized formulation of the in-house synthesized RuMS stain was compared with
other stains for its sensitivity, linear dynamic range and compatibility with mass
spectrometry.

3.4c Comparison of sensitivity of various stains
Figure 3.19 gives identically prepared gels stained with colloidal Coomassie, silver,
commercial Sypro Ruby and in-lab synthesized RuMS. Clearly, colloidal Coomassie can
detect up to 0.5 ng of protein, however only after repeated staining for three times. Silver
can also detect down to 0.5 ng of protein but the background was darker at lower ng level
of protein, and the gel showed inherent artifacts due to silver staining. Both Sypro ruby
and in-lab synthesized fluorescent RuMS had comparable sensitivities and could detect
0.5 -1 ng of protein. Commercial RuMS had a sensitivity of about 1 ng. It is clear from
the gels that there is some amount of difference in sensitivity from protein to protein
which depends on the inherent amino acid composition of each protein and how the stains
interact with them. Ovalbumin and lysozyme showed differential staining with colloidal
Coomassie. This could be explained because of the heavy glycosylation on ovalbumin
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that interferes with the binding of the dye to the protein as reported by Fountoulakis et al.
[62]. As previously reported in colorimetric labeling of protein [63-65], lysozyme was
more lightly stained with Coomassie down to about 10 ng. This could also be due to the
glycosylation in lysozyme. In the case of silver staining, trypsin inhibitor and lysozyme
proteins stained more intensely than the other protein markers and showed artifacts
associated with this staining method. Sypro Ruby and in-lab synthesized RuMS showed
much less protein to protein variability.

3.4d Linearity in staining response
To minimize protein-to-protein variability, stain and batch differences, the mean band
volume from three gels run and stained with either of the dyes was plotted against the ng
of protein loaded (Table 3.3, Figure 3.20 and 3.21). For each protein band selected, linear
treadlines were added and R2 values determined. The in-lab synthesized RuMS was
found to be comparable to commercially available Sypro Ruby in terms of its linearity,
but the staining intensity was greater than with Sypro Ruby and with greater signal to
noise ratio. Both Sypro Ruby and in-house RuMS showed linear response from 0.5 to 100
ng protein. Silver staining, as reported earlier, is sensitive down to 1 ng and maybe even
0.5 ng of protein. But since the band volume at 0.5 ng protein load is very close to the
band volume for 1 ng protein, it showed a linearity of dilution from 1 to 50 ng of protein.
The linearity in response for colloidal Coomassie stained gels was 5 ng to 100 ng. There
was considerable batch-to-batch difference in silver staining most likely owing to
variability introduced due to critical timing. Relative standard deviation (%RSD) was less
than ± 5 for both Sypro Ruby and RuMS, which shows good batch-to-batch
reproducibility.
Figures 3.20 and 3.21 give the graphs of the linear relationships for raw band volumes of
proteins from gels after background subtraction. The band volumes for 5 ng of BSA from
gels stained with the different staining solutions were normalized and histogram plotted
(Figure 3.22). From the bar graph, we can see that there is no significant difference
between the different stains – CCB G 250, silver nitrate, in-house RuMS and Sypro
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Ruby- in terms of sensitivity. Though the stains had similar sensitivity, each stain had its
own limitations. CCB G250 had sensitivity down in the ng levels of proteins only after
repeated staining and destaining steps for at least three times. This is a very time
consuming process that takes up to a week. Silver nitrate on the other hand, had very poor
reproducibility due to a constant hands-on protocol that required routine preparation of
fresh solutions. Sypro Ruby had good sensitivity but the major disadvantage was the cost
involved in buying the stain. In-house synthesized RuMS had comparable sensitivity to
Sypro Ruby and was very cost-effective.

3.4e Compatibility of stains with mass spectrometry
Once proteins are separated by 2-DE, they are visualized using a suitable staining
solution and the protein spot profiles are analyzed using image analysis software. The
protein spots of interest are then excised and subjected to enzymatic digestion. The
resulting peptide fragments are then analyzed using mass spectrometry (MS). With
fluorescent stains, the sensitivity of the protein stains has improved and the challenge is
now to acquire good mass spectra from especially low abundance proteins. Therefore, it
is imperative that the dye does not interfere with MS methods. Interfering dyes (like
silver nitrate) can result in ion suppression resulting in fewer measurable peptides
obtained and a reduction in signal intensity.
Two complementary MS methods used for proteomic studies are MALDI-TOF and ESLC-MS/MS. To evaluate the compatibility of different stains with these two mass
spectrometry methods, gel plugs were harvested and digested with trypsin. The resulting
tryptic peptides were subjected to both matrix assisted laser desorption ionization
(MALDI-TOF) and liquid chromatography tandem mass spectrometry (LC-MS/MS).

•

Stain compatibility with MALDI-TOF

Tryptic peptides were subjected to MALDI-MS as described earlier. A representative
peptide mass fingerprint (PMF) analysis for all the 100 ng BSA protein is shown in figure
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3.23. The summarized MALDI data from all the trypsin digested proteins is provided in
Table 3.4. The number of successfully identified peptides and the resultant sequence
coverage were slightly better for the in-lab synthesized stain than for commercial Sypro
Ruby. Although silver staining is a very sensitive visualization method, poor mass spectra
were obtained. Out of 12 proteins that were subjected to MALDI-TOF after silver stain,
peptides were detected for only 6 samples. No peptides from BSA were correctly
identified after MALDI-TOF. Low peptide recovery and sequence coverage of silver
stained proteins may be due to their modification by formaldehyde (alkylates α and ε
amino groups of proteins) during the staining process. Unfortunately, formaldehyde
cannot be omitted or substituted for in the staining protocol.
Colloidal Coomassie performed fairly well in the MS compatibility study, however it is
very difficult to get rid of the stain completely, and this could pose difficulties with MS
identification. Also the gel stained with colloidal Coomassie was stabilized in a saturated
solution of ammonium sulfate which could interfere with PMF analysis. It should be
noted from table 3.4 that different staining methods enabled different peptides to be
identified. Our data indicate that both fluorescent stains namely; Sypro Ruby and inhouse RuMS are fully compatible for protein identification by peptide mass finger
printing using MALDI-TOF mass spectrometry.

•

Stain compatibility with ES-LC-MS/MS

Data dependent MS/MS experiments were performed on a Thermo LCQ Classic
quadrupole ion trap mass spectrometer. Mass spectra were searched against the human
sub-database from the Swiss-Prot database using the Mascot algorithm. One missed
trypsin cleavage was allowed and a variable modification of oxidation of methionine was
set. Peptide tolerance and MS/MS tolerance were both set at ± 0.8 Da. Representative
ES-LC-MS/MS spectra are shown in figure 3.24. Table 3.5 summarizes the LC-MS/MS
data for all the trypsin digested samples. Silver staining yielded few matches when
compared to other stains. Fewer peptides were seen for proteins from silver stained gels.
Colloidal Coomassie seemed to perform fairly better than the silver staining method.
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Sypro Ruby and in-lab synthesized stain gave the most number of peptides detected with
highest Mowse score and sequence coverage.
In conclusion, all stains tested in this work demonstrate some degree of MS
compatibility. Silver stain gave significantly better results with LC-MS/MS than
MALDI-TOF and colloidal Coomassie gave slightly better results with LC-MS/MS than
MALDI-TOF. The in-lab synthesized RuMS stain is slightly better than commercially
available Sypro Ruby in terms of MS compatibility. More peptides were recovered and
detected by both MALDI-TOF and LC-MS/MS for proteins stained with the in-lab stain
and gave better Mascot search results with high Mowse score and sequence coverage.

•

Evaluation of protein sequence coverage

The level of protein sequence coverage for the six marker proteins stained with different
stains is shown in Tables 3.4 and 3.5. Coverage was determined from the Mascot search
results for proteins that gave significant identification by searching against the protein
database. For proteins that did not give a significant match but had peptides detected by
the mass spectrometer, coverage was calculated manually. Sequence coverage for
proteins extracted from in-lab RuMS stained gels was better than that obtained from
Sypro Ruby stained gels. It is important to note here that higher protein coverage is not
necessary for protein identification, especially with ES-MS/MS.

3.4f Cost-effectiveness of RuMS stain
The specific aim of this project was to synthesize a fluorescent ruthenium complex inhouse to be able to use it as a cost-effective alternative to Sypro Ruby. The following
section explains how RuMS synthesized in our lab proved to be a cost-effective protein
stain.
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In most proteomics labs, 2-DE is employed to analyze the proteome and hence staining
solutions are used in huge quantities. The goal of this project is to synthesize a ruthenium
complex that can be used as a cost-effective alternative to expensive Sypro Ruby. This
section discusses the cost-effectiveness of the in-house synthesized RuMS staining
solution in comparison to the commercial RuMS and Sypro Ruby. Sypro Ruby as
mentioned earlier is highly sensitive and has linear response over a wide range of protein
load but is highly expensive. An alternative to Sypro Ruby should be able to stain the
proteins with similar sensitivity and give linear dynamic range but in a much more costeffective manner. Commercial Sypro Ruby costs approximately $200 and it can be used
to stain only two large format (20 x 20 cm) gels. A half liter solution of our in-house
synthesized RuMS costs about $100 to buy the required chemicals and solvents and an
aliquot of 1.5 mL is used to stain one gel. Hence 500 mL of the in-house staining solution
can be used to stain ~ 330 gels. Chemicals worth $200 can be used to synthesize 1 L of
staining solution which can be used to stain roughly about 600 gels. Commercial RuMS
costs about $150 which can be used to make 250 mL of 16 nM solution. Forty mL of this
staining solution can stain one large format gel. Hence one 250 mL solution can be used
to stain 6 gels. A summary of pros and cons of the fluorescent stains evaluated is shown
in the flow chart below (Table 3.6).
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Table 3.6 Pros and cons of various fluorescent stains.

Sypro Ruby

Commercial RuMS

In-house RuMS

Highly sensitive (0.5ng of

Highly sensitive (1 ng of

Highly sensitive (1- 0.5 ng

protein)

protein)

of proteins)

MS compatible

MS compatible

MS compatible

Easy staining and

Easy staining protocol and

Easy staining protocol and

destaining protocol

no destaining required

no destaining required

Expensive (2 gels)

More cost-effective (6 gels)

Most cost-effective (600
gels)
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3.5 Conclusion

For a successful bottom-up proteomics involving 2-DE, an essential requirement is a
protein staining technique that is sensitive, quantitative and compatible with MS. Using
standard proteins on SDS-PAGE, we have showed that the ruthenium complex (RuMS)
synthesized in our lab after optimization of the staining formulation is very similar in
staining properties to commercially available fluorescent protein stain Sypro Ruby in
terms of both sensitivity and linear dynamic range. Our results show that in-house RuMS
has better compatibility with mass spectrometric identification than Sypro Ruby both in
terms of the “goodness” of fit between the theoretical and observed peptide masses
during the database search using the Mascot algorithm and in terms of better protein
sequence coverage. The staining protocol is also simple and easy to follow with
effectively no destaining required. Colloidal Coomassie and silver staining methods are
commonly used but have pitfalls when used in proteomic studies, such as low linear
dynamic range, batch-to-batch and protein-to-protein variations and incompatibility with
further mass spectrometric identification of proteins. In-lab synthesized ruthenium
complex stain is routinely used in our laboratory to stain 2-DE gels (example shown in
Figure 3.25) and has given satisfactory results with respect to sensitivity and mass
spectrometric identification by both MALDI-TOF and LC-MS/MS.
Even though the characterization of the RuMS solution was not successful, the presence
of RuMS is evident from the mass spectral data. Other characterization attempts indicated
the presence of an additional minor component present in the solution, which we
speculate to be RuBPS form. Comparing the staining efficiency between the in-house
synthesized RuMS and commercial RuMS, in-house RuMS had a better signal-to-noise
ratio and this could be explained by the additional component in the RuMS solution. As
explained earlier, presence of both RuMS and RuBPS enable a synergistic effect in the
binding of the dye molecules to the protein and there is amplification of the signal. This
allows for even low levels of proteins to be detected as number of dye molecules stack-up
to give an amplified signal. The capability of synthesizing the fluorescent complex inhouse proves to be very cost-effective. Sypro Ruby is highly expensive and 500 mL of
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the solution can be used to stain only two large format gels; however for the same amount
of money in terms of reagents (not including man power or quality control) 1 L of RuMS
can be synthesized in-house which can be used to stain hundreds of gels. Thus, the
optimized formulation of the in-house RuMS staining solution proved to be the most
cost-effective alternative to the commercially available Sypro Ruby.
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Figure 3.25 2-DE gel from 400 μg of SY5Y whole cell lysate stained with in-house

synthesized RuMS staining solution. The gel image acquired using Versadoc was
inverted so that the spots are darker than the background.
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CHAPTER FOUR

PROTEOMIC INVESTIGATION OF MALATHION-INDUCED DIFFERENTIAL
PROTEIN EXPRESSION IN HUMAN NEUROBLASTOMA CELLS

4.1 Introduction

Pesticides play a vital role in agricultural and industrial pest control. However,
widespread use and overuse of these chemicals have increased awareness of the potential
pesticide-related health hazards. An example is the class of organophosphates (OP) that
are important chemical compounds used mainly as crop protective pesticides. Potent
organophosphate such as chlorpyrifos is usable as insecticide yet is also capable of
causing learning disabilities especially in exposed young children [66]. Animal studies
have reported that exposure to chlorpyrifos can cause developmental neurotoxicity by
affecting basic processes of neuronal development like axonogenesis, neuritogenesis and
synaptic function [66-69]. This led to the restriction in the use of chlorpyrifos in the
United States [70, 71].
Malathion, another organophosphate (with a different leaving group) is used widely in
both agriculture and domestic areas because it is thought to be a more benign OP. About
3.4 million pounds have been applied to non-agricultural areas such as golf courses,
public and home gardens for the Mediterranean fruit fly quarantine and mosquito
abatement to-date [72]. Close to 17 million pounds of malathion are sprayed annually in
the U.S. to control boll weevils on cotton and other pests [73]. In 1999, malathion was
also used in eradication of West Nile virus carrying mosquitoes.
On one end of the spectrum is the more potent OP chlorpyrifos shown to cause
developmental neurotoxicity that has been banned from domestic use while on the other
end there is the “less toxic” malathion that is used extensively for both agriculture and
house-hold purposes. The effect of the more potent OP, chlorpyrifos on levels of protein
was studied in our lab using SY5Y as model system. Since it is equally important to
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study the effect of a benign OP as a control that made up the other end of the spectrum of
OP toxicity, the proteomic investigation on the effect of malathion was carried out. The
initial hypothesis is that malathion does not cause any significant change in levels of
protein. SY5Y cell cultures were used as model system to test the effect of malathion
using proteomics techniques.
The primary mode of action of malathion and other OPs (including chlorpyrifos) in
insects is inhibition of acetylcholinesterase (AChE) and thus interfere with normal
functioning of the nervous system. In vivo AChE inhibition occurs when malaoxon, a
metabolite of malathion, binds to acetylcholinesterase; thus, symptoms may be delayed
after exposure owing to the need for metabolism. Covalent AChE binding results in
accumulation of acetylcholine at the synapse causing repeated stimulation of neurons and
a number of neurotoxic effects – especially muscarinic and nicotinic effects. Muscarinic
effects include: Salivation, Lacrimation, Urination, Diarrhea, GI upset and Emesis
(acronym: SLUDGE). Nicotinic effects include: tachycardia, muscle fasciculation and
respiratory shutdown resulting from diaphragmatic failure, which ultimately causes
death.
Previous studies have shown that malathion induces genotoxicity [74]. Using animal
models, researches have shown that malathion greatly inhibits AChE in the cerebellum
and hippocampus [75]. Experimental animal studies have revealed that malathion causes
chromosomal aberrations and micronuclei formation [76-78]. Malathion is also now
known to be an inhibitor of gap junction intercellular communication (GJIC) [79].
Akhgair et al. measured the levels of thiobarbituric acid reactive substances (TBARS) in
the liver and blood of rats and showed that malathion inhibition of AChE activity was
accompanied by oxidative stress [80]. In addition to its mutagenic, carcinogenic and
teratogenic effects determined by in vitro and in vivo studies [81, 82], malathion reduces
antibody titers to different antigens in a dose-dependent manner in experimental animals.
This effect was most pronounced during the secondary immune response [83, 84].
Malathion was also shown to induce allergic reactions in children [85]. Rodgers et al.
reported that malathion causes dysregulation of peritoneal mast cells [86].
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There exists a number of possible ways humans get exposed to pesticides, which could be
due to one or more of the following reasons: accidental poisoning, occupational exposure
and off-target exposure from aerial spraying of the pesticide in crop fields. In view of the
widespread use of pesticides, the potential is very high for repeated exposures to one or
simultaneous exposure to various pesticides. Pesticide intoxication poses severe problems
which can be exacerbated if not prevented. Most of the reports studying toxicity of
malathion were focused on secondary effects after exposure, symptomology in particular.
There is an overall lack of information on the protein targets and their levels that can be
altered after exposure to pesticides. Significant biochemical pathways may be hindered
by organophosphate insecticides exposed enzymes, receptors or structural proteins.
Proteomic investigation of the effect of malathion was performed using human
neuroblastoma cell (SY5Y cells). The SY5Y neuroblastoma cell line was used as it
exhibits neuronal phenotype which provides a convenient model system to study
neurotoxicity of organophosphates [87]. SY5Y cells express muscarinic acetylcholine
receptors [88], mostly subtype M3 [89] and exhibit higher activities of neurotoxic
esterases (NTE) and acetylcholinesterase compared to other cell lines [90]. Barber et al.
showed that organophosphate-treated human neuroblastoma cells gave similar responses
to those in hens exposed to these compounds which are currently the Environmental
Protection agency (EPA) prescribed animal model to test OP toxicity [91-93]. Barber et

al. thereby validated SY5Y cells as a useful model and Ehrich et al. also validated the use
of human neuroblastoma cells for the initial screening of OPs [89]. Criticism exists that
neuroblastoma cells are not a part of “normal” tissue and the responses seen may be
consequence of cancerous behavior. However, asking pointed questions and strategically
designing the experiments with well-defined end-points can minimize this fear. As a
minimum criterion, this involves carefully comparing the control (no malathion
treatment) against the treated samples. Veronesi et al. agree that the in vitro system using
human cell lines that house the target enzymes for the OPs are relevant to risk assessment
[94]. Also cells of human origin provide good models for studying OP toxicity because of
the direct correlation to humans as opposed to animal studies in which extrapolation of
the results to humans is needed.
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The initial hypothesis that malathion does not cause any significant change in levels of
proteins was proved false. We present evidence that malathion does cause significant
change in protein levels in SY5Y cells exposed to the organophosphate. With the aid of
proteomic tools such as two-dimensional gel electrophoresis (2-DE) and mass
spectrometry, we have identified the candidate SY5Y proteins whose levels were altered
(up- or down-regulated) after treatment with malathion. Finally, western blot analysis
was carried out to confirm alterations in levels of specific proteins seen in 2DE studies.
We found that many chaperone proteins and metabolic enzymes were down-regulated
coordinately, suggesting that malathion perturbs protein turnover. We hypothesized that
the decrease in chaperone proteins may sensitize the cells to oxidative stress as shown by

in vivo and in vitro studies.

4.2 Materials and Methods

4.2a Materials
Isoelectric pH gradient (IPG) strips (0.5 mm wide, 17 cm long, pH 3-10 linear), urea, Tris
(electrophoresis grade), IPG rehydration /sample buffer containing 8M urea, 2% CHAPS,
50 mM DTT, 0.2% Bio-Lyte 3/10 ampholyte, trace bromophenol blue, readyprep overlay
agarose and mineral oil were obtained from Bio-Rad (Hercules, CA). SDS, TEMED,
ammonium persulfate, ammonium bicarbonate, acetonitrile, formic acid, acrylamide,
bisacrylamide and were purchased from Sigma (St.Louis, MO). For protein staining in
gels, ruthenium complex prepared in our lab was employed. DTT, iodoacetamide, glacial
acetic acid (ACS grade), glycine (tissue culture grade) and methanol (HPLC grade) were
all purchased from Fisher Scientific (Fair Lawn, NJ). Lyophilized sequencing grade
modified trypsin was purchased from Promega (Madison, WI). Fused silica capillary
tubing 320 μm I.D. x 435 μm O.D. for liquid chromatography column was purchased
from Polymicro Technologies (Phoenix, AZ) while the reverse phase packing material
Polymer X (3 μm) was purchased from Phenomenex (Torrance, CA). All other LC
accessories including zero dead volume (ZDV) unions, frits, ferrules were obtained from
Upchurch Scientific (Oak Harbor, WA).
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4.2b Cell Culture
SY5Y neuroblastoma (American Type Culture Collection CRL 2266) [87] cells were
grown to confluence in 75 cm2 flasks in Dulbecco’s minimum essential medium
supplemented with 55 mM glucose, 26 mM NaHCO3, 16 mM KCl, 1.36 mM pyruvic
acid, 2 mM glutamine, 10 mg/mL gentamicin sulfate and 10%v/v clarified bovine serum
(pH 7.4) in an environment of 94% air/6% CO2 at 37°C. Cultures were split 1:3 every
two to three days by removal of media and incubation in 0.25% trypsin/0.03% EDTA
until cells detach. Five mL of media was then added and cells pelleted by centrifugation
at 3,000 x g for 10min. For each malathion treatment, the cells were switched to Lock’s
medium and treated with appropriate concentrations of malathion. Following treatment,
cultures were washed extensively with phosphate buffer saline (pH 7.4) and cells were
gently scraped into 3 mL PBS and pelleted by centrifugation at 800 x g for 10min. The
pellet was then resuspended in 200 μL of distilled/deionized water and homogenized
using a micro Dounce homogenizer. Cell viability test was checked by (3-(4, 5Dimethylthiazol-2-yl)-2, 5-diphenyltetrazolium bromide) (MTT) assay and protein
content determined using Pierce BCA method.

4.2c Cell Viability Assay
Confluent cultures were split from one flask into three 96-well culture plates. When
confluent, cultures were switched to Lock’s medium consisting of 154 mM NaCl, 56 mM
KCl, 2.3 mM CaCl2, 1.0 mM MgCl2, 3.6 mM NaHCO3, 10 mM glucose, 5 mM HEPES
(pH 7.2) with 10 mg/L gentamicin sulfate and treated with malathion (25 to 2000 μM) in
1% DMSO. Eight wells per concentration were treated with each concentration or with
vehicle alone (control). After 24hours, cell viability is assayed by addition of 10 μL or 1
mg/mL MTT solution that is converted to formazan crystals by the cellular enzymes [95].
The level of formazan dye formed is directly correlated to metabolically active cells in
culture. After addition of MTT, cultures were placed in the incubator for an additional 1
hour. The media was quickly aspirated and the formazan crystals dissolved in 100 uL
DMSO. Formazan absorbance was then measured at 620 nm using a multi-well plate
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reader. Results were calculated for each well as percent of control absorbance and are
expressed as the mean ± SD control absorbance. Cell viability was also assessed by
adding 10 μL WST-1(4-[3-(4-Iodophenyly)-2-(4-nitrophenyl)-2H-5-tetrazolio]-1, 3benzene disulfonate), which is converted to a water soluble formazan by reductase
system and is a measure directly in the media. There was no significant difference in
viability measured by the two assays. Using commercially available software, statistical
analysis was carried out. ANOVA with Dunnett’s post hoc test was performed for
differences.

4.2d Malathion Treatment
For proteomic analysis of changes in protein expression in SY5Y neuroblastoma cells,
the cultures were treated with 100 μM malathion for 24 and 48 hours in the same way as
the cell viability assay.

4.2e Two-dimensional gel electrophoresis
Pierce BCA method was used to determine protein content [96]. A protein concentration
of 400 μg of whole cell lysate was dried in a vacuum centrifuge. A volume of 300 μL of
rehydration buffer was added to the pellet and the solution was loaded on IPG strip and
after 12 hours of active rehydration at 50 V, the proteins were focused in the Protean IEF
cell from Bio-Rad using a 6 step program (100 V, 300 V, 500 V, 1000 V and 2500 V for
1 hour each and 5000 V for 16 hours). A limiting current (50 μA per strip) was
maintained.
After IEF, the strips were equilibrated (30 min) with 6 M urea, 32 mM DTT, 0.375 M
Tris-HCl pH6.8, 10%(w/v) SDS, 50% (v/v) glycerol and for 20 min in the dark with 63
mM iodoacetamide in the above equilibration buffer instead of urea. Each strip was
loaded on an 8-16% gradient polyacrylamide gel and proteins were electrophoresed at 30
mA constant current using a Protean II XL (Bio-Rad) in a buffer that contained 25 mM
Tris, 192 mM glycine and 0.1% SDS until the blue dye reached the bottom of the gel.

124

4.2f Staining of proteins
The 2-DE separated proteins were stained with a solution of Ruthenium II ((bis
bathophenanthroline) (bathophenanthroline disulfonate)) that was synthesized in-lab
using a modified protocol [53]. The gels were fixed in an aqueous solution containing
30% ethanol and 10% glacial acetic acid overnight. Gels were washed with aqueous
solution of 20% ethanol three times and incubated overnight in solution containing the
ruthenium complex. Thereafter, the gels were washed once with distilled water. Stained
gels were stored in distilled water at 4°C.

4.2g Image and statistical analyses
Stained gels were scanned with a Versadoc 3000 scanner from Bio-Rad (Hercules, CA).
Images were analyzed using the PD Quest software (Bio-Rad). Spots were detected and
matched by both automated matching following the instructions in the software and also
by manual matching. The spot volumes were normalized to the total density in the gel
image to avoid any non-expression related variations between matched spots. The
statistical significance of the data was determined by the Student’s t test. A difference in
spot volume was considered statistically significant at p<0.05 and confidence level of
95%.

4.2h In-gel proteolysis of proteins
Protein spots were picked and digested with trypsin using Bruker Daltonics prep/digest
station. In brief, the gel pieces were washed 6 times alternating with 50 mM NH4HCO3
and 1:1 ACN: NH4HCO3 (50 mM) for 5 min each at 20°C and dried with ACN for 10
min at 20°C. A 10 μL volume of trypsin (66.67ng) solution in 25 mM NH4HCO3 was
added and gel pieces were allowed to swell for 30 min at 20°C. Digestion was allowed to
proceed for 4 hours at 50°C. Peptides were extracted after terminating the digestion with
1 μL of 1% aq. formic acid.
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4.2i MALDI-TOF mass spectrometry analysis
MALDI-TOF mass spectra were generated using Bruker Autoflex (Billerica, MA) in the
reflectron mode. The Bruker Daltonics prep/digest station was used to spot the matrix and
the peptide solution on the anchorchip target. Briefly, matrix solution (10 mg/mL of αcyano-4-hydroxycinnamic acid in 90% acetone and 2% TFA) was spotted and 1.5 μL of
peptide solution was added to the matrix spot and allowed to air dry. On target washing
was carried out with 0.2% TFA. Spectra were recorded and 100-300 laser shots were
added to one spectrum. The spectra were externally calibrated against the monoisotopic
mass of a standard solution containing 1 μg/μL Bradykinin ([M+H]+ 757.399),
Vasopressin ([M+H]+ 1084.445), Angiotension II ([M+H]+1046.542), Substance P
([M+H]+ 1347.735) and oxidized form of Substance P ([M+H]+ 1363.731) and internally
calibrated using known trypsin autolysis peaks.

4.2j LC-MS/MS analysis
The trypsin digested samples were also analyzed using a Thermo Electron Corporation’s
LCQ Classic quadrupole ion trap mass spectrometer (San Jose, CA). The tryptic peptides
were resolved on in-house constructed capillary column. The column was fabricated by
packing 15 cm of Phenomenex Polymer X (3 μm particle size) into a 320 μm I.D fused
silica capillary using a home-made stainless steel packing cell pressurized with helium to
1000 psi. Five μL of tryptic peptides were injected into the column and eluted at a flow
rate of ~ 4 μL/min, using a binary gradient of 5-80% ACN (with 0.1% formic acid)
within 55 min. Spectra were acquired with a probe spray voltage of 4 kV and a heated
capillary temperature of 175°C.

4.2k Database search
•

PMF

The MS data were searched against tryptic peptides sequences from the Swiss-Prot
database using the Mascot algorithm. The search was restricted to trypsin generated
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peptides allowing up to two missed cleavages. A variable modification for oxidation of
methionine and carbamidomethylation of cysteines were set. The taxonomy was human
and the peptide tolerance was ± 0.5Da.

•

LC-MS/MS

Mass spectra were searched against the human sub database from the Swiss-Prot database
using Mascot algorithm. One missed trypsin cleavage was allowed and a variable
modification of oxidation of methionine was set. Peptide tolerance and MS/MS tolerance
were both set at ± 0.8 Da.
At the above settings for both PMF and LC-MS/MS, probability based Mowse scores
greater than 33 indicated identity or extensive homology. Additional criteria like more
than one peptide must be identified and the ion score of at least one peptide must be
greater than 30 were used to identify proteins.

4.2l Western blot analysis
For western blotting after SDS-PAGE, a standard protocol after Towbin et al. was used
[36]. Briefly, 25 μg of whole cell lysate from SY5Y treated with 100 μM malathion for
24 hours and the corresponding control samples were mixed with sample buffer
containing 60 mM Tris-HCl pH 6.8, 10% glycerol, 10% SDS, 0.1% bromophenol blue
and 5% β-mercaptoethanol, boiled for 5 min and on a 12% SDS-polyacrylamide gel.
Electrophoresis was carried out at 100 V for about 2 hours. The proteins were blotted
onto a nitrocellulose membrane at 100 V for 1 hour. Transfer of proteins to the
nitrocellulose membrane is confirmed by Ponceau S staining. The membrane was
blocked with blocking buffer (5% non fat milk in Tris buffer saline containing 0.05%
Tween-20). After blocking for 1 hour 30 min, the membrane was incubated with the antihuman rabbit primary antibody in blocking buffer overnight at 4°C. Both UCH L1 and
rhoGDI antibodies were used at 1:2000 dilutions. After washing, the membranes were
incubated with the secondary peroxidase conjugated goat anti-rabbit antibody (1:2500
dilutions in wash buffer). Signals were developed with an enhanced chemiluminescence
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(ECL) kit from GE Healthcare (Waukesha, Wisconsin). The developed ECL film was
scanned and the tiff images were analyzed by Scion Image software. Excel was used to
perform statistical analyses. The GAPDH protein was also probed for to check on the
efficiency in loading the sample.

4.3 Results

4.3a Dose-dependent effects of malathion on cell viability
Malathion dose-dependently increased cell viability in SY5Y cells after exposure with
concentrations up to 250 μM for 24 hours. The results were calculated for each well as
percent of control absorbance (viability) and are expressed as the mean ± SD control
absorbance (Figure 4.1). Cultures exposed to 1000 and 2000 μM malathion showed
significantly decreased cell viability compared to control cultures. Surprisingly, lower
concentrations of malathion (25 μM to 250 μM) significantly increased mitochondrial
function.

4.3b Identification of proteins using mass spectrometry
Two-dimensional gel electrophoresis was carried out on 400 μg of whole cell lysate
protein from SY5Y cells and 2-DE map of the whole cell lysate proteins were generated
(Figure 4.2). Using PD Quest gel image analysis software around 400 proteins spots were
detected on the 2-DE gel. A total of 122 proteins were identified using mass spectrometry
after subjecting the proteins to in-gel trypsin proteolysis (Appendix A and B). Mass
spectra were searched against the human sub database from the Swiss-Prot database using
the Mascot algorithm [97]. The search parameters described in the methods section gave
unambiguous protein identification with adequate number of peptides identified and
reasonable sequence coverage for the proteins.
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Figure 4.1 Dose dependent effect of malathion on cell viability of SY5Y cultures. Cell

viability was measured by MTT assay and the percentage control for each treatment is
expressed as mean ± SD values.
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4.3c Analysis of SY5Y proteome after treatment with malathion
2-DE was performed four times on whole cell lysate from control cell cultures (no
malathion) and cell cultures treated with 100 μM malathion for 24 hours and 2 times each
on 100 μM malathion for 48 hours and their corresponding control samples. The average
number of spots detected from the fluorescence-stained gel images using the PD Quest
software was about 400 spots in the treated and control gels. Figure 4.2 shows the typical
2-DE gel performed on the whole cell lysate from control sample (no malathion
treatment). 2-DE maps of 400 μg of whole cell lysate from treated cell cultures are shown
in figures 4.3 to 4.5. From the 400 spots, 123 spots were identified with both MALDITOF and LC- MS/MS combined (Appendix A and B). Twenty one proteins were
differentially expressed in the malathion treated samples (p<0. 05%) and the fold change
relative to control is given in Table 4.1. Figure 4.6 shows the sections of gel for the
differentially expressed proteins UCH L1, GST and for the protein rho GDI that was
unchanged after treatment along with the histograms. Figure 4.7 gives the gel sections
and the histogram for calmodulin that was down-regulated by about 2 fold when treated
with 100 μM malathion for 48 hours. Sixteen proteins were down-regulated and 5
proteins were up-regulated in the malathion-treated SY5Y cultures. These differentially
expressed proteins fall under different classes of proteins namely chaperone proteins,
calcium binding proteins, cytoskelatal proteins and proteins involved in degradation
pathways. A representative MS/MS spectrum along with the Mascot search results for
protein UCH L1 is shown in figure 4.8. Figure 4.9 gives the MALDI-TOF mass spectrum
for protein GRP 75.
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pH 3

10

66

44

Mr
(kDa) 31

21

14

Figure 4.2 A representative 2D gel image of 400 μg of control SY5Y samples (no

Malathion) resolved first on a pH 3 to 10 IPG strip, separated on 8-16% gradient
polyacrylamide gel and annotated with spot numbers. The protein spots were visualized
by staining with in-lab synthesized fluorescent ruthenium complex. The numbers on the
annotated gel indicate proteins that were identified by mass spectrometry and correspond
to numbers assigned in Tables 1 and 2.
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Figure 4.3 A representative 2D gel image of 400 μg of whole cell lysate from SY5Y cell

cultures treated with 50 μM malathion for 16 hours and resolved first on a pH 3 to 10 IPG
strip and separated on 8-16% gradient polyacrylamide gel. The spot numbers indicated in
the gel are landmark proteins, the protein names of which are given in appendix A and B.
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Figure 4.4 A representative 2D gel image of 400 μg of whole cell lysate from SY5Y cell

cultures treated with 100 μM malathion for 24 hours and resolved first on a pH 3 to 10
IPG strip and separated on 8-16% gradient polyacrylamide gel. The spot numbers
indicated in the gel are landmark proteins, the protein names of which are given in
appendix A and B.
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Figure 4.5 A representative 2D gel image of 400 μg of whole cell lysate from SY5Y cell

cultures treated with 100 μM malathion for 48 hours and resolved first on a pH 3 to 10
IPG strip and separated on 8-16% gradient polyacrylamide gel. The spot numbers
indicated in the gel are landmark proteins, the protein names of which are given in
appendix A and B.
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Table 4.1 List of proteins altered due to treatment with malathion. Seq.Cov. % denotes the percentage of protein sequence covered by

the trypsin digested peptides
Spot

Protein

#

Theoretical

Theoretical

Seq.

Mowse

Prot

Mr

pI

Cov.

score

ID

(kDa)

Swiss

Peptides matched

%

Fold Changes
16 hr

24 hr

48 hr

0.92

0.84

0.49

1.2

0.74

0.30

0.61

1.1

0.33

0.83

0.83

0.56

1.01

1.0

0.53

KMK, EAFR, DGDGTITTK
DGNGYISAAELR
1

Calmodulin

P62158

4.09

16.7

18

67

MADQLTEEQIAEFK
EAFSLFDKDGDGTITTK,
LTDESLSMPLISSFCPR

Enhancer
of
6

rudimentary

P84090

12.2

5.62

23

62

RQAQQAGK
EKIYVLLR, MYEEHLKR

homolog

ISSPTETER
TEFLSFMNTELAAFTK
9

Calgizzarin

P31949

11.7

6.56

40

102

NQKDPGVLDR,DPGVLDR,
AVPSQKR
TLSDYNIQK

10

Ubiquitin

P62988

0.85

6.56

7

84

TITLEVEPSDTIENVK
TITLEVEPSDTIENVKAK

12

Galectin 1

P09382

14.5

5.34

23

180

SFVLNLGK, LPDGYEFK
LNLEAINYMAADGDFK

Isoform 1
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Spot #

13

Protein

Galectin 1

Theoretical

Theoretical

Seq.

Mowse

Prot

Mr

pI

Cov.

score

ID

(kDa)

Swiss

P09382

Peptides matched

Fold Changes

%

14.5

5.34

17

92

isoform 2

LPDGYEFK

16 hr

24 hr

48 hr

1.07

0.68

0.16

1.1

0.65

0.40

0.8

1.0

0.58

1.3

0.64

0.51

1.1

0.90

1.7

LNLEAINYMAADGDFK
QAEILQESR

17

Tubulin specific

O75347

12.7

5.25

19

74

LEAAYLDLQR
KQAEILQESR

Chaperone A

RLEAAYLDLQR
FEDENFILK
ALSTGEKGFGYK
22

Cyclophilin A

P05092

7.82

17.8

10

184

VSFELFADKVPK
TEWLDGKHVVFGK
VKEGMNIVEAMER
FEELGVK, VLGMTLIQK

35

Glyoxalase 1

Q04760

20.5

5.25

27

104

FSLYFLAYEDKNDIPK
GLAFIQDPDGYWIEILNPK

MLLADQGQSWK
42

Glutathione S

O15217

25.7

7.89

20

71

PPYTVIVYFPVR
AFLASPEYNLPINGNGKQ

transferase A4

ALPGQLKTLLSQNQGGK

136

Spot

Protein

#

Theoretical

Theoretical

Seq.

Mowse

Prot

Mr

pI

Cov.

score

ID

(kDa)

Swiss

Peptides matched

Fold Changes

%
16 hr

24 hr

48 hr

1.08

0.52

0.13

0.87

0.82

0.57

0.77

0.58

VPFSLLR
LFDQAFGLPR
43

HSP 27

P04792

5.98

22.7

21

148

VSLDVNHFAPDELTVK
LATQSNEITIPVTFESR

ALVILAK, APLVLKD
GAEEMETVIPVDVMRR
44

DJ 1 protein

Q99497

6.33

19.8

15

187

GPGTSFEFALAIVEALNGKEVAA
QVK
EGPYDVVVLPGGNLGAQNLSES
AAVKEILK

LGVAGQWR, QFLSETEK
52

UCH L 1

P09936

5.33

24.8

34

269

LGFEDGSVLK
QIEELKGQEVSPK

Isoform 1

QFLSETEKMSPEDR
MPFPVNHGASSEDTLLK
MQLKPMEINPEMLNK
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0.89

Spot

Protein

#

Swiss

Theoretical

Theoretical

Seq

Mowse

Prot

Mr

pI

Cov

score

ID

(kDa)

Peptides matched

%

Fold Changes

16 hr

24 hr

48 hr

1.1

0.78

0.70

1.1

1.46

1.51

1.8

2.7

5.2

ELASQPDVD
QSLGELIGTLNAAK
62

TIM

P60174

26.5

6.51

29

190

KQSLGELIGTLNAAK
VVLAYEPVWAIGTGK
GFLVGGALKPEFVDIINAK
DLQNVNITLR
VLPSITTEILK
FDAGELITQR

67

Prohibitin

P35232

29.8

5.57

38

94

QVSDDLTER
QVAQQEAER
NVPVITGSK
EFTEAVEAK
IFTSIGEDYDER
ILFRPVASQLPR
KLEAAEDIAYQLSR
VSDEEKVR,
LLLNNDNLLR

72

F actin

P52907

32.9

5.45

24

107

FITHAPFNEVFNDVR

Capping

IEGYEDEHGDLGNSR

protein

FDHLRK, ESCDSALR

138

Spot

Protein

#

Swiss

Theoretical

Theoretical

Seq

Mowse

Prot

Mr

pI

Cov

score

ID

(KDa)

Peptides matched

%

Fold Changes

16 hr

24 hr

48 hr

MLVIEQCKNSR

spot

1.45

2.45

IDDIRKPGESEE

not

0.39

0.09

AVTIFIR, NLIRDNR
FSELTAEK,
VGGRLEDTK
MIIEEA,IADGYEQAAR
QQISLATQMVR
107

Tcomplex protein

P48643

59.6

5.45

19

155

1 ε subunit

DVDFELIKVEGK

detected

KQQISLATQMVR
EKFEEMIQQIK

GYISPYFINTSK
GVMLAVDAVIAELKK
ISSIQSIVPALEIANAHR
108

HSP 60

P10809

57.9

5.24

33

303

TLNDELEIIEGMKFDR
IQEIIEQLVTTSEYEKEK
QSKPVTTPEEIAQVATIS
ANGDK

139

0.67

Spot #

Protein

Swiss

Theoretical

Theoretical

Seq

Mowse

Prot

Mr

pI

Cov

score

ID

(kDa)

Peptides matched

%

Fold Changes

16 hr

24 hr

48 hr

0.97

1.76

1.75

1.1

0.49

0.50

LTPEEIER, ITITNDQNR
VYEGERPLTK,
EFFNGKEPSR
VEIIANDQGNR,
DAGTIAGLNVMR
SDIDEIVLVGGSTR
109

Glucose regulated

P11021

70.4

5.01

23

176

AKFEELNMDLFR
NGRVEIIANDQGNR

protein

KSDIDEIVLVGGSTR
TKPYIQVDIGGGQTK
IINEPTAAAIAYGLDKR
STMKPVQKVLEDSDLK
DNMALQR, LVGMPAKR
YAEEDRR, VLENAEGAR
NVPFKIVR,DSTGENIR
KDSETGENIR,RYDDPEVQK
DAGQISGLNVLR,
VQQTVQDLFGR,AIVTDLIR,
TTPSVVAFTADGER
110

GRP75

P38646

68.7

5.44

29

255

SDIGEVILVGGMTR,
AFEGIVTDLIRR
LYSPSQIGAFVLMK,
LGTLIGIPPAPR
VQQTVQDLFGRAPSK
NAVITVPAYFNDSQR
QAVTNPNNTFYATKR
SQVFSTAADGQTQVEIK
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Spot #

Protein

Swiss

Theoretical

Theoriticalp

Seq

Mowse

Prot

Mr

I

Cov

score

ID

(kDa)

Peptides matched

%

Fold Changes

16 hr

24 hr

48 hr

0.92

0.68

0.53

MALDIEIATYRK,
HLREYQDLLNVK
KVESLQEEIAFLK
ILLAELEQLKGQGK
ISLPLPNFSSLNLR
ETNLDSLPLVDTHSK
122

Vimentin

P08670

53.5

5.06

19

497

FADLSEAANRNNDALR
ETNLDSLPLVDTHSKR
EMEENFAVEAANYQDTIGR
LLQDDFSLADAINTEFKNTR
QMREMEENFAANYQDTIGR
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Figure 4.6 Close-up of the gel sections showing differential expression of protein UCH

L1(spot # 52), rho GDI (spot # 40) and GST (spot # 42) (A) and protein calmodulin (spot
#1)(B) between control (CTRL), 16 hour (MAL 16), 24 hour (MAL 24) and 48 hour
(MAL 48) malathion treated SY5Y cells. The protein spots are numbered corresponding
to appendix A and B. The difference in expression is shown in the histogram at the
bottom of the gel picture. The expression profile is presented as bar chart with error bars.
Each bar represents intensity ± S.D. of blots from quadruplet runs for control (CTRL) and
24 hour malathion (MAL 24) treated samples while duplicate for 16 hour (MAL 16) and
48 hour malathion treatment (MAL 48).
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Figure 4.7 Close-up of the gel sections showing differential expression of protein

calmodulin (spot #1) between control (CTRL), 16 hour (MAL 16), 24 hour (MAL 24)
and 48 hour (MAL 48) malathion treated SY5Y cells. The protein spots are numbered
corresponding to appendix A and B. The difference in expression is shown in the
histogram at the bottom of the gel picture. The expression profile is presented as bar chart
with error bars. Each bar represents intensity ± S.D. of blots from quadruplet runs for
control (CTRL) and 24 hour malathion (MAL 24) treated samples while duplicate for 16
hour (MAL 16) and 48 hour malathion treatment (MAL 48).
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MS/MS Fragmentation of
MQLKPMEINPEMLNK Found in
UCHL1

Mascot search result for UCH L1

Sequence Coverage: 34% Matched peptides shown in Bold Black
1 MQLKPMEINP EMLNKVLSRL GVAGQWRFVD VLGLEE
ESLG SVPAPACALL 51 LLFPLTAQHE NFRKKQIEEL
KGQEVSPKVY FMKQTIGNSC GTIGLIHAVA 101 NNQDK
LGFED GSVLKQFLSE TEKMSPEDRA KCFEKNEAIQ
AAHDAVAQEG 151 QCRVDDKVNF HFILFNNVDG
HLYELDGRMP FPVNHGASSE DTLLKDAAKV 201
CREFTEREQG EVRFSAVALC KAA

Figure 4.8 Representative example of MS/MS spectrum for the peptide fragment

MQLKPMEINPEMLNK along with the database search result for protein UCH L1
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MALDI-TOF mass spectrum
of GRP 75
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Sequence Coverage: 30% Matched peptides shown in Bold Black
1 MISASRAAAA RLVGAAASRG PTAARHQDSW NGLSHEAFRL
VSRRDYASEA 51 IKGAVVGIDL GTTNSCVAVM EGKQAKVLEN
AEGARTTPSV VAFTADGERL 101 VGMPAKRQAV TNPNNTFYAT
KRLIGRRYDD PEVQKDIKNV PFKIVRASNG 151 DAWVEAHGKL
YSPSQIGAFV LMKMKETAEN YLGHTAKNAV ITVPAYFNDS 201
QRQATKDAGQ ISGLNVLRVI NEPTAAALAY GLDKSEDKVI
AVYDLGGGTF 251 DISILEIQKG VFEVKSTNGD TFLGGEDFDQ
ALLRHIVKEF KRETGVDLTK 301 DNMALQRVRE AAEKAKCELS
SSVQTDINLP YLTMDSSGPK HLNMKLTRAQ 351 FEGIVTDLIR
RTIAPCQKAM QDAEVSKSDI GEVILVGGMT RMPKVQQTVQ 401
DLFGRAPSKA VNPDEAVAIG AAIQGGVLAG DVTDVLLLDV
TPLSLGIETL 451 GGVFTKLINR NTTIPTKKSQ VFSTAADGQT
QVEIKVCQGE REMAGDNKLL 501 GQFTLIGIPP APRGVPQIEV
TFDIDANGIV HVSAKDKGTG REQQIVIQSS 551 GGLSKDDIEN
MVKNAEKYAE EDRRKKERVE AVNMAEGIIH DTETKMEEFK 601
DQLPADECNK LKEEISKMRE LLARKDSETG ENIRQAASSL
QQASLKLFEM 651 AYKKMASERE GSGSSGTGEQ KEDQKEEKQ

Figure 4.9 Representative MALDI-TOF spectrum for the for protein GRP 75 along with

the matched peptides shown in bold black
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4.3d Validation of the 2-DE results by Western Blotting
To confirm the fidelity of results obtained by 2-DE, western blot analysis was carried out
for two proteins: one protein that was significantly down-regulated namely UCH L1 and
one protein rho GDI that was unchanged due to treatment with malathion. The western
blot data correlate with the 2-DE result for the analyzed proteins (Figure 4.10).
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(% control)

60

*

40

20
0

CTRL24 Mal 24 CTRL24 Mal 24
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Figure 4.10 Western blot analysis of protein UCH L1 that was upregulated in malathion

treated samples and rhoGDI that was changed due to treatment. The difference in
expression is shown in the histogram. The expression profile is presented as grouped bar
chart with error bars. Each bar represents relative intensity (% of control) ± S.D. of blots
from duplicate runs.
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Western blot bands were normalized to GAPDH bands and quantified in comparison to
control cells. Data are given as percentages of the control value (mean ± SD; n = 2
experiments; p<0.05). Exposure to 100 μM malathion for 24 hours results in a significant
decrease in UCH L 1 however, no significant change is seen in rho GDI protein.

4.4 Discussion

Large quantities of organophosphates are being used as insecticides to control pests in
both agricultural and domestic areas. The widespread use of malathion has created
awareness of related adverse effects on particularly non-target organisms. Most of the
reports studying toxicity of malathion were focused on secondary effects after exposure
and symptomology in particular. On the other hand, specific mechanisms involved in
malathion-induced in vitro toxicity have not been extensively described. The study is the
first proteomic investigation of the alteration in protein levels after treatment with
malathion using SY5Y cells as model system. These studies enable us to better
understand the underlying mechanisms by which malathion can potentially induce
toxicity.

4.4a Cell viability
Cell viability measurements based on MTT assay assess the mitochondrial activity of
healthy cells in a sample [95]. Treatment of SY5Y cells with 100 μM malathion for 24
hours lead to about 25% increase in the amount of MTT reduction compared to control
cell cultures (not treated with malathion) (Figure 4.1). MTT is reduced to formazan by
mitochondrial enzymes present exclusively in viable cells. Increased MTT reduction seen
when cultures were treated with 25 to 250 μM malathion denotes enhancement of
mitochondrial function in these cells. However, it does not provide any information on
the actual number of viable cells. In other words there could actually be fewer viable cells
present in the culture after treatment with malathion which show increased mitochondrial
activity. Treatment with concentrations greater that 1000 μM malathion caused
significant decrease in mitochondrial activity relative to control.

147

For our proteomic investigation, the SY5Y cell cultures may be treated with
concentrations of malathion ranging from 25 to 250 μM (Figure 4.1). It was however,
decided to treat the SY5Y cells with 100 μM malathion for two time periods namely: 24
hours and 48 hours and 50 μM malathion for 16 hours. This was done to enable
comparison of malathion toxic effects with another study that involving another
organophosphate insecticide, namely chlorpyrifos, on the SY5Y proteome. Chlorpyrifos
was also being studied in the lab and it was important that similar responses to the cell
viability assay for both chlorpyrifos and malathion were to be maintained to compare
their toxic effects.

4.4b Alteration in levels of proteins after treatment with malathion
Investigation of the SY5Y proteome after treatment with malathion showed significant
change in the levels of specific proteins when comparing results for control SY5Y
samples (no treatment) and malathion-treated samples. SY5Y cultures treated with 50 μM
malathion for 16 hours showed slight alteration in protein levels; these alterations became
more conspicuous in cultures treated with 100 μM malathion for a period of 24 and 48
hours (Table 4.1). The PD Quest software used for detection of the protein spots was also
used to estimate the protein spot volume that is directly proportional to the level of
protein in the sample. Normalization of the spot volume to the total density in the gel
image was carried out to avoid any non-expression related changes. A difference in spot
volume (and hence the protein level) was considered statistically significant at p<0.05
and confidence level of 95%.
The proteins whose levels were altered significantly after treatment with malathion fall
under five major classes of proteins: calcium binding proteins, chaperones, protein
involved in degradation pathways, cytoskeletal proteins and other miscellaneous proteins.
Each class of proteins is individually discussed in the following section.
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•

Calcium binding proteins

Calmodulin (spot #1) and calgizzarin (spot #9) are two calcium (Ca2+) modulators whose
levels were down-regulated by two and three fold respectively in SY5Y cell cultures after
treatment with 100 μM malathion for a period of 48 hours. There exists numerous
cellular processes within the eukaryotic cells that are Ca2+ dependent and/or Ca2+
regulated as reviewed by Clapham [98]. Calmodulin [99] is an ubiquitous protein that can
bind up to 4 Ca2+ ions and regulate various signaling pathways within the cell. Some of
CaM targets include: cyclic nucleotide metabolism, phosphorylation pathways,
dephosphorylation and calcium transport [100]. It has been reported that oxidative
modification of CaM results in degradation of the protein by the proteosome and
subsequently a decrease in the levels of functional CaM in rats [101]. Since CaM is the
major Ca2+ binding protein, reduction in calmodulin affects calcium levels within cells.
Calgizzarin is another Ca2+ binding protein that regulates various cellular events
including protein phosphorylation, enzyme activation, interaction with cytoskeletal
proteins and calcium homeostasis [102].
A balance in cytosolic calcium concentration is maintained not only by calcium binding
proteins but also by various other intracellular calcium buffers like mitochondria [103105]. But both calmodulin and calgizzarin that are primarily responsible for maintaining
calcium homeostasis within the cell were significantly down-regulated in cell cultures
treated with malathion compared to control cultures. The down-regulation of calmodulin
and calgizzarin in malathion-treated SY5Y cell cultures may result in an imbalance in
calcium concentration within the cell affecting various signaling pathways.

•

Chaperones

Chaperones are proteins that assist in the proper folding of other proteins by preventing
misfolding, unfolding misfolded proteins and maintaining unfolded conformations by
providing molecular and physical environments for correct folding. Many chaperones are
heat shock proteins (see more below) that are highly expressed during cellular stress to
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facilitate proper protein folding [106]. Some chaperones act to repair the potential
damage caused by misfolding while others are involved in folding newly synthesized
proteins as they are extruded from the ribosome. Other types of chaperones are involved
in transport across membranes, for example in the mitochondria and endoplasmic
reticulum [107, 108]. Chaperone proteins that are involved in the proper folding of
nascent proteins into their native functional state are also called chaperonins.
a. Heat shock proteins

Heat shock proteins (Hsp) are present during normal conditions whose expression is
greatly induced during stress [109, 110]. A common aspect of stress is generation of
misfolded proteins; when the stress is intense heat shock proteins are highly expressed to
cope with the increase in misfolded proteins. For this reason Hsps are also referred to as
stress proteins. Hsps are also considered to play a general role in protection against
cellular injury [111-113]. Hsps are highly conserved across species and since they play
vital role in protein translocation, folding and assembly are also known as molecular
chaperones [114, 115]. The Hsps are named according to their molecular weight and are
classified as small Hsps (between 10 – 30kDa) and large Hsps (greater than 30 kDa). A
number of heat shock proteins were identified in the whole cell lysate from SY5Y cells
(Appendix A and B and Table 4.1). The two heat shock proteins whose levels were
significantly altered after treatment with malathion are Hsp 27 and Hsp 60.
Hsp 27 belongs to a class of small heat shock proteins (sHsps) that can protect cells from
oxidative stress [116, 117]. sHsps act as molecular chaperones preventing unfolded
proteins from irreversible aggregation [118-120] and along with other factors such as
Hsp70 and adenosine tri-phosphate (ATP), they facilitate productive refolding of
unfolded proteins [121, 122]. Four protein spots #43, #48, #49 and #56 in figure 4.2 were
identified as Hsp 27 by mass spectrometry and the most acidic form [9] was downregulated significantly in SY5Y cells treated with malathion, yet without any significant
change in the total Hsp levels between control and treated samples. It is known that Hsp
27 has three phosphorylation sites (Ser15, Ser78 and Ser82) that can be potentially
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phosphorylated by protein kinases [123, 124] and phosphorylation decreases the pI of a
protein. The protein spots identified, as Hsp 27 may be the different phosphorylated
forms. Both Lavoie et al. and Loktionova et al. report that phosphorylation of Hsp 27
changes the quaternary structure of Hsp 27 resulting in the formation of dimers and
tetramers of the protein, which in turn is responsible for stabilization of actin
microfilaments by acting as actin capping protein [125, 126]. Down-regulation of the
most acidic isoform of Hsp 27 (phosphorylated) in malathion-treated cells suggests
disruption of actin polymerization.
Hsp 60 is an essential mitochondrial protein that promotes the folding of several proteins
imported into the mitochondrial matrix [127, 128]. Hsp 60 also refolds and prevents
aggregation of denatured proteins [129]. Three protein spots #108, #112 and #113 were
identified as Hsp 60 (Figure 4.2). Fratelli et al. report three isoforms of Hsp 60 in
oxidatively stressed human T lymphocytes, a result of glutathionylation (posttranslational modification) of the protein [130]. Our results indicated that the most acidic
isoform was identified to be down-regulated in the malathion treated SY5Y cells. Taking
into account that the main role of Hsp 60 is in the proper folding of proteins within the
mitochondria, the down-regulation of the acidic form in the malathion treated SY5Y cell
cultures could result in an accumulation of misfolded proteins within the mitochondria.
To reiterate, the acidic isoforms of both stress proteins Hsp 27 and Hsp 60 were
significantly down-regulated in malathion-treated SY5Y cell cultures. The downregulation of these proteins could also contribute to an increased susceptibility of the
cells to oxidative stress since these chaperones are thought to attenuate the proteolysis of
misfolded proteins (formed as a result of oxidative stress) by binding to them and
assisting in their repair. Further characterization of the function of each protein isoform
may reveal in-depth information about the relevance of these findings.

151

b. Chaperonins

A number of other chaperones were identified as significantly altered after treatment with
malathion in SY5Y cells. These included tubulin-specific chaperone A, cyclophilin A,
prohibitin, T complex 1 protein, glucose-regulated protein 78 (GRP 78) and glucoseregulated protein 75 (GRP 75). Tubulin specific chaperone A protein is essential for the
formation of functional tubulin heteromers and binds to tubulin folding intermediate
formed by the synthesis of tubulin polypeptide with chaperonin T complex protein [131].
T complex protein (TCP) in addition to its role in formation of tubulin, also aids in the
folding of other proteins [132, 133]. It is thought to act in concert with various protein
degradation and modification pathways and maintain cellular homeostasis. TCP was upregulated 2.5 fold in the SY5Y cells treated with malathion. The up-regulation of TCP is
an indication that SY5Y cells treated with malathion are stressed.
Spots #20, #21, #22 and #23 in figure 4.2 were all identified as peptidyl prolyl cis-trans
isomerase (cyclophilin A). From the amino acid composition of the protein, the
isoelectric point is expected to be 7.8; however, based on the computed course of the pH
gradient and the positions of other identified proteins in the gel, the actual pI spans a
range from 7 through 8. Three isoforms of cyclophilin A have been reported earlier with
possibility of phosphorylation as PTM [134]. In our study, four different isoforms were
identified. There was no significant change in total protein level, however, spot #22 was
significantly down-regulated in malathion-treated samples. Cyclophilin A catalyzes the
cis-trans isomerization of proline imidic peptide bonds in oligopeptides and accelerates
protein folding [135]. Cyclophilin A has been implicated in diverse functions such as the
heat-shock response [136], in the nuclear import of some proteins [137] and in various
signal tranduction pathways [138], but its exact function is not fully understood. It has
also been demonstrated that decreasing the level of cyclophilin A in neuronal B50 cells
inhibits the activation of caspases that are involved in triggering apoptosis [139]. There is
however, no information in the literature on the specific role of these different isoforms
of the protein, but the significant change in the levels of one particular isoform (acidic
isoform) after treatment with malathion is definitely worth exploring. It is possible that
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malathion is triggering apoptosis in the SY5Y cells, but decreased cyclophilin A isoform
(may be the functional isoform) renders the cells resistant to apoptosis.
Spot #67 was identified as prohibitin, a mitochondrial protein. Prohibitin is a membrane
chaperonin that stabilizes mitochondrial proteins [140]. Prohibitin also plays a pivotal
role in cell cycle regulation, aging, apoptosis and mitochondrial function [141, 142].
Coates et al. showed that prohibitin was up-regulated during metabolic stress due to
imbalance in the synthesis of mitochondrial proteins [143]. Prohibitin was also upregulated in malathion-treated SY5Y cells by a factor of 1.5 fold when compared to
control cultures which could very well be due to malathion-induced mitochondrial stress.
Two glucose regulated proteins GRP 78 (spot # 109) and GRP 75 (spot #110) were
identified as significantly altered in SY5Y cells after treatment with malathion. GRP 78
has been implicated in unfolded protein response (UPR) during which it is up-regulated
to correct the misfolded proteins [144]. GRP 78 transiently binds to a wide repertoire of
proteins traversing the endoplasmic reticulum (ER) and facilitates their correct folding,
glycosylation, assembly and turnover [145-147]. It is reported that GRP 78 induction
protects cells from undergoing apoptosis and maintain cell viability under ER stress [148,
149]. Induction of the corresponding grp78 gene can occur in response to different
stimuli including glucose starvation, hypoxia and ER Ca2+ pool depletion [150].
Interestingly, GRP 78 was also up-regulated in SY5Y cells treated with malathion. GRP
75 on the other hand was down-regulated significantly in malathion-treated SY5Y cells.
GRP 75 is involved in the transport of proteins and their assembly inside the
mitochondria [151]. Furthermore, GRP 75 may influence the pattern of proteins
synthesized in the mitochondria, facilitate the assembly of mitochondrial proteins and
then protect the proteins from proteolytic degradation [152, 153]. The alterations in levels
of these ER and mitochondria specific glucose regulated proteins indicate malathion
induced stress to these organelles in SY5Y cells.
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•

Proteins involved in ubiquitin proteosome pathway

Studies indicate that most intracellular protein degradation takes place via the ubiquitin
proteosome pathway (UPP) [154]. The UPP maintains cellular homeostasis by removing
misfolded dysfunctional proteins. Ubiquitin carboxy terminal hydrolase L1 (UCH L1)
(spot # 52 and # 54) is an essential enzyme in the UPP that is specifically involved in the
recycling of ubiquitin by releasing it from the polyubiquitin tail [154] . Choi et al. report
the presence of three different isoforms of UCH L1 in the brain of Alzheimer’s disease
(AD) patients [155]. It should be noted here that we have identified two isoforms that
have similar molecular weight but different isoelectric points (pIs). The more acidic
isoform was down-regulated about 2 fold when SY5Y cell cultures were treated with 100
μM malathion for a period of 48 hours. In addition to the hydrolase activity, it has been
suggested that UCH L1 is also a regulator of apoptosis [156].
The UPP involves ubiquitination of damaged or misfolded proteins that is to signal the
degradation of proteins; however, damaged proteins are not removed when ubiquitin is
reduced or mutated [157]. There is evidence that UCH L1 associates with ubiquitin
during the UPP [156, 157]. It has been reported that UCH L1 deletion in mice cause
gracile axonal dystrophy (gad), a recessive neurodegenerative disease [158]. In our study
both UCH L1 (an acidic isoform) and ubiquitin were identified to be down-regulated in
malathion-treated SY5Y cell cultures. We know that under stress most proteins can
become misfolded and non-functional. Down-regulation of these two critical proteins
involved in the removal of dysfunctional proteins in the malathion treated SY5Y cells
could render the cells more susceptible to the accumulation of toxic misfolded proteins.
Further study is required to identify the PTM and elucidate the functional significance of
the acidic isoform of UCH L1.

•

Cytoskeletal proteins

Seven proteins spots (# 76, #77, # 78, #88, #89, #90, and #122 in figure 4.2) were
identified as vimentin, the intermediate filament protein. The various isoforms had
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different molecular weights and pIs. The isoforms differed in molecular weight may be
result of fragmentation of the parent protein itself, while the isoforms that differed in pI
resulted most likely from PTMs. Studies have reported that vimentin is essential for
axonal initiation in differentiating neuroblastoma cells [159]. It is a major contributor to
the mechanical strength of a cell. Significant down-regulation of one isoform of vimentin
was observed in SY5Y cells exposed to malathion along with a down-regulation of total
vimentin levels when compared to control cultures. Spot # 72 was identified as F actin
capping protein; this is a cytoskeletal-associated protein that was significantly upregulated by 5 fold in malathion-treated cultures. F actin capping protein is involved in
capping the barbed ends of the actin filaments during polymerization and thus prevents
the addition of actin units to the end [160]. The alterations in the levels of these structural
proteins in malathion-treated SY5Y cells indicate disruption of cytoskeletal architecture.

•

Miscellaneous proteins

Two isoforms of galectin-1 (spot # 12 and 13) were identified and both were downregulated in SY5Y cell cultures treated with malathion. Galectin-1, a β-galactosidebinding lectin has been suggested to play a role in cell adhesion, proliferation and
apoptosis [161]. Galectin-1 also acts as a negative growth regulator in neuroblastoma
cells, and, in fact, galectin-1 is a probable effector in the sialidase-dependent growth
control of neuroblastoma cells [162]. DJ-1 protein (spot # 44), a multifunctional protein
involved in transcription and oxidative stress, is down-regulated after treatment with
malathion. Deletion of the DJ-1 gene is associated with Parkinson’s disease which is
thought to be due to the loss of the DJ-1 protein [163]. It has also been suggested that the
loss of DJ-1 protein in neurons makes the cells more susceptible to oxidative stress and
ER stress [164]. In the malathion-treated SY5Y cell cultures that show evidence for
stress, down-regulation of DJ-1 protein can make these cells more vulnerable to ER
stress.
Triose phosphate isomerase (spot # 62) catalyzes the isomerization of dihydroxyacetone
phosphate to D-glyceraldehyde 3-phosphate [165]. The isomerization involves the
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formation of the cytotoxic intermediate methylglyoxal, which is eliminated by glyoxalase
1 (spot #35) preventing the formation of advanced glycation end products [166]. Downregulation of both these proteins in SY5Y cell cultures treated with malathion is
intriguing but further investigation needs to be done to elucidate the significance.
Glutathione S transferase A4 (spot # 42) is a phase 2 detoxifying enzyme that conjugates
glutathione to a number of toxic electrophiles [167]. Lechner et al. report that GST
activity in rat liver homogenate was increased two fold after treatment with malathion
[168]. The increased levels of this enzyme in malathion-treated SY5Y cells suggest that it
may carry out a protective measure against the insult. It is clear that malathion has the
potential to disrupt cellular antioxidant defenses in SY5Y cell cultures. Spot # 6 was
identified as enhancer of rudimentary homolog and the protein is a transcriptional coregulator that is highly conserved from plants to humans [169]. Little is known about its
function, but its down-regulation observed in SY5Y cells treated with malathion can have
consequences in the transcription machinery.
The alteration in protein levels in SY5Y cell cultures after treatment with malathion is an
important finding in regard to the OP toxicity, since there has been limited literature in
this area. The level of any protein in a cell at any given time is controlled by the rate of
transcription of the gene, efficiency of translation of the mRNA into the protein and the
rate of degradation of the protein in the cell. 2-DE offers a powerful way of taking a
snapshot of the state cells are, at a given time. However it should be noted that whether
the alteration in protein levels studied by 2-DE is due to imbalance in proteolysis and
protein synthesis warrants further investigation. Based on the altered levels of major
proteins identified in our study, we propose the following model for the effect of
malathion (Figure 4.11).
Reports have indicated that organophosphates in addition to inhibiting AChE, can
directly bind to muscarinic receptors (which are receptors for AChE) present in cells
[170, 171]. Similarly, malathion can bind to muscarinic receptors present in the SY5Y
cells. Binding of malathion to the receptor stimulates the phosphotidyl inositol pathway
and activates the enzyme phospholipase C. Phospholipase C hydrolyzes phosphoinositide
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bis-phosphate to inositol tri-phosphate (IP3) and diacylglycerol (DAG), IP3 acts as a
second messenger and stimulates the release of calcium into the cytoplasm from
intracellular stores like the ER. Increased cytoplasmic calcium has been reported as a
definite event in the mechanism of many OP induced neuronal disorders [172, 173].
Elevation in intracellular calcium was also reported during an early phase of malathion
induced apoptosis in the grass carp cell line ZC 7901 [174]. The increase in cytoplasmic
calcium levels might be due to decreased activity of calcium expelling systems. Two
calcium modulators: calmodulin and calgizzarin were significantly down-regulated in the
malathion treated SY5Y cells. Ca2+ ATPase is another important calcium effluxing
enzyme that extrudes calcium in order to maintain calcium homeostasis. Sharma et al.
report the decrease in Ca2+ ATPase activity in hens after exposure to OP [175]. Though
there is no direct indication of reduced Ca2+ ATPase in the malathion-treated SY5Y cells,
the various other observations point out that malathion might increase cytoplasmic
calcium levels. Since calcium is a known second messenger, increased levels of calcium
within the malathion-treated SY5Y cells could lead to a cascade of intracellular events
including impairment of mitochondrial oxidative phosphorylation and generation of free
radicals [176].
Mitochondria start to accumulate calcium when the cytoplasmic calcium concentration is
over a threshold value and this occurs via a uniporter that is driven by the mitochondrial
membrane potential [177, 178]. Hansford [179] and McCormack [180] found three Ca2+stimulated mitochondrial dehydrogenases: pyruvate dehydrogenase, α-ketoglutarate
dehydrogenase and isocitrate dehydrogenase coupled to the electron-transport system.
Activation of these dehydrogenases results in stimulation of both electron transport and
ADP phosphorylation. The greater MTT reduction (mainly brought about by
mitochondrial dehydrogenases) that was observed in the malathion treated SY5Y cell
cultures can be explained by the stimulation of the above mentioned mitochondrial
dehydrogenases by increased calcium concentration within the mitochondria. The uptake
of calcium also activates mitochondrial phospholipases (like phospholipase A that
catalyze the formation of arachidonic acid; reactive oxygen species generator) and seems
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to trigger increased production of reactive oxygen species (ROS) [181-183] as well as
release of mitochondrial proteins, some of which are proapoptogenic [184].
Cadenas et al. report that in normal cells up to 5% of the oxygen reduced by
mitochondria is converted by complex I of the respiratory chain to superoxide [185].
While ROS are proposed to play important roles in coordinating and regulating a number
of cellular signaling pathways (redox signaling), oxidative stress results when the
formation of ROS exceeds the capacity of antioxidant defense systems [186]. Increased
mitochondrial activity coupled to imbalance in Ca 2+ ion concentration within the
mitochondria results in increased production of ROS. Oxidative stress has already been
implicated in malathion-induced cytotoxicity [80]. The production of ROS damages the
cell structures including the DNA, proteins and lipids [187].
Free radicals attack cell and organelle membranes, decrease the membrane fluidity by
modifying lipids via a process termed lipid peroxidation and significantly alter membrane
properties and possibly even disrupt the function of membrane-associated proteins [188].
Free radical oxidation causes proteins unfold/misfold [189-191]. Grune et al.
demonstrated that oxidative modifications of proteins significantly accelerate protein
aggregation and crosslinking [192]. To maintain proteins in a properly folded state, cells
utilize a variety of chaperones that facilitate refolding, and if a protein is unable to be
refolded it is degraded, often via the ubiquitin-proteasome pathway (UPP). However, in
the malathion treated SY5Y cells, the chaperone proteins namely heat shock proteins,
TCP, cyclophilin A and other proteins involved in UPP like ubiquitin and UCH L1 were
significantly down-regulated. This means that in the SY5Y cells exposed to malathion,
the damaged proteins may not be efficiently removed/degraded leading to their toxic
accumulation.
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Figure 4.11 Proposed model for malathion induced cytotoxicity in neuroblastoma cells.
Malathion binds to muscarinic acid receptor and stimulates the phospholipase pathway resulting
in production of inositol tri phosphate (IP3). IP3 binds to its receptors present in endoplasmic
reticulum (ER) and causes the release of Ca2+ from the ER. Down-regulation of calcium
modulators like calmodulin, calgizarrin and Ca-ATPase causes increase in cytosolic Ca2+ and
results in calcium influx into the mitochondria. Imbalance in Ca2+ inside the mitochondria causes
stimulation of various lipases, proteases and other enzymes. Activation of phospholipase A2
causes increased generation of reactive oxygen species (ROS). The electron transport chain
(ETC) is also activated and this adds to the ROS produced. The increased ROS and downregulation of antioxidant systems result in oxidative stress. The free radicals generated cause a
number of undesirable effects that includes damage to the membrane and protein misfolding. The
hydroxyl radical generated can cause ER stress that is seen in the up-regulation of GRP 78
protein. Both ER and mitochondria are stressed due to treatment with malathion that is seen by
the up-regulation of the stress specific proteins. Down-regulation of UCH L1, ubiquitin and other
chaperone proteins that are involved in the removal of misfolded proteins indicates potential
accumulation within the cells that can lead to malathion-induced cytotoxicity.
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Since malathion is thought to cause oxidative stress, one would predict that in response
the levels of Hsps would be high in SY5Y cells exposed to malathion. Yet, 2-DE data
find low levels of these proteins, thus the paradoxically low levels of Hsps accentuate the
oxidative damage incurred by exposure to malathion leaving the cells vulnerable and
more prone to such damage.
Another organelle that is susceptible to ROS damage is the ER. The free radicals
generated within the mitochondria are converted to H2O2 by the enzyme superoxide
dismutase [193]. The H2O2 so formed can react with intracellular Fe2+ ions possibly by
Fenton reaction and result in the formation of hydroxyl radicals that are highly
undesirable for ER and induce ER stress [194]. In addition to this oxidative stress due to
ROS, ER is also susceptible to protein misfolding. Proteins unable to fold correctly cause
ER stress and activate the unfolded protein response (UPR). As stated earlier, GRP 78 is
a protein that is up-regulated when the ER is under stress due to misfolded proteins [148,
149]. In the SY5Y cells treated with malathion too the GRP 78 was significantly upregulated indicating that malathion is capable of causing ER stress in these
neuroblastoma cells. While increase in GRP 78 indicates ER stress, a decrease in DJ-1
protein levels also points out at an ER stressed environment. DJ-1 protein was downregulated significantly when the SY5Y cells were treated with malathion.
In addition to ER, mitochondria being one of the major sites of ROS production in a cell
are also highly sensitive to impairment in ROS levels. Prohibitin, a mitochondrial specific
stress protein was significantly up-regulated in SY5Y cells treated with malathion. This
indicates malathion-induced stress to the organelle. Chen et al. reported that malathion
induced cytotoxicty in grass carp cells by directing damaging mitochondria due to
intracellular Ca2+ elevation, generation of reactive oxygen species (ROS) and ATP
depletion [174]. Taken together, our results suggest that malathion induces oxidative
stress leading to possible misfolding of protein that can potentially accumulate and cause
cytotoxicity in neuroblastoma cell cultures.
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The 2-DE technique employed is a powerful tool to investigate differential protein
expression in a complex system because it has the ability to resolve a complex mixture of
proteins like that of the whole cell lysate. However, it should be realized that 2-DE can
only provide a snapshot of the most abundant proteins that are expressed at a given time
point. Although these results allow a glimpse of malathion toxicity at the proteome level,
it is hard to know if such alteration is a cause or a consequence of the treatment. Future
work should be focused on the sub-proteome of mitochondria and ER from SY5Y cells
after treatment with malathion. This will provide insight into the biochemical pathways
that are associated with stress caused by malathion.
Although neuroblastoma cells are the preferred model to test the in vitro toxicity caused
by organophosphates, it should be realized that they are cancerous in. More precise
information about the implication to human exposure can be deduced by employing
primary cell lines (non-cancerous) or from animal studies. Overall, the current study
provides a foundation for studies on cell culture, pesticide exposure and altered levels of
proteins.

4.5 Conclusion

The hypothesis tested is exposure of SY5Y cells to malathion causes alteration in protein
levels. The current study identified a number of stress response proteins, including
calcium binding proteins, proteins involved in degradation pathways, cytoskeletal and
tumor suppressor proteins to be significantly altered following treatment with malathion
in the SY5Y cell cultures. The identification of differential protein expression in SY5Y
cells after treatment with malathion is an important finding in regard to the OP toxicity,
since there has been limited knowledge in this area.
In conclusion, the data obtained in this study represent the first proteome profiling of
SY5Y cells response to malathion. It was observed that there was significant alteration in
levels of proteins when the cells were treated with 100 μM malathion for a period of 24
hours that was exaggerated when the exposure was prolonged for 48 hours. This means
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that the changes seen in protein levels could be an early indication of impending cellular
damage. Cumulative evidence from previous experiments along with our data shows that
oxidative stress is an important trigger for malathion toxicity. In our study, 122 proteins
were identified from the SY5Y whole cell lysate out of which 21 proteins were
significantly altered after treatment with malathion. Sixteen proteins were downregulated while 5 proteins were up-regulated due to treatment with malathion. Our results
suggest that exposure to malathion causes perturbation in calcium homeostasis within the
mitochondria that leads to generation of free radicals, accumulation of misfolded proteins
and cause stress to mitochondria and ER in the SY5Y cell cultures. With increased
awareness in pesticide related adverse effects, this oxidative stress induced by malathion
in human neuroblastoma cells becomes especially critical when it comes to non-target
exposure of elderly individuals to malathion. Such individuals, who are already
susceptible to the damaging effects of oxidative stress due to process of aging, are
exposed to malathion there is all possibility that the undesirable effects be more
exacerbated. However, implication of this finding has to be further investigated using
either primary cell lines and/or animal models to be able to extrapolate the effect to
humans as well.
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CHAPTER FIVE

COMPARISON OF ALBUMIN-INTERACTOME IN VENTRICULAR
CEREBROSPINAL FLUID BETWEEN ALZHEIMER’S DISEASE AND
NORMAL SUBJECTS

5.1 Introduction

Alzheimer’s disease (AD) is a progressive neurodegenerative disorder that is
characterized by deterioration of cognitive functions and is the most common form of
dementia [195]. AD symptoms form a continuum with normal aging-related memory loss
and this makes diagnosis difficult. Currently the only way to confirm AD is during
autopsy of the patient by examining the brain for the presence of senile plaques and
neurofibrillary tangles that are hallmarks of AD [196]. Protein β amyloid 1-42 (Aβ42) is
the main protein that constitutes the senile plaques in the brain [197, 198]. Cerebrospinal
fluid (CSF) from AD patients has reduced levels of Aβ42 relative to normal individuals,
but there is no clear explanation for this [199-202]. Neurofibrilliary tangles in the brain of
AD patients are a result of hyperphosphorylation of the tau protein (9). Aβ42, total tau
(T-tau) and phosphorylated tau (P-tau) have been suggested as diagnostic markers for AD
in clinical practice [203]. The changes in the levels of these proteins, however, overlap
with other neurodegenerative disorders and hence are not specific to AD.
The development of valid and reliable biomarkers that signify the disease condition is
essential for the clinical diagnosis of AD. Biological fluids like serum, urine and
cerebrospinal fluid (CSF) are being tested for AD biomarkers. CSF is most suited for the
identification of biomarkers for diseases affecting especially the brain. CSF produced by
the choroids plexus is a complex mixture of proteins and a difference in levels of these
proteins indicate a disease condition [204]. CSF is in direct contact with the extra-cellular
space of the brain and there is constant exchange of substances between the CSF and the
brain. Hence, any change in the brain due to the disease pathology must be reflected in
the surrounding CSF.
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The CSF proteome has been characterized by several researchers, some of them
elucidating the proteome [75-89] and others aimed at discovering biomarkers for
neurodegenerative diseases like AD [90-99]. A major challenge involved in the analysis
of CSF is the complexity of the sample. There exists enormous dynamic range in the
levels of CSF proteins ranging from μg to ng. Albumin and immunoglobulins are the
most abundant proteins found in the CSF constituting on average about 50% and 25%,
respectively [205]. The complexity of CSF makes fractionation an essential step in the
analysis of the proteome. Different methods can be used to achieve this, which include
acetone precipitation, ultrafiltration, HPLC, capillary isoelectric focusing, liquid IEF and
traditional 2-DE. By a combination of albumin and immunoglobulin depletion and
MUDPIT analysis, 249 proteins were identified in human ventricular CSF [206].
Normally, to facilitate the analysis of low abundance proteins in biological fluids like
serum and CSF, the most abundant proteins- albumin and immunoglobulins- are depleted
using commercially available depletion kits or by using specific antibodies [207-209].
Albumin is a carrier and transport protein that interacts with a number of other small
proteins and peptides [210-212]. Depletion of albumin could lead to the concomitant
removal of low molecular weight proteins and result in the loss of information from these
potentially interesting proteins and peptides [213]. However, selective isolation of this
“interactome” fraction ( that consists of albumin interacting proteins) will enable
identification of these low molecular weight proteins that are also potential biomarkers
for the AD.
The primary goal of this project was to isolate and compare the albumin-interactome in
CSF between AD and normal subjects. Changes in protein levels in this fraction of the
CSF proteome can provide insights into the disease pathology and help understand the
progression of the disease.
A crude isolation of the albumin-interactome was performed using membrane cut-off
filters. A number of proteins along with their different isoforms as a result of posttranslational modifications (PTM) were observed in the albumin-containing fraction that
showed significant difference in expression levels between CSF from AD and normal
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subjects. To pinpoint the proteins that make up the albumin-interactome,
immunoprecipitation of albumin from CSF was carried out. Our results clearly indicated
the successful isolation of the albumin-interactome by immunoprecipitation, which
thereby enabled the identification of proteins that are otherwise difficult to identify by
direct analysis of CSF. Analysis of the 2-DE gel from the cut-off filter study showed
differences in expression of specific isoforms of proteins that constituted the albumininteractome, emphasizing the importance of elucidation of PTMs along with studies
related to levels of each isoform as opposed to examining the total protein content for
biomarker discovery.

5.2 Materials and Methods

5.2a Materials
Cut-off filters were purchased from Millipore (Billerica, MA). Protein G sepharose beads
were purchased from GE healthcare (Princeton, NJ) and the rabbit anti-human albumin
antibody was a product of Research Diagnostics Inc. (Flanders, NJ). Spin-X centrifuge
tube filters with cellulose acetate membranes having a pore size of 0.45 μm were
acquired from Corning Incorporated Life Sciences (Acton, MA). Dimethyl pimelimidate
(DMP), sodium borate, acrylamide, bisacrylamide, ethanolamine and ammonium
persulfate were purchased from Sigma (St. Louis, MO). Sodium phosphate monobasic
and dibasic, phosphoric acid, Tris-HCl, methanol, formic acid and acetonitrile were
obtained from Fisher Scientific (Fair Lawn, NJ). Ammonium sulfate was obtained from
EMD chemicals (Gibbstown, NJ). Protein staining reagent Coomassie G250, TEMED
and the low-range marker proteins were purchased from Bio-Rad (Hercules, CA).
Lyophilized sequencing grade modified trypsin was purchased from Promega (Madison,
WI). Fused silica capillary tubing 320 μm I.D. x 435 μm O.D. for liquid chromatography
column was purchased from Polymicro Technologies (Phoenix, AZ) while the reverse
phase packing material Polymer X (3 μm) was purchased from Phenomenex (Torrance,
CA). All other LC accessories including zero dead volume (ZDV) unions, frits, ferrules
were obtained from Upchurch Scientific (Oak Harbor, WA)
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5.2b Human ventricular CSF sample
Post mortem human CSF samples were obtained from Sanders-Brown Center on Aging
(University of Kentucky, Lexington, KY). CSF samples were collected during autopsy
from 6 AD and 6 normal control subjects. All AD subjects met NINCDS-ADRDA
workgroup criteria for the clinical diagnosis of probable AD [214]. The subjects also met
the criteria for histopathologic diagnosis of AD [215]. Control CSF samples were
obtained from subjects who underwent annual neuropsychological testing as a part of
normal volunteer, longitudinal aging studies at Sanders-Brown Center on Aging and were
without a history of dementia or any other neurological disease. Evaluation of control
brains revealed only age related alterations. CSF samples were collected as described
previously by Lovell et al. [216]. Immediately after collection, 2 mL aliquots of CSF
samples were stored at -80°C until analysis. The pilot study with Microcon filters used
ventricular CSF samples from 6 AD and 6 normal age-matched individuals. For
immunoprecipitation, 200 μL of CSF each from 4 AD samples were pooled together to
form the pooled AD CSF sample and similarly 200 μL of CSF from 4 normal individuals
were combined to form the pooled control CSF sample. The samples were pooled to
minimize the individual differences in protein expression and normalize the amount of
protein among the population.

5.2c Efficacy of Microcon cut-off filters
The efficacy of cut-off filters was tested using the standard low-range marker proteins. A
30 kDa cut-off filter was pre-rinsed with distilled water to get rid of any glycerol that
might be present. A solution of 200 ng of each protein in the low-range marker proteins
in 150 μL of 0.2% formic acid in 50% ACN was added to the pre-rinsed 30 kDa cut off
filter and centrifugation was carried out at 4000 g for 15 min. A solution of 100 μL of
0.2% formic acid in 50% ACN was added to the filter and centrifugation was carried out
at 1000 g for 1 min. The wash was repeated and the flow-through from the filter was
collected. A volume of 100 μL of 0.2% formic acid in 50% ACN was added to the filter
and the above 30 kDa fraction was collected after centrifugation at 1000 g for 1 min. The
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flow-through and the fraction above 30 kDa (retentate) from the cut-off filter were dried
in a vacuum centrifuge, 25 μL of sample loading buffer was added, boiled and the sample
was loaded onto a 12% polyacrylamide gel. Electrophoresis was carried out at constant
voltage of 200 V until the dye front reached the bottom of the gel.

5.2d Isolation of albumin-interactome using Microcon cut-off filters
A crude isolation of albumin-interactome was performed by subjecting a volume of 400
μL of post mortem human ventricular CSF from 6 AD and 6 age matched normal subjects
(control) to fractionation based upon their molecular weight using Microcon 100 kDa and
50 kDa cut-off filters. The cut-off filters were pre-rinsed with distilled water to remove
glycerol. CSF was added to the 100 kDa filter that is stacked on top of a 50 kDa cut-off
filter and centrifugation was carried out at 2000 g for 30 min. The flow-through from the
50 kDa and the retentate from the above 100 kDa were collected. A solution of 200 μL of
1 mM DTT in 20% acetonitrile was added to the 50 kDa membrane and after incubation
for 2 minutes, the between 100 and 50 kDa fraction was collected after centrifugation at
5000 g for 5 min. The wash was repeated two more times with 200 μL and 100 μL of
DTT/ACN solution respectively. The washes from the 50 kDa filter were collected and
added to another fresh pre-rinsed 50 kDa cut-off filter and centrifugation was carried out
at 5000 g for 5 min to remove albumin (that has a molecular weight of ~ 60 kDa will
remain above the filter). The flow through from the second 50 kDa cut-off filter that
contains proteins interacting with albumin, was subjected to 2-DE.

5.2e Crosslinking of anti-human albumin antibody to Protein G beads
Immunoprecipitation of albumin from CSF was carried out after crosslinking to Protein G
sepharose beads using a modified protocol published by Zhou et al. [213]. Briefly 300 μL
of wet protein G sepharose beads were added to a Spin-X filter and centrifugation was
carried out at 1500 g for 1.5 min. Five hundred micro liter of 0.1 M phosphate saline
buffer (PBS) was added to the beads and centrifugation was carried out at 1500 g for 1.5
min. The PBS wash was repeated two more times after which the beads were incubated
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with 100 μL of a 10 μg/ μL stock solution of rabbit anti-human albumin antibody and 400
μL of PBS for 1 hour on a rocker at room temperature. The beads were subjected to
centrifugation at 1500 g for 1.5 min to get rid of any unbound antibody. The beads were
washed three times each with 500 μL of 0.2 M sodium borate buffer pH 9.0. The
antibodies were crosslinked to Protein G using 500 μL of 25 mM DMP in 0.2 M sodium
borate buffer pH 9.0. After incubation for 30 min at room temperature on a rocker, the
beads were centrifuged at 1500 g for 1.5 min to remove the un-reacted DMP. The
crosslinking of antibody to the beads was carried out two more times with 500 μL
aliquots of DMP each time. The crosslinking reaction was stopped by a quick rinse with
500 μL of 0.1 M ethanolamine (pH 9.0) followed by incubation in 500 μL 0.1 M
ethanolamine for 30 min at room temperature on a rocker. After incubation with
ethanolamine, the beads were washed twice with 500 μL of PBS to remove any residual
ethanolamine. The anti-albumin antibody conjugated protein G beads were re-suspended
in PBS and stored at 4°C until use.

5.2f Immunoprecipitation of albumin-interactome
A volume of 300 μL of the rabbit anti-human albumin antibody conjugated Protein G
beads was incubated with 250 μL of raw CSF at room temperature on a rocker for 1.5
hours. The depleted CSF was collected by centrifugation at 1500 g for 1.5 min and the
beads were washed twice with 500 μL of PBS. Various solvents were tested for optimal
elution of just the bound proteins. Fifty percent acetonitrile containing 0.2% formic acid
was the ideal elution buffer under the given conditions and the proteins (after
immunoprecipitation) were eluted using 200 μL of this solution after incubation at room
temperature for 2 min. The beads were washed twice with 150 μL of elution buffer and
the flow-through from the washes was collected in one eppendorf tube. The elute was
dried in a vacuum centrifuge and re-suspended in 50 μL 1 X SDS loading buffer and
loaded onto a 12% polyacrylamide gel and electrophoresis was carried out.
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5.2g 1D gel electrophoresis
Proteins from the efficacy study were subjected to 1D gel electrophoresis. After drying
the protein sample in the vacuum centrifuge, samples were re-suspended in 50 μL 1x
loading buffer, boiled for about 5 min, loaded onto a 12% polyacrylamide gel and
electrophoresis was carried out at constant voltage of 150 V. The gels were stained with a
colloidal suspension of Coomassie G250.

5.2h 2-DE
The flow-through from the second 50 kDa cut-off filter was subjected to 2-DE. The
sample was dried in a vacuum centrifuge, re-suspended in 125 μL of sample/rehydration
buffer containing 8 M urea, 2% CHAPS, 50 mM DTT, ampholytes and bromophenol
blue and loaded on IPG strip. After 12 hours of active rehydration period at 50 V, the
proteins were focused in the Protean IEF cell from Bio-Rad using a 4-step program (300
V, 1000 V, 2500 V for 1 hour each and 4500 V for 4 hours). A limiting current (50 µA
per strip) was maintained. After IEF, the strips were equilibrated (30 min) with 6 M urea,
32 mM DTT, 0.375 M Tris-HCl pH6.8, 10%(w/v) SDS, 50% (v/v) glycerol and for 20
min in the dark with 63 mM iodoacetamide in the above equilibration buffer instead of
urea. Each strip was loaded on a 12% polyacrylamide gel and electrophoresis was carried
out at 150 V using a Protean II mini (Bio-Rad) in a buffer that contained 25 mM Tris,
192 mM glycine and 0.1% SDS until the blue dye reached the bottom of the gel. The 2DE separated proteins were stained with a solution of colloidal Coomassie G 250 [56].

5.2i Image and statistical analyses
Stained gels were scanned with a Versadoc 3000 scanner from Bio-Rad. Images were
analyzed using the PD Quest software from Bio-Rad. Spots were detected and matched
by both automated matching following the instructions in the software and also by
manual matching. Normalization was carried out to avoid any non-expression related
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variations between matched spots. A difference in spot volume was considered
statistically significant at p<0.05 and confidence level of 95%.

5.2j Identification of proteins using mass spectrometry
Proteins of interest were excised from the gel and in-gel proteolysis was carried out with
trypsin. In brief, the gel pieces were washed 6 times alternating with 50 mM NH4HCO3
and 1:1 ACN: NH4HCO3 (50 mM) for 5 min each at 20°C and dried with ACN for 10
min at 20°C. A volume of 10 μL of trypsin (66.67 ng) in 25 mM NH4HCO3 was added
and gel pieces allowed to swell for 30 min at 20°C and digested at 50°C for 4 hours.
Peptides were extracted with 10 μL of 1% aq. formic acid at 20°C for 30 min.The tryptic
peptides were analyzed using a Thermo Electron Corporation’s LCQ Classic quadrupole
ion trap mass spectrometer (San Jose, CA). Briefly, the tryptic peptides were resolved on
a 15 cm in-house C18 packed capillary column and eluted using a typical gradient elution
within 55 min. Spectra were acquired with a probe spray voltage of 4 kV and a heated
capillary temperature of 175°C. The resulting mass spectra were searched against the
human sub database from the Swiss-Prot database using Mascot algorithm and the protein
was identified.

5.3 Results

5.3a 2-DE of un-processed CSF
A volume of 150 μL of CSF was subjected to 2-DE. It was observed that albumin, light
and heavy chains of immunoglobulins were the major proteins that were present in the
gel (Figure 5.1).

5.3b Efficacy of Microcon cut-off filters
The efficacy of Microcon cut-off filters was tested using low range molecular weight
marker proteins. As seen from figures 5.2 and 5.3, greater than 80% of proteins less than
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30 kDa were filtered through while only roughly about 20% remained above the filter.
Seventy percent of the protein sample whose molecular weight same as that of the cut-off
value is filtered through. The cut-off filters fractionated the proteins efficiently.

pH 3

10

97
Albumin

66

IgG heavy
chain

Mr
45
(kDa)
31

IgG light
chain
21
14

Figure 5.1 A volume of 150 μL of un-processed CSF was subjected to 2-DE. A volume

of 125 μL of sample buffer was added to the sample that was dried in vacuum centrifuge.
2-DE was carried out using a 7 cm IPG strip pH 3-10 and a mini (7 cm) 12%
polyacrylamide separating gel. The gel was stained with colloidal Coomassie G250.
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97
66
45
Mr
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21
14

Protein

Filtrate

Retentate

Figure 5.2 Efficacy of Microcon 30 kDa cut-off filter. A solution of 200 ng of each

protein in the low-range standard proteins in 150 μL of 0.2% formic acid in 50% ACN
was added to the pre-rinsed 30 kDa cut off filter and centrifugation was carried out at
4000 g for 15 min. The cut-off filter was washed with 2 x 100 μL of 0.2% formic acid in
50% CAN. The flow-through and the retentate were collected and loaded on a 12%
polyacrylamide gel and electrophoresis carried out.
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Table 5.1 Protein recovery using Microcon cut-off filters

Protein

Total

Flow

Retentate

protein

through

(Band

(Band

(Band

volume / %)

volume / %)

volume / %)

anhydrase

1534/100

923/60

496/32

Trypsin

1344/100

1142/85

362/27

245/100

227/93

15/5

Carbonic

inhibitor

Lysozyme

100
90
80
70
60

Percentage
of protein

50
40
30
20
10
0

CA
(31 kDa)

Tryp
Inhibitor
(21 kDa)

Lysozyme
(14 kDa)

Figure 5.3 Recovery of proteins using 30 kDa cut-off filters (

through and ( ) whole protein.
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) Retentate ( ) Flow

5.3c Crude isolation of albumin-interactome using Microcon cut-off filters
Two molecular weight cut-off filters; 100 kDa and 50 kDa were employed to fractionate
ventricular CSF and three fractions were obtained (above 100 kDa, between 100 and 50
kDa and below 50 kDa). The between 100 and 50 kDa fraction was denatured with
DTT/ACN solution and filtered through another 50 kDa cut-off filter and the filtrate that
contains only the small proteins interacting with albumin was analyzed by 2-DE. Figures
5.4 and 5.5 show the composite gel image containing proteins from both AD and control
sample set and the representative images of CSF proteins from AD and control subjects
generated by PD Quest software respectively.
Twenty one protein spots were identified and 9 proteins showed significant changes in
expression levels between AD and control (p <0.05) (Table 5.2 and 5.3) subjects. In-gel
proteolysis was carried out with trypsin, the tryptic peptides were separated in a reverse
phase capillary column and the amino acid sequence was determined. Therefore, an
accurate and unambiguous identification is achieved. Comparing the intensities of protein
spots between six AD and six normal individuals, 9 proteins were significantly altered
(p<0.05). These altered proteins are summarized in Table 5.2. Proteins that were
significantly reduced in CSF of AD patients included one isoform (basic) of
prostaglandin D2 synthase (PGDS2), one isoform (more basic) of transthyretin, and two
isoforms of phosphotidyl ethanolamine binding protein. Proteins that were significantly
up-regulated in AD included retinol binding protein and four isoforms of PGDS2 with
one isoform being present exclusively in AD CSF.

174

pH 3

10

13

Mr
(kDa)

31

19

14

15

16

12

20

17

18

21

9

21

11

6

5

10

14
7

8
4
2

3

1

Figure 5.4 Composite (master) gel from the image analysis software shows all protein
spots present in both populations – AD and control. The spot numbers correlate to the
protein names in Table 5.1.
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Figure 5.5 Two-dimensional electrophoresis analysis of proteins in the albumin
containing fraction after fractionation using cut-off filters. (A) AD and (B) control.
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Table 5.2 List of proteins identified by LC-MS/MS in samples from the 2-DE gel using
cut-off filters

Spot
#

Protein

Mr
(kDa)

pI

Sequence
coverage (%)

Mowse
score

1

β 2 microglobulin

11.7

6.07

16

80

VEHSDLSFSK
VNHVTLSQPK

2

β 2 microglobulin

11.7

6.07

16

60

VEHSDLSFSK
VNHVTLSQPK

3

Cystatin C

13.3

8.75

18

97

LVGGPMDASVEEEGVR
ALDFAVGEYNK

4

Cystatin C

13.3

8.75

7

51

ALDFAVGEYNK

5

Cu-Zn SOD

15.8

5.7

9

36

GDGPVQGIINFEQK

6

Cu-Zn SOD

15.8

5.7

15

73

GDGPVQGIINFEQK
LACGVIGIAQ

7

Transthyretin

13.7

5.35

39

153

AADDTWEPFASGK
TSESGELHGLTTEEEFVEGIYK
YTIAALLSPYSYSTAVVTNPKE

GSPAINVAVHVFR
KAADDTWEPFASGK
TSESGELHGLTTEEEFVEGIYK
ALGISPFHAEVVFTANDSGPR
YTIAALLSPSYSTTAVVTNPKE

8

Transthyretin

13.7

5.35

64

307

9

Plasma retinol
binding protein
(RBP)

21

5.27

20

52

10

Neuropolypeptide
h3 (PEBP)

20.9

7.43

26

159

Peptides matched

KDPEGLFLQDNIVAEFSVDETG
QMSATAK
MKYWGVASFLQK
NRPTSISWDGLDSGK
LYTLVVTDPDAPSR
GNDISSGTVLSDYVGSGPPK

Contd. next page
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Spot
number

Protein

Mr (kDa)

pI

Sequence
coverage
(%)

Mowse
score

11

Neuropolypeptide h3

20.9

7.43

10

56

GNDISSGTVLSDYVGSGPPK

12

Carbonic anhydrase II
(CA II)

29.1

6.86

3

40

VVDVLDSIK

13

Carbonic anhydrase II

29.1

6.86

16

94

YDPSLKPLSVSYDQATSLR
AVQQPDGLAVLGIFLK
VVDVLDSIK

14

Prostaglandin D2
synthase(PGD2S)

18.7

8.37

20

155

15

Prostaglandin D2
synthase

18.7

8.37

17

133

TMLLQPAGSLGSYSYR
AQGFTEDTIVFLPQTDK

16

Prostaglandin D2
synthase

18.7

8.37

17

124

TMLLQPAGSLGSYSYR
AQGFTEDTIVFLPQTDK

17

Prostaglandin D2
synthase

18.7

8.37

8

61

AQGFTEDTIVFLPQTDK

18

Prostaglandin D2
synthase

18.7

8.37

17

148

TMLLQPAGSLGSYSYR
AQGFTEDTIVFLPQTDK

19

Prostaglandin D2
synthase

18.7

8.37

31

108

20

Prostaglandin D2
synthase

18.7

8.37

32

200

18.7

8.37

8

61

21

Prostaglandin D2
synthase
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Peptides matched

TMLLQPAGSLGSYSYR
FTAFCK
AQGFTEDTIVFLPQTDK

AALSMCKSVVAPATDGGLTST
FLR
TMLLQPAGSLGSYSYR
AQGFTEDTIVFLPQTDK
FLGR, GPGEDFR, FTAFCK,
AELK,TMLLQPAGSLGSYSYR
MATLYSR,
AQGFTEDTIVFLPQTDK
AQGFTEDTIVFLPQTDK

Table 5.3 Differential expression of proteins in AD and control (CTRL) ventricular CSF
as determined by the image analysis software PD Quest.

spot #

Protein name

AD
(spot
intensity)

Ratio
AD:CTRL

CTRL
(spot
intensity)

Ratio
CTRL:CTRL

19

PGD2S

3984

3.37

1181

1

14

PGD2S

12808

1.73

7408

1

9

RBP

4891

1.55

3158

1

15

PGD2S

23726

1.31

18132

1

8

TTR

3654.4

0.33

10956

1

21

PGD2S

1689.3

7.37

229.1

1

11

PEBP

806.6

0.49

1649.5

1

10

PEBP

1438.8

0.45

3185.8

1

17

PGD2S

128.9

0.01

12721

1
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5.3d Optimization of immunoprecipitation of albumin-interactome from CSF
Immunoprecipitation using antibodies is the most frequently employed technique to test
whether two proteins are interacting in vivo. Albumin was used as the bait protein to fish
out other small proteins that might be interacting with it in the CSF.

•

Evaluation of elution buffer

Optimization of the elution condition was carried out and various solvents like 0.01%
SDS, 20% ACN and 0.2% formic acid in 20% ACN (Figure 5.6) were evaluated for their
ability to strip proteins bound to the bead without stripping the antibodies itself. This
study evaluating different buffers in eluting proteins from beads, was carried out in which
the rabbit anti-albumin antibodies used were not crosslinked to the beads.
Figure 5.7 is a schematic of immunoprecipitation of the albumin-interactome. The gel
images shown in figures 5.8 to 5.10 are few attempts that were carried out to optimize the
various parameters in the immunoprecipitation protocol. Figure 5.8 shows the gel image
of one of the very first attempts to isolate the albumin-interactome from CSF. Ten
microliter of Protein G bound sepharose beads were incubated with 10 μg of anti-albumin
antibody at 4°C for 3 hours. The antibody was crosslinked to Protein G after incubation
with DMP for 30 min. The crosslinking reaction was terminated by incubation with
ethanolamine for 30 min. The antibody crosslinked beads were incubated with 10 μL of
CSF for 4 hours at 4°C. Albumin interactome was eluted using 50 μL of 1X SDS-PAGE
loading buffer. There was no protein observed in the elution fraction. The depleted CSF
contained some amount of albumin but the bands were all skewed because of the
presence of high amounts of PBS.
After a series of optimization experiments, it was decided to incubate the antibody with
Protein G beads at room temperature for 1 hour for binding, incubate the antibody
containing beads three times with freshly prepared DMP and finally incubate beads with
CSF for 1 hour and 30 min at room temperature for sufficient binding of the albumin-
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interactome with the antibody. In the next attempt, 200 μL of beads were incubated with
200 μg of anti-albumin antibody. Crosslinking was carried out as described in the earlier
section with DMP and 100 μL of un-processed CSF was added and the sample was
incubated at room temperature for 1 hour and 30 min. Proteins were stripped using 3 x 50
μL of 1X SDS loading buffer and SDS-PAGE was carried out (Figure 5.9).

97
66

4

1
2

6

45

Mr
(kDa) 31

5

3

21
7

14
Standard

0.01% SDS

20% ACN

0.2% formic
acid in 20 % ACN

Figure 5.6 SDS-PAGE analysis of the CSF proteins eluted from the anti-albumin
attached Protein G beads. 200 μL of CSF was applied to the beads and eluted with
different elution buffers. Elute was dried and resuspended in loading buffer and
electrophoresis carried out at 200 V and gel stained with colloidal Coomassie G 250. The
proteins identified (numbered on the gel) are given in table 5.4
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Table 5.4 Proteins identified from 1D gel evaluating three elution buffers, by LC-MS/MS

Band
number

Protein

Swiss-Prot

Molecular
weight
(KDa)

Sequence
coverage
(%)

Mowse
score

1

Human serum
albumin

P02768

66.5

27

627

2

Rabbit Ig
gamma chain
C

P01870

50

26

203

Rabbit Ig
Kappa b4
chain C

P01840

25

36

140

P02787

75.1

24

612

3

4

Human
Serotransferrin

5

Rabbit Ig
Kappa b4
chain C

P01840

25

23

63

Rabbit Ig
gamma chain
C

P01870

50

27

310

P02766

13.7

59

360

6

7

Human
transthyretin
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Anti albumin Antibody

Cross link with DMP

Agarose beads
w/ Protein G
CSF
Human
albumin

Unbound proteins are eluted
Albumin
depleted CSF

Process for proteins interacting
with albumin (bead fraction)

Bead with protein G along with
albumin and other proteins
interacting with it

Elute
Formic
acid/ACN

Filter through Microcon
YM 50
(to get rid of albumin)

Filtrate containing less
than 50KDa proteins
IEF
pH 3

pH 10

SDS-PAGE

Figure 5.7 Schematic for the immunoprecipitation of the albumin-interactome from CSF
using rabbit anti-albumin antibody (top box, immunoprecipitation; lower box, elution and
analysis)
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Figure 5.8 SDS-PAGE analysis of proteins isolated by immunoprecipitation from 10 μL

CSF using 10 μL of Protein G beads and 10 μg of anti-albumin antibody. Lane 1, 100 ng
of low range molecular weight markers, Lane 2, 10 μL of un-processed CSF, Lane 3,
elute fraction using 50 μL of 1X SDS loading buffer and Lane 4, depleted CSF fraction

184

97
66

Mr
(kDa)

45
31

21
14

Lanes

1

2

3

4

5

Figure 5.9 SDS-PAGE analysis of the CSF albumin-interactome using Protein G

sepharose beads. The gel was stained with colloidal Coomassie G 250. Lane 1, 200 ng of
low range marker proteins. Lane 2, 10 μg of standard HSA protein. Lane 3, 100 μg antialbumin antibody. Lane 4, 100 μL of un-processed CSF. Lane 5, elute fraction using 50

μL 1X SDS-loading buffer.
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To enable maximum enrichment of the albumin-interactome, larger volumes of Protein G
beads, anti-albumin antibody and CSF were used. One milligram of anti-albumin
antibody was added to 300 μL of wet Protein G beads to saturate all the binding sites
with anti-albumin antibody. The antibody was covalently crosslinked to beads after
incubation with DMP. Crosslinking reaction was terminated by the addition of
ethanolamine and beads incubated with 250 μL of CSF (Figure 5.10). This protocol gave
maximum recovery of albumin and also revealed the presence of other proteins (though
faint) in addition to albumin. The presence of phosphate buffer saline (PBS) in the
albumin depleted CSF fraction caused the lateral diffusion of proteins. This distortion
was prevented by removal of PBS from the albumin depleted fraction using a 3 kDa cutoff filter. To verify if there is any interaction between the beads and the proteins in CSF,
beads with no anti-albumin antibody were incubated with 250 μL of CSF and after
washing off CSF, the beads were stripped and the elute loaded on the polyacrylamide gel
(lane 6 Figure 5.10). There were some proteins in the CSF that non-specifically bound to
the beads. Similarly, to test if the proteins in the elution fraction are a result of stripping
of the Protein G and anti-albumin antibody itself, the beads were incubated with antialbumin antibody, crosslinked and eluted using formic acid in ACN. Very faint high
molecular weight protein bands were observed (lane 5 Figure 5.10). The proteins seen in
lanes 5 and 6 of figure 5.10 were mostly high molecular weight proteins (> ~50 kDa) that
are not a part of the fraction-of-interest (the fraction-of-interest being the low molecular
weight proteins interacting with albumin).
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Figure 5.10 Immunoprecipitation of albumin-interactome from CSF using anti-albumin
crosslinked Protein G beads. Anti-albumin antibody was covalently crosslinked to
Protein G using DMP and then beads were incubated with 250 μL CSF. Lane 1, 200 ng
of standard proteins. Lane 2, 250 μL CSF. Lane 3, Elute fraction from beads using 0.2%
formic acid in 50% ACN. Lane 4, albumin depleted CSF. Lane 5, Elute from beads
incubated with anti-albumin antibody. Lane 6, Elute from beads incubated with CSF (no
antibody)
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Immunoprecipitation of the albumin-interactome fraction from pooled CSF samples from
6 AD and pooled CSF samples from 6 normal individuals was performed using antialbumin antibody covalently crosslinked to Protein G beads. Candidate proteins bound to
albumin were eluted using 0.2% formic acid in 50% ACN and analyzed by SDS-PAGE
(Figure 5.11).
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Figure 5.11 Immunoprecipitation of albumin interactome from CSF using anti-albumin

crosslinked Protein G beads. (A) Anti-albumin crosslinked Protein G beads were incubated with 250
μL pooled and control CSF from 6 individuals and albumin-interactome eluted using 0.2% formic acid in
50% ACN. Lane 1, standard marker proteins. Lane 2 and 3 are 250 μL of straight unprocessed AD and
control CSF. Lane 4 and 5 are elutes from AD and control CSF samples respectively. (B) Aliquot of
depleted CSF samples from AD (lane 2) and control (lane 3).The proteins with spot numbers labeled on the
gel were identified by LC-MS/MS and are given in table 5.5
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Table 5.5 List of proteins identified from the 1D gel after immunoprecipitation of

albumin-interactome from CSF

Band

Protein

#

Mr

Seq

Mowse

(kDa)

Covg

score

Peptides matched

(%)
LVTDLTK, AEFAEVSK, YLYEIAR,
DDNPNLPR, FQNALLVR, TYETTLEK,
QTALVELVK, TPVSDRVTK,
LDELRDDEGK,KQTALVELVK,
LVNEVTEFAK, FKDLGEENFK,
i

Albumin

67

30

971

AVMDDFAAFVEK, RHPDYSVVLLLR,
DVFLGMFLYEYAR,
KVPQVSTPTLVEVSR,
HPYFYAPELLFFAK,
RHPYFYAPELLFFAK,

ii a

PGDS2

21

17

130

TMLLQPAGSLGSYSYR,
AQGFTEDTIVFLPQTDK
VVDVLDSIK, SADFTNFDPR,
QSPVDIDTHTAK,

ii b

CA II

29

32

262

AVQQPDGLAVLGIFLK,
ILNNGHAFNVEFDDSQDK,
YDPSLKPLSVSYDQATSLR
GSPAINVAVHVFR,
KAADDTWEPFASGK,

iii

TTR

15

68

458

AADDTWEPFASGK,
TSESGELHGLTTEEEFVEGIYKVEIDTK,
YTIAALLSPYSYSTTAVVTNPKE
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5.4 Discussion

The CSF proteome holds great promise as a source of biomarkers for diseases like
Alzheimer’s disease that affect the brain. Despite the potential, it is challenging to
analyze such complex proteomes because of the dynamic range of protein concentrations
that exists in the CSF. As seen in figure 5.1, albumin and immunoglobulins dominate the
CSF proteome and this makes the detection of low abundant proteins very difficult. Thus,
reduction of sample complexity is essential when analyzing CSF. One way to circumvent
this dynamic range problem is to deplete the high abundant proteins using commercially
available depletion kits based on affinity methods using specific antibodies against
albumin and immunoglobulins. However, serum proteome studies indicate that such
affinity depletion methods result in concomitant removal of small low molecular weight
proteins along with albumin and immunoglobulins [213]. The hypothesis of this study is
that the high abundance protein, albumin in CSF, acts as a “molecular sponge” and soaks
up small low molecular weight proteins. Selective enrichment of these low molecular
weight proteins interacting with the high abundance proteins using immunoprecipitation
will enable un-biased analysis of this fraction of the proteome, and comparison of the
albumin-interactome between AD and control subjects is likely to provide useful
biomarkers for the disease.

5.4a Efficacy of Microcon cut-off filters
A crude isolation of the albumin-interactome was carried out using cut-off filters after
fractionating the complex CSF. A key point is the efficacy of the Microcon filters that
needs to be tested to confirm its ability to effectively separate a complex proteome such
as the CSF. To test the efficacy of the filters, a volume equal to 200 ng of each standard
marker proteins was added to a 30 kDa cut-off filter and centrifuged. The flow through
(below 30 kDa) and the retentate (above 30 kDa) were collected and subjected to 1D gel
electrophoresis (Figure 5.2). The efficiency of cut-off filters in filtering the proteins is
dependent on the molecular weight of the proteins. Our data indicate that the cut-off
filters separated the proteins based upon their molecular weight quite effectively.
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The Microcon cut-off filters have been used earlier for sample preparation and trypsin
digestion in proteomic analysis using standard proteins [217]. Our studies indicated that
the Microcon filters can be used for fractionation of proteins based upon their molecular
weight facilitating isolation of the albumin-interactome. Almost 80-90% of proteins less
than the cut-off value were filtered through the cut-off filters but with increasing
molecular weight the recovery was less.

5.4b Crude isolation of CSF albumin-interactome using Microcon cut-off filters
Cut-off filters were used to isolate albumin-interactome after fractionation of CSF
proteome based upon molecular weight. Using two filters- 100 and 50 kDa- three
fractions were obtained. The fraction between 100 and 50 kDa (containing albumin) was
disrupted for non-specific interactions that can exist between proteins and filtered
through a second 50 kDa filter. The filtrate was subjected to 2-DE. Nine unique proteins
were identified along with their various isoforms as a result of post-translational
modifications.
It should be noted here that the molecular weight of the proteins identified in this study
were all less than 50 kDa. However, the proteins were initially from the fraction between
100 and 50 kDa and were denatured by the addition of DTT in ACN. Given that the cutoff filters passed approximately 90% of the proteins effectively (as seen from our
efficacy study), the presence of these proteins in the between fraction indicated that they
are either interacting with other proteins in the CSF or among themselves. Since the
combined molecular weight is greater than their actual individual molecular weights they
are hence retained in the fraction between 100 and 50 kDa. The addition of a solution of
DTT in ACN disrupted this interaction and proteins smaller than 50 kDa were filtered
through the second 50 kDa cut-off filter. To test our hypothesis that albumin acts a
protein scaffold and interacts with other small proteins, immunoprecipitation using antialbumin antibody coupled Protein G sepharose beads was carried out. Albumin along
with other proteins that might be interacting with albumin was immunoprecipitated under
non-denaturing condition.
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This offers advantages:
(1) it is a rapid procedure to isolate/enrich the albumin interactome;
(2) the purity of proteins is high; and
(3) it allows for the identification of proteins interacting with albumin.

•

Altered proteins in AD CSF

2-DE experiments on CSF fractions indicated the presence of eight proteins with
molecular weight less than 50 kDa in the fraction between 100 and 50 kDa (after
fractionation using cut-off filters). Out of these eight proteins, four unique proteins and
their various isoforms were significantly altered in the CSF from AD subjects (Table
5.3). These proteins included PGDS2, transthyretin, PEBP and RBP. To test the
hypothesis that the proteins might be interacting with albumin, immunoprecipitation of
the albumin-interactome was carried out using anti- albumin antibody crosslinked Protein
G beads.

5.4c Immunoprecipitation of albumin-interactome
A more precise isolation of the albumin-interactome was carried out using
immunoprecipitation of albumin. A series of immunoprecipitation experiments were
performed to optimize the various conditions for successful isolation of the albumininteractome from the CSF. These experiments included optimization of the ratio of antialbumin antibody and protein G beads for a given volume of CSF, determination and
optimization of the necessary incubation times to ensure strong antigen-antibody
interaction, the number and volume of wash steps to eliminate the CSF proteins nonspecifically interacting with the beads itself, and optimization of the number of elution
steps required to elute the bound protein fraction.

192

•

Evaluation of elution buffer

In immunoprecipitation, elution conditions are intended to break the ionic, hydrophobic
and hydrogen bonds that hold the antigen to the antibody. Ideally, elution should release
only the protein bound to the antibody attached to Protein G beads and not the antibody
itself. Three different elution buffers- 0.01% SDS, 20% ACN and 0.2% formic acid in
50% ACN were evaluated for their effectiveness in stripping the proteins from the
Protein G beads. SDS and ACN both eluted about the same amount of proteins from the
beads. Elution buffer containing 0.2% formic acid in 50% ACN gave more proteins than
the other two solvents. All three buffers, however, stripped the anti-albumin antibody
attached to the protein G beads (Figure 5.6, Table 5.4). In order to prevent the elution of
the anti-albumin antibody itself, the antibody in further experiments was covalently
crosslinked to Protein G beads using dimethylpimelimidate (DMP).

•

Optimization of immunoprecipitation of albumin-interactome

The immunoprecipitation protocol involves a multitude of steps to isolate the target
protein from a complex mixture of proteins like CSF. Various parameters were
investigated to obtain an optimized protocol that can selectively isolate the albumininteractome from CSF. From our elution buffer evaluation study, formic acid in ACN
buffer stripped proteins from the beads better than SDS and 20% ACN; however it was
also able to elute out anti-albumin antibodies (not crosslinked to Protein G in our elution
buffer evaluation study). The elution of antibodies could, however, be prevented by
covalently crosslinking the antibody to Protein G beads. Hence, for all further studies, the
antibodies were chemically crosslinked to Protein G beads and 0.2% formic acid in 50%
ACN was used as the elution buffer. The optimized immunoprecipitation protocol (given
in experimental section) was repeated at least two times to verify the reproducibility and
to establish standard operation procedures. A high reproducibility was achieved and the
protein elution profiles were almost identical. Our immunoprecipitation results clearly
supported our hypothesis that the proteins PGDS2, transthyretin and carbonic anhydrase
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II were all interacting with albumin. The levels of these proteins were altered in CSF
from AD patients.
Prostaglandin D synthase (PGDS2) was originally known as β trace and was discovered
by Clausen in 1961 in human CSF [218]. PGDS2 is a sialic acid (SA) containing
glycoprotein with a molecular weight of 27 kDa [219]. PGDS2 is produced by
leptomeninges and the choroid plexus of the brain [220-222]. In addition to the enzymatic
function in the synthesis of prostaglandin D, PGDS2 is also believed to be involved in the
transport of various lipophilic moieties including thyroid hormone and retinoic acid in
CSF [219, 223-225]. There is increasing evidence that isoforms of proteins are
differentially altered in AD, hence it becomes imperative to study the differentially
expressed levels of post-translational modifications in AD biomarker discovery to
understand the neuropathology [226]. Several studies have investigated post-translational
modifications (PTM) of PGDS2 in CSF of patients with neurological diseases. Hiraoka et

al. have studied the microheterogeneity of PGDS2 in the CSF of patients with various
neurological diseases like Amyotrophic lateral sclerosis (ALS), Alzheimer’s disease
(AD) and Parkinson’s disease (PD) using capillary isoelectricfocusing [227]. Since
PGDS2 has two oligosaccharide chains and each chain has two SA groups, the protein
has in total four SA groups. This allows for the possibility of 8 different isoforms for the
protein. Various studies have identified four isoforms of PGDS2 in human CSF [227,
228]. Studies investigating these different isoforms of PGDS2 will help to provide more
insight about PGDS2 function in CSF. Currently, PGDS2 is used as a marker to detect
the presence of CSF in nasal secretions from patients suffering from rhinorrhea [229].
PGDS2 was also reported as a marker for N-glycosylation defects in the brain [230].
Earlier work indicated that the acidic isoforms of PGDS2 were decreased in the CSF of
patients suffering from neurological diseases [231, 232]. From our 2-DE study, 8 protein
spots (with different pIs but almost the same molecular weight) were identified as
PGDS2. The measurement of total PGDS2 in spot intensity in AD and control gels using
PD Quest software indicated that the protein level was only slightly increased in AD (by
10%) when compared to levels in control samples. However, the three most acidic
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isoforms were significantly up-regulated in AD, and one isoform at pI of approximately 7
was present exclusively in the AD sample. One basic isoform of PGDS2 was downregulated significantly in AD. Since the various isoforms of PGDS2 have similar
molecular weight but different pI, the most likely PTM of PGDS2 is glycosylation.
Glycosylation of a protein changes its pI to be more acidic due to the addition of a
carbohydrate moiety. Since the acidic isoforms of PGDS2 was found to be up-regulated
in AD, our data suggests that there is increased glycosylation of PGDS2 in AD. Altered
glycosylation of tau, cholinesterases and transferrin in AD have already been described,
suggesting that aberrant glycosylation changes occur in AD [233-235]. Hashimoto et al.
reported that sialylation of amyloid precursor protein (APP) increased the secretion of
neurotoxic metabolites like amyloid beta peptide (Aβ) [236]. It was reported that
hyperglycosylation of tau protein caused an increase in phosphorylation of tau resulting
in hyperphosphorylated tau in the AD brain [233]. The differential expression levels of
PGDS2 in CSF of AD patients further validated the impaired glycosylation in AD.
Since glycosylation plays a pivotal role in various cellular processes like signaling and
protein folding, and is synergistic with phosphorylation events, it is most likely that
alteration in glycosylation can induce signaling cascades that mediate neurodegeneration
[237]. Watanabe et al. reported that serum albumin could bring about the synthesis of
prostaglandin D2 from prostaglandin E (i.e. the function of PGDS2) in platelets [238].
This indicates a PGDS2-like activity of albumin in platelets. Hence, either, PGDS2 and
albumin have a common substrate (PGE2) that might be responsible for the interaction of
PGDS2 with albumin observed in the immunoprecipitation study and could explain the
presence of PGDS2 in the albumin-interactome fraction or albumin is associated with
PGDS2 and this combination can carry out prostaglandin E conversion to PGD2. PGDS2
was also reported to be present in human atherosclerotic plaques [239]. Since PGDS2 is a
protein that is made up of mainly β sheets [240], it is possible that due to aberrant
glycosylation of the protein, it aggregates in the brain of AD patients as well; however,
more work is required to prove this speculation.
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Two isoforms of transthyretin were identified in 2-DE gel and the more basic isoform
was down-regulated three-fold in CSF from AD subjects. Transthyretin was also
identified as one of the proteins present in the albumin-interactome. Transthyretin,
formerly known as prealbumin, is a homotetrameric protein with a molecular weight of
approximately 55 kDa. TTR is synthesized and released into the CSF by the choriod
plexus [241]. A small amount of TTR synthesized in the liver also exists as a
homotetramer in serum and constitutes about 0.5% of serum proteins [242]. Serum TTR
cannot cross the blood brain barrier and hence TTR present in CSF is exclusively from
the choroid plexus. TTR in CSF is predominantly in the monomeric form, but in the
choriod plexus is a tetramer [231, 243].
Transthyretin was identified in the neurofibrillary tangles as well as in amyloid plaques in
the brain of AD patients [244]. It was reported that the lower the levels of TTR in CSF,
the more demented were the patients [52]. The monomeric form of TTR in the CSF was
found to sequester amyloid β protein (Aβ), which is responsible for the formation of
amyloid plaques in the brain of AD patients [245]. TTR forms soluble complexes with
Aβ and inhibits its aggregation. However, TTR itself is capable of forming amyloid
fibrils that are associated with diseases such as familial amyliod cardiomyopathy (FAC),
senile systemic amyloidosis (SSA) and familial amyloiotic polyneuropathy (FAP) [246,
247].
Transthyretin is a β-sheet rich protein and any event triggering misconformation can
result in the stacking-up of these β sheets to form aggregates. Various PTMs of
transthyretin have been detected in CSF and include sulfonation, cysteinylation and
glutathione conjugation [248-250]. The isoforms that were detected in the 2-DE gels, in
this study, were all of about the same molecular weight but had different isoelectric
points. This suggested that the two isoforms were a result of either sulfonation or
phosphorylation. The more basic isoform (with greater pI) was found to be downregulated significantly by approximately three-fold in the CSF of AD patients. The downregulation of TTR is in agreement with other published work [52]. The decrease in TTR
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isoform could cause Aβ to be more susceptible for aggregation. More investigations are
required to identify the PTM in TTR.
Transthyretin was identified to be a component of the albumin-interactome through the
described immunoprecipitation technique. One possible explanation for the presence of
TTR in the albumin-interactome is the common substrates that both TTR and albumin
share. TTR in CSF functions as a carrier protein mainly for thyroxin (T4) and vitamin A
(retinol through the association with retinol binding protein-RBP) [251, 252]. The thyroid
hormone and retinol are essential for normal development of brain [253, 254]. It was
reported that TTR has high affinity for T4 while albumin has a low affinity but high
capacity for T4 [255]. Albumin is the most abundant protein in CSF and being a known
transport protein, it is quite possible that albumin is carrying with it other small proteins
like TTR that have a common substrate such as T4 to lock onto. Our data show that
retinol binding protein (RBP) was up-regulated by approximately 1.5 fold in the CSF of
AD subjects. This is in agreement with results published earlier on the increased level of
one isoform of RBP in the CSF from AD patients [226, 256, 257].
Two isoforms of phosphotidyl ethanolamine binding protein (PEBP) were identified in
the 2-DE gel and both isoforms were significantly down-regulated by 2-fold in the CSF
from AD subjects compared to control. In humans, PEBP is also known as
neuropolypeptide h3 and contains the hippocampal cholinergic neurostimulating peptide
(HCNP). Decreased levels of PEBP have been reported earlier in the hippocampus of
brain from Tg2576 (mouse model of AD) [258]. It was also reported that PEBP
immunoreactivities were found on amyloid plaques of both Tg2576 and AD brain
sections [258]. The HCNP peptide is involved in the differentiation of neurons in the
hippocampus where the protein also enhances the synthesis of choline acetyl transferase
[259]. PEBP was not identified as a part of the albumin-interactome.
Other proteins like SOD1, cystatin C, β-2 microglobulin and carbonic anhydrase II (CA
II) were identified in the cut-off filter study. However, only CA II was observed in the
immunoprecipitated albumin-interactome fraction. This observation suggested that
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proteins other than CA II are not interacting with albumin but might be interacting with
other proteins including themselves and thus have molecular weights greater than their
actual individual molecular weights and hence be retained in the fraction between 100
and 50 kDa. The other possibility is that the proteins are present in such low levels that
they are not detected on the 1-D gel carried out after immunoprecipitation.
Most of the altered proteins detected in the CSF from AD subjects, in our study, are rich
in β-sheets, and some have already been identified in the amyloid plaques and NFTs. Any
event triggering misconformation could result in aggregation of these proteins. The
proteins also exhibit different isoforms, and differential expression of the isoforms
indicate the importance of elucidation of PTMs. Studies related to levels of each isoform
are important for biomarker discovery instead of total protein content. The observation
that levels of certain proteins are altered in CSF from AD subjects is of considerable
interest but must be interpreted cautiously. For example, one interpretation is that protein
deficiency triggers one or more cascades of molecular events that cause
neurodegeneration. On the other hand, reduced levels of protein isoforms in a
neurodegenerative disorder like AD may represent an expected secondary consequence of
neuronal cell loss.

5.5 Conclusion

Measurements of changes in the expression of multiple proteins and their isoforms
provide a powerful strategy for understanding pathophysiological processes of diseases.
Owing to its proximity to brain, CSF is an ideal target to identify biomarkers for diseases
like AD that mainly affect the brain. However, the challenge in analyzing the CSF
proteome by 2-DE is the huge dynamic range of the proteins. The current trend in
biomarker discovery is to deplete albumin from the CSF sample; however, it should be
realized that this could lead to removal of small proteins and peptides that might be
interacting with albumin. The present study involves analysis and identification of the
albumin-interactome that constitute the albumin-interacting proteins and comparison of
this albumin-interactome between AD and control subjects to help in identification of
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biomarkers for the disease. To test our hypothesis that albumin acts as a protein scaffold
and “soaks-up” other small proteins, a crude isolation of the albumin-interactome was
carried out using cut-off filters. The presence of proteins whose molecular weight is less
than 50 kDa, in the fraction between 100 and 50 kDa that predominantly contains
albumin, indicates that the highly abundant carrier protein albumin can sequester low
molecular weight proteins in CSF. To reaffirm the observation that these low molecular
weight proteins in the fraction between 100 and 50 kDa were indeed interacting with the
carrier protein albumin, immunoprecipitation of the albumin-interactome using albumin
as the “bait” protein was carried out, and the albumin-interactome studied using 1-D gel
electrophoresis.
Using this selective enrichment of the albumin-interactome, 21 protein spots were
identified that comprised 9 unique proteins and their post-translational modifications.
This is the first study to our knowledge that has successfully isolated albumininteractome from the CSF and compared these fractions of CSF proteome between AD
and control subjects for differences.
Various isoforms of prostaglandin D2 synthase, transthyretin, carbonic anhydrase II, β 2
microglobulin, phosphatidyl ethanolamine binding protein, retinol binding protein,
neuropolypeptide h3, SOD 1 and cystatin C were identified in the albumin containing
fraction from cut-off filter study by 2-DE. Of these 9 proteins PGDS2, TTR and CA II
were identified in the albumin-interactome after immunoprecipitation, using albumin as
the bait protein. Our 2-DE results indicate alteration in the levels of various isoforms of
proteins in the CSF from AD subjects. In particular, the acidic isoform of PGDS2 was
up-regulated in the CSF from AD subjects. Other proteins that were altered in the CSF
from AD subjects included the basic isoform of TTR, two isoforms of PEBP and one
isoform of RBP. The observation that various isoforms of proteins were altered in the
CSF from AD patients supports the glycosylation defects present in AD.
In conclusion, the data presented herein demonstrate that albumin indeed interacts with
small low molecular weight proteins in CSF. The levels of these small proteins
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constituting the albumin-interactome are significantly altered in the CSF from AD
subjects. The ability to detect these proteins in the CSF was the key finding of this work.
The alterations in levels of the isoforms of proteins like PGDS2 support the concept that
glycosylation defects are implicated in Alzheimer’s disease. Furthermore, the data
implicate the acidic isoform of PGDS2 as a potential biomarker of AD.
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CHAPTER SIX

CONCLUSION

Proteomics is a rapidly expanding field of research that has carved a niche of its own in
life sciences. At its core, proteomics is all about separation and identification--the process
of taking a sample of interest, separating out all of the proteins within, and then
identifying them. As one can imagine there exists an array of proteomics tools to help
accomplish this formidable task of protein analysis. Specifically, two-dimensional gel
electrophoresis and mass spectrometry- two milestone technologic breakthroughs
facilitated the ability to simultaneously look at multitude of proteins. Tremendous
improvements in both methodologies are providing improved strategies to speed
biological discovery. Though many chromatographic techniques are being introduced,
two-dimensional gel electrophoresis has been the method of choice for the analysis of
proteomes for nearly 35 years mainly because of its enormous resolving power and
ability to simultaneously separate thousands of proteins. A number of modifications to
the 2-DE methodology have been introduced and improvements in key components of the
technology such as use of immobilized pH gradient gels and fluorescent staining have
greatly improved reproducibility and sensitivity.
The sensitivity of stains that are used to detect proteins after their separation by 2-DE, has
been one factor influencing the amount of information that can be extracted from the 2DE gels. The development of a fluorescent ruthenium complex (RuMS) for staining
proteins separated by gel electrophoresis with high sensitivity, broad linear dynamic
range and that is compatible with mass spectrometry for subsequent identification of
proteins (as described in chapter three of this dissertation) is quite valuable in this
context. With the low detection limit of 1 ng of protein and cost-effective potential
available with this in-house synthesized RuMS staining solution, it is not difficult to see
why the development of this staining solution is a very practical and worthwhile avenue
to pursue. Knowledge of exact composition of the stain will prove to be very beneficial in
being able to reproducibly synthesize the stain and exploit its potential to the fullest. One
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can envision using different ratios of the commercially available different ruthenium
complexes- RuMS, RuDS and RuBPS to probe and obtain the exact composition of the
in-house RuMS staining solution that is a value added information.
Proteomics has diverse applications in various fields like medicine, toxicology, pharmacy
and many others. The incredible potential of proteomics to discover new disease
biomarkers and toxicity signatures were explored as described in this dissertation. The
emerging field of toxicoproteomics integrates two disciplinary areas of toxicology and
differential protein analysis and allows for better understanding of protein expression
during toxicity and environmental stress for the advancement of public health. Proteomic
techniques were applied to study the in vitro effect of malathion, an organophosphate
insecticide on protein expression using human neuroblastoma cells. Our studies indicated
that out of 122 human neuroblastoma proteins identified, 21 proteins were significantly
altered after treatment with malathion. Results suggest significant down-regulation of key
calcium modulators and chaperones in the malathion-treated cells. A model was proposed
based on the altered proteins that malathion induces oxidative stress leading to possible
misfolding of protein that can potentially accumulate and cause cytotoxicity in
neuroblastoma cell cultures. The identification of differential protein expression in
neuroblastoma cells after treatment with malathion is an important finding in regard to
the OP toxicity, since there has been limited knowledge in this area. Though
neuroblastoma cells are the preferred model to study in vitro OP toxicity, studies
involving primary cell lines and animal models will provide more precise information on
the implication of OPs on humans. One can also envision a similar kind of investigation
performed on the liver proteome of OP exposed animals to identify protein targets of OP
toxicity. The near-term payoffs of this type of work are two-fold. One is the
understanding of mechanisms of toxicity and the other is the identification of biomarkers
of exposure. While investigations presented here offered a basic foundation for
understanding OP toxicity at the protein level, a closer examination involving analysis of
sub-proteome will surely provide a greater appreciation of the underlying mechanisms of
OP toxicity.
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A major benefit of proteomic technology is its use in the development of biomarkers for
diseases. Proteomic techniques can be applied to study innumerable human diseases
ranging from cancer to infectious diseases. Alzheimer's disease (AD) affects more than
4.5 million Americans. There is no cure for Alzheimer's disease yet and the primary goal
of biomarker research is to detect and diagnose the disease before symptoms surface.
Proteomics is most suited for mining biomarkers and tools allow comparing protein
profiles of normal and diseased body fluids such as blood, CSF and urine. A proteomic
analysis of CSF albumin-interactome was undertaken to identify and compare the protein
constituents of this fraction of the CSF proteome between AD and normal subjects. The
novel immunoprecipitation-based proteomics approach to AD biomarker discovery
proved successful in isolating and identifying the otherwise difficult-to-analyze albumininteracting proteins and their isoforms. The immunoprecipitation method to analyze
interactomes in CSF is both feasible and effective. With increased efforts to diagnose and
treat AD by early intervention and even towards prevention, it is evident that biomarkers
will gain significance as tools to aid research and ultimately clinical practice. Our results
indicated presence of small proteins including prostaglandin D2 synthase (PGDS2) and
transthyretin to be components of CSF albumin-interactome. A key finding is the
alteration in levels of different isoforms of these proteins constituting the albumininteractome in CSF from AD subjects and their potential to serve as biomarkers for AD.
One can envision a careful evaluation of relative abundance of the different isoforms of
the albumin-interactome proteins in CSF from AD, mild congnitive impairment and no
cognitive impairment subjects be carried out to help generate a fingerprint model that can
successfully delineate the various stages. A clear understanding of the post-translational
modifications involved in these proteins will provide insight into the etiology of the
disease. The methodology developed herein can also be applied to serum proteome that
will enable non-invasive diagnosis of the disease. Though, this is a challenging endeavor,
given the potential of various proteomics technologies, it should be possible to identify a
sufficient number of biomarkers to revolutionize early detection.
Application of two vital proteomics methodologies namely 2-DE and mass spectrometry
along with the in-house developed staining solution described in this dissertation clearly
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demonstrates the power of the technology to analyze complex proteomes like whole cell
lysate and cerebrospinal fluid. With the potential that proteomics carries with it, it will
not be too far in the future that mass spectrometry-based proteomic technologies will play
key role in clinical diagnosis of diseases. With development of miniature mass
spectrometers, field application of the technology is a promising area of pursuit that will
enable detection of for example, toxic chemicals during warfare. Questions like how the
technology can be implemented and what costs are involved in doing so, to accomplish
the above-said vision, must be considered. The versatility of various proteomics
methodologies is endless and the alliance of various separation techniques with mass
spectrometry has the potential to improve quality of life.
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Appendix A. List of proteins identified on 2-DE gels by MALDI-TOF mass

spectrometry

Spot

Protein

number

Swiss-

Mr (kDa)

pI

Prot

%

# of

Sequence

peptides

coverage

matched

2

Calmodulin

P62158

16.7

4.09

18

7

3

Parvalbumin α

P20472

11.9

4.98

46

5

4

Ubiquitin like

P55854

0.89

5.57

20

3

P84090

12.2

5.62

23

3

Q9UDP3

11.7

6.28

28

3

protein SMT 3A

Enhancer of
6

rudimentary
homolog
Putative S100

7

Ca2+ binding
protein

8

Parvalbumin α

P20472

11.9

4.98

56

5

9

Calgizzarin

P31949

11.7

6.56

40

5

Retinoic acid

P29762

15.4

5.31

41

8

14

binding protein
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15

17

Serum amyloid A
protein precursor

P02735

11.6

5.89

25

3

Tubulin specific

O75347

12.7

5.25

19

4

P35080

14.9

6.78

30

4

P61088

17.1

6.13

25

4

chaperone A

18

Profilin II

Ubiquitin
19

conjugating
enzyme E2N

20

Cyclophilin A

P05092

17.8

7.82

20

5

25

60s ribosomal

P40429

23.4

10.94

21

6

protein L13a

26

Histone H4

P62805

11.2

11.36

47

6

27

Glucagon

P01275

18.6

5.62

28

4

P32119

21.8

5.66

32

6

17.4

5.57

16

3

precursor

28

Peroxiredoxin 2

29

Retinal binding

O43924

protein

206

31

Stathmin I

P16949

17.1

5.77

47

9

39

hn RNP

P22626

37.4

8.97

18

6

Q96AX2

24.6

5.96

15

3

A2/B1

Ras related
41

protein Rab 37

43

HSP 27

P04792

22.7

5.98

21

4

45

Peroxiredoxin 1

Q06830

22.1

8.27

39

10

46

Peroxiredoxin 1

Q06830

22.1

8.27

34

9

Q9UCY6

22.2

9.35

25

6

Orphan nuclear
47

receptor
steroidogenic
factor 1

49

HSP 27

P04792

22.7

5.98

13

4

50

Tropomyosin α 1

P09493

32.7

4.69

13

6

P07339

26.6

5.56

12

6

O15217

25.7

7.89

13

4

chain
51

Cathepsin D
precursor
Glutathione S

53

transferase A4
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Ras related

P20336

24.9

4.85

18

3

55

protein Rab 3A

56

HSP 27

P04792

22.7

5.98

13

4

57

Proteosome

P49720

22.9

6.14

16

4

subunit β type 3

58

Mn SOD

P04179

22.2

6.86

18

4

60

Peroxiredoxin 6

P30041

24.9

6.02

36

9

63

ARC34

O43513

27.2

5.5

13

4

65

Tropomyosin α 4

P07226

28.5

4.67

21

6

66

Tropomyosin α 4

P07226

28.5

4.67

23

6

67

Prohibitin

P35232

29.8

5.57

38

10

O95865

29.6

5.66

26

8

P30040

25.8

6.08

26

8

NG,NG,
68

dimethylarginine
dimethylamino
hydrolase 2

69

ERp 28
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Eukaryotic
70

translation

Q15056

27.3

6.67

18

4

P52907

32.9

5.45

24

6

P01189

26.6

6.54

17

5

P00338

36.5

8.46

8

4

initiation factor
4H
F actin capping
72

protein α 1
subunit

73

Corticotropin
Lipotropin

74

L-lactate
dehydrogenase

A

chain

76

Vimentin

P08670

53.5

5.06

26

16

77

Vimentin

P08670

53.5

5.06

22

12

78

Vimentin

P08670

53.5

5.06

19

11

79

N-myc interactor

Q13287

35.1

5.24

20

6

80

Actin β

P02570

41.7

5.29

21

9

81

α enolase

P06733

47

6.99

23

9

209

82

Actin α

P04270

41.7

5.23

9

4

(cardiac)

83

Actin β 1

P60709

41.6

5.29

28

11

84

Actin γ

P02571

41.6

5.31

31

12

85

Actin β

P60709

41.6

5.29

24

10

87

SERCA3

Q93084

113.9

5.42

6

9

88

Vimentin

P08670

53.5

5.06

22

14

89

Vimentin

P08670

53.5

5.06

28

17

91

β Tubulin 5

P04350

49.5

4.81

8

6

92

α enolase

P06733

47.0

6.99

23

9

97

α tubulin 6

Q9BQE3

49.8

4.96

23

7

100

hnRNP H

P31943

49.2

5.89

16

5

P52209

53.0

6.88

11

4

6 phospho
101

gluconate
dehydrogenase
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102

Fascin

103

T complex protein

Q16658

54.4

6.81

19

9

1 β subunit

P78371

57.4

6.01

14

7

105

α tubulin 6

Q9BQE3

49.8

4.96

19

6

106

Tubulin β 4 chain

Q13509

50.4

4.83

12

5

107

T complex protein

P48643

59.6

5.45

19

12

protein

P11021

70.4

5.01

23

14

110

GRP75

P38646

68.7

5.44

29

20

114

HSP 90 α

P07900

84.5

4.94

13

12

115

HSP 90 β

P08238

83.1

4.97

13

10

116

Pyruvate kinase

P14618

57.8

7.95

10

5

P11172

52.2

6.81

13

7

1ε

109

Glucose regulated

M1 isozyme
117

UMP synthase

211

118

Actin β 1

P60709

41.6

5.29

25

10

119

Aldehyde

P48448

42.7

5.92

9

4

O00469

842

6.06

6

5

P61978

50.9

5.39

17

9

P08670

53.5

5.06

19

11

dehydrogenase

120

Lysyl hydroxylase
2

121

hnRNP K isoform
a

122

Vimentin

212

Appendix B. List of proteins identified on 2-DE gels by LC-MS/MS

Spot

Protein

number

Swiss-

Mr (kDa)

pI

Prot

%

# of

Sequence

peptides

coverage

matched

1

Calmodulin

P62158

16.7

4.09

45

7

5

Myotropin

P58546

12.8

5.27

14

2

10

Ubiquitin

P62988

0.85

6.56

7

5

Thioredoxin (ALT

P10599

11.6

4.82

31

5

11

derived factor)

12

Galectin 1

P09382

14.5

5.34

23

3

13

Galectin 1

P09382

14.5

5.34

17

2

16

Retinol binding

P09455

15.7

4.99

40

5

protein

21

Cyclophilin A

P62937

17.8

7.82

39

6

22

Cyclophilin A

P62937

17.8

7.82

10

5
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23

Cyclophilin A

P62937

17.8

7.82

39

7

24

Profilin I

P07737

14.9

8.47

51

9

30

Stathmin I

P16949

17.1

5.77

24

3

32

Cofilin 1

P23528

18.5

8.22

19

3

33

DJ 1 protein

Q99497

19.8

6.33

31

6

34

ATP synthase δ

P30049

15

4.53

16

3

35

Glyoxalase 1

Q04760

20.5

5.25

27

4

36

Peroxiredoxin 2

P32119

21.8

5.66

36

10

37

NM 23-H1

P15531

17.1

5.83

32

6

38

Neuropolypeptide

P30086

20.9

7.43

35

6

h3

40

Rho GDI

P52565

23.2

5.03

7

2

42

Glutathione S

O15217

25.7

7.89

20

4

transferase A4

214

44

DJ 1 protein

Q99497

19.8

6.33

21

5

48

HSP 27

P04792

22.7

5.98

25

4

52

UCH L1

P09936

24.8

5.33

34

7

54

UCH L1

P09936

24.8

5.33

24

4

59

Mn SOD

P04179

22.2

6.86

13

3

61

Chain A of TIM

P60174

26.5

6.51

23

4

62

TIM

P60174

26.5

6.51

29

5

64

Tropomyosin 3

P06753

32.8

4.68

26

5

71

Tubulin β 1

P07437

49.7

4.75

7

3

P00354

36.1

8.26

11

3

Glyceraldehyde 3
75

PO4
Dehydrogenase

86

Calreticulin

P27797

46.4

4.29

5

2

90

Vimentin

P08670

53.5

5.06

32

9
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93

α enolase

P06733

47

6.99

31

10

94

α enolase

P06733

47

6.99

21

6

95

MT HSP 75

Q12931

80

8.05

14

8

96

Tubulin α 6

Q9BQE3

49.8

4.96

13

8

98

Protein disulfide

P30101

56.6

6.10

40

24

P30101

56.6

6.10

29

17

organizing protein

P31948

62.6

6.40

18

9

108

HSP 60

P10809

57.9

5.24

33

6

111

Lamin A

P02545

74.1

6.57

16

4

112

HSP 60

P10809

57.9

5.24

21

7

113

HSP 60

P10809

57.9

5.24

19

6

isomerase

99

Protein disulfide
isomerase

104

HSP 70/90
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